0001564590-21-055256.txt : 20211108 0001564590-21-055256.hdr.sgml : 20211108 20211108161613 ACCESSION NUMBER: 0001564590-21-055256 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211108 DATE AS OF CHANGE: 20211108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 211388165 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20210930.htm 10-Q 9-30-2021 uht-10q_20210930.htm
false Q3 0000798783 --12-31 3 1 2 2 http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember 0.0050 1 1 1 3 1 2 2 P5Y P5Y 0.0050 1 1 1 P5Y P10Y P10Y 125000000 0.60 0.30 0.60 0.0150 0000798783 2021-01-01 2021-09-30 xbrli:shares 0000798783 2021-10-31 iso4217:USD 0000798783 uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember 2020-01-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0000798783 2021-07-01 2021-09-30 0000798783 2020-07-01 2020-09-30 0000798783 2020-01-01 2020-09-30 0000798783 us-gaap:ManagementServiceMember 2021-07-01 2021-09-30 0000798783 us-gaap:ManagementServiceMember 2020-07-01 2020-09-30 0000798783 us-gaap:ManagementServiceMember 2021-01-01 2021-09-30 0000798783 us-gaap:ManagementServiceMember 2020-01-01 2020-09-30 iso4217:USD xbrli:shares 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-01-01 2020-09-30 0000798783 2021-09-30 0000798783 2020-12-31 0000798783 us-gaap:CommonStockMember 2020-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000798783 us-gaap:RetainedEarningsMember 2020-12-31 0000798783 uht:CumulativeDividendsMember 2020-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000798783 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-01-01 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000798783 us-gaap:CommonStockMember 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000798783 us-gaap:CommonStockMember 2021-06-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000798783 us-gaap:RetainedEarningsMember 2021-06-30 0000798783 uht:CumulativeDividendsMember 2021-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000798783 2021-06-30 0000798783 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-07-01 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000798783 us-gaap:CommonStockMember 2019-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000798783 us-gaap:RetainedEarningsMember 2019-12-31 0000798783 uht:CumulativeDividendsMember 2019-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000798783 2019-12-31 0000798783 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-01-01 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000798783 us-gaap:CommonStockMember 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000798783 2020-09-30 0000798783 us-gaap:CommonStockMember 2020-06-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000798783 us-gaap:RetainedEarningsMember 2020-06-30 0000798783 uht:CumulativeDividendsMember 2020-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000798783 2020-06-30 0000798783 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-07-01 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 xbrli:pure 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-09-30 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-09-30 uht:Property 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:SubsequentEventMember 2021-11-08 0000798783 uht:UniversalHealthServicesIncMember srt:MinimumMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember srt:MaximumMember 2021-01-01 2021-09-30 uht:Time 0000798783 uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2021-07-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2021-01-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2020-07-01 2020-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2020-01-01 2020-09-30 uht:Hospital 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 uht:RenewalOption 0000798783 uht:WellingtonRegionalMedicalCenterMember srt:MinimumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember srt:MaximumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember srt:MinimumMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember srt:MaximumMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember 2020-01-01 2020-12-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BaseRentsMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BaseRentsMember 2020-01-01 2020-12-31 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BonusRentsMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:BonusRentsMember 2020-01-01 2020-12-31 0000798783 uht:FireMesaOfficeBuildingMember 2021-05-01 2021-05-31 0000798783 uht:GraysonPropertiesTwoLPMember uht:DenisonTexasMember 2019-09-30 0000798783 uht:UniversalHealthServicesIncMember 2019-09-01 2019-09-30 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-01 2019-07-31 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-31 uht:Lease 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-01-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-12-31 0000798783 uht:AtMarketATMProgramsMember 2020-06-30 0000798783 uht:AtMarketATMProgramsMember 2021-01-01 2021-09-30 0000798783 uht:AtMarketATMProgramsMember 2020-04-01 2020-06-30 0000798783 uht:AtMarketATMProgramsMember us-gaap:OtherExpenseMember 2021-01-01 2021-09-30 0000798783 uht:AuburnMedicalOfficeBuildingIIMember us-gaap:SubsequentEventMember 2021-11-01 0000798783 uht:FireMesaOfficeBuildingMember uht:UniversalHealthServicesIncMember 2021-05-01 2021-05-31 0000798783 uht:UniversalHealthServicesIncMember 2021-05-31 utr:sqft 0000798783 uht:MedicalOfficeBuildingsMember 2021-06-01 2021-06-30 0000798783 uht:MedicalOfficeBuildingsMember 2021-01-01 2021-09-30 uht:Acquisition uht:Disposition 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember uht:MedicalOfficeBuildingsMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:SubsequentEventMember 2021-10-01 2021-11-08 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:BrunswickAssociatesMember 2021-09-30 0000798783 uht:GraysonPropertiesMember 2021-07-01 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember srt:MaximumMember uht:DenisonTexasMember 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-07-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-07-01 2020-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesTwoLPMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesTwoLPMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesTwoLPMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember 2021-09-30 0000798783 srt:MinimumMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BaseRentsMember 2020-01-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:BonusRentsMember 2020-01-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember uht:TenantReimbursementsMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-01-01 2020-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2021-01-01 2021-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2021-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2020-01-01 2020-12-31 uht:Bed 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2021-01-01 2021-09-30 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2020-01-01 2020-12-31 0000798783 uht:EvansvilleRehabilitationHospitalEvansvilleIndianaMember 2021-01-01 2021-09-30 0000798783 uht:CorpusChristiCorpusChristiTexasMember 2021-01-01 2021-09-30 uht:Land 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 2021-07-02 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 0000798783 uht:RevolvingAFacilityMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember us-gaap:BaseRateMember srt:MaximumMember 2018-03-27 2018-03-27 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember uht:FederalFundsEffectiveRateMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember srt:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingAFacilityMember srt:MaximumMember 2018-03-27 2018-03-27 uht:Option 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingBFacilityMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember 2021-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2020-12-31 uht:Derivative 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-01 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000798783 us-gaap:InterestRateSwapMember 2021-01-01 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-07-01 2021-09-30 uht:Segment

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                      

Commission file number 1-9321

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

 

 

Maryland

 

23-6858580

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

 

 

 

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, Pennsylvania

 

19406

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (610265-0688

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

 

Trading Symbol(s)

 

Name of each exchange on which registered

Shares of beneficial interest, $0.01 par value

 

UHT

 

New York Stock Exchange

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated Filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of common shares of beneficial interest outstanding at October 31, 2021—13,784,412.

 

 

 

 

 


 

 

UNIVERSAL HEALTH REALTY INCOME TRUST

INDEX

 

 

 

 

 

PAGE NO.

PART I. FINANCIAL INFORMATION (unaudited)

 

 

Item 1.

 

Financial Statements

 

 

 

 

Condensed Consolidated Statements of Income—Three and Nine Months Ended September 30, 2021 and 2020

 

4

 

 

Condensed Consolidated Statements of Comprehensive Income—Three and Nine Months Ended September 30, 2021 and 2020

 

5

 

 

Condensed Consolidated Balance Sheets—September 30, 2021 and December 31, 2020

 

6

 

 

Condensed Consolidated Statements of Changes in Equity—Three and Nine Months Ended September 30, 2021 and 2020

 

7 through 8

 

 

Condensed Consolidated Statements of Cash Flows—Nine Months Ended September 30, 2021 and 2020

 

9

 

 

Notes to Condensed Consolidated Financial Statements

 

10 through 21

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

22 through 33

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

34 through 35

Item 4.

 

Controls and Procedures

 

35

PART II. OTHER INFORMATION

 

36

Item 1A. Risk Factors

 

36

Item 6.

 

Exhibits

 

36

 

 

 

 

 

SIGNATURES

 

37

 

 

 

This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Note 2 to the condensed consolidated financial statements—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986, and as amended and restated as of January 1, 2019. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to wholly-owned subsidiaries of UHS, one of our hospital facilities is leased to a joint venture between a wholly-owned subsidiary of UHS and a third party, and subsidiaries of UHS are tenants of nineteen medical office or general office buildings or free-standing emergency departments, that are either wholly or jointly-owned by us. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%.  As of September 30, 2021, we had investments in five jointly-owned LLCs/LPs. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the condensed consolidated financial statements included herein).  

 

 

3


 

 

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three and Nine Months Ended September 30, 2021 and 2020

(amounts in thousands, except per share information)

(unaudited)

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Lease revenue - UHS facilities (a.)

 

$

7,574

 

 

$

6,381

 

 

$

21,971

 

 

$

18,243

 

  Lease revenue - Non-related parties

 

 

13,115

 

 

 

12,841

 

 

 

39,324

 

 

 

38,526

 

  Other revenue - UHS facilities

 

 

236

 

 

 

232

 

 

 

669

 

 

 

667

 

  Other revenue - Non-related parties

 

 

280

 

 

 

238

 

 

 

816

 

 

 

744

 

 

 

 

21,205

 

 

 

19,692

 

 

 

62,780

 

 

 

58,180

 

Expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  Depreciation and amortization

 

 

6,813

 

 

 

6,399

 

 

 

20,551

 

 

 

19,160

 

  Advisory fees to UHS

 

 

1,121

 

 

 

1,039

 

 

 

3,272

 

 

 

3,082

 

  Other operating expenses

 

 

5,980

 

 

 

5,614

 

 

 

17,485

 

 

 

16,573

 

 

 

 

13,914

 

 

 

13,052

 

 

 

41,308

 

 

 

38,815

 

Income before equity in income of unconsolidated limited liability companies ("LLCs"), gain on sale and interest expense

 

 

7,291

 

 

 

6,640

 

 

 

21,472

 

 

 

19,365

 

  Equity in income of unconsolidated LLCs

 

 

303

 

 

 

517

 

 

 

1,341

 

 

 

1,371

 

Gain on sale of real estate assets

 

 

-

 

 

 

-

 

 

 

1,304

 

 

 

-

 

Interest expense, net

 

 

(2,250

)

 

 

(1,964

)

 

 

(6,566

)

 

 

(6,289

)

Net income

 

$

5,344

 

 

$

5,193

 

 

$

17,551

 

 

$

14,447

 

Basic earnings per share

 

$

0.39

 

 

$

0.38

 

 

$

1.28

 

 

$

1.05

 

Diluted earnings per share

 

$

0.39

 

 

$

0.38

 

 

$

1.27

 

 

$

1.05

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding - Basic

 

 

13,762

 

 

 

13,748

 

 

 

13,755

 

 

 

13,741

 

Weighted average number of shares outstanding - Diluted

 

 

13,783

 

 

 

13,770

 

 

 

13,777

 

 

 

13,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a.) Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively.

 

 

See accompanying notes to these condensed consolidated financial statements.

 

4


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three and Nine Months Ended September 30, 2021 and 2020

(amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

 

September 30,

 

 

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net income

 

$

5,344

 

 

$

5,193

 

 

$

17,551

 

 

$

14,447

 

Other comprehensive (loss)/gain:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized derivative gains/(loss) on cash flow hedges

 

 

471

 

 

 

234

 

 

 

3,259

 

 

 

(5,709

)

Total other comprehensive gains/(loss):

 

 

471

 

 

 

234

 

 

 

3,259

 

 

 

(5,709

)

Total comprehensive income

 

$

5,815

 

 

$

5,427

 

 

$

20,810

 

 

$

8,738

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

5


 

 

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(amounts in thousands, except share information)

(unaudited)

 

 

September 30,

 

 

December 31,

 

 

 

2021

 

 

2020

 

Assets:

 

 

 

 

 

 

 

 

Real Estate Investments:

 

 

 

 

 

 

 

 

Buildings and improvements and construction in progress

 

$

610,338

 

 

$

605,292

 

Accumulated depreciation

 

 

(230,827

)

 

 

(216,648

)

 

 

 

379,511

 

 

 

388,644

 

Land

 

 

56,947

 

 

 

55,157

 

               Net Real Estate Investments

 

 

436,458

 

 

 

443,801

 

Investments in and advances to limited liability companies ("LLCs")

 

 

23,123

 

 

 

4,278

 

Other Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

9,347

 

 

 

5,742

 

Lease and other receivables from UHS

 

 

4,246

 

 

 

3,199

 

Lease receivable - other

 

 

6,841

 

 

 

7,504

 

Intangible assets (net of accumulated amortization of $17.7 million and

   $19.5 million, respectively)

 

 

10,392

 

 

 

11,742

 

Right-of-use land assets, net

 

 

8,891

 

 

 

8,914

 

Deferred charges and other assets, net

 

 

11,012

 

 

 

8,829

 

Assets of property held for sale

 

 

7,371

 

 

 

-

 

               Total Assets

 

$

517,681

 

 

$

494,009

 

Liabilities:

 

 

 

 

 

 

 

 

Line of credit borrowings

 

$

276,800

 

 

$

236,200

 

Mortgage notes payable, non-recourse to us, net

 

 

57,397

 

 

 

58,895

 

Accrued interest

 

 

352

 

 

 

351

 

Accrued expenses and other liabilities

 

 

11,261

 

 

 

19,802

 

Ground lease liabilities, net

 

 

8,891

 

 

 

8,914

 

Tenant reserves, deposits and deferred and prepaid rents

 

 

11,092

 

 

 

10,842

 

Liabilities of property held for sale

 

 

77

 

 

 

-

 

               Total Liabilities

 

 

365,870

 

 

 

335,004

 

Equity:

 

 

 

 

 

 

 

 

Preferred shares of beneficial interest,

   $.01 par value; 5,000,000 shares authorized;

   none issued and outstanding

 

 

-

 

 

 

-

 

Common shares, $.01 par value;

   95,000,000 shares authorized; issued and outstanding: 2021 - 13,784,401;

   2020 - 13,771,287

 

 

138

 

 

 

138

 

Capital in excess of par value

 

 

268,232

 

 

 

267,368

 

Cumulative net income

 

 

698,278

 

 

 

680,727

 

Cumulative dividends

 

 

(814,281

)

 

 

(785,413

)

Accumulated other comprehensive loss

 

 

(556

)

 

 

(3,815

)

     Total Equity

 

 

151,811

 

 

 

159,005

 

               Total Liabilities and Equity

 

$

517,681

 

 

$

494,009

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 


 

6


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Nine Months Ended September 30, 2021

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

January 1, 2021

 

 

13,771

 

 

$

138

 

 

$

267,368

 

 

$

680,727

 

 

$

(785,413

)

 

$

(3,815

)

 

$

159,005

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued, net

 

 

13

 

 

 

 

 

 

161

 

 

 

 

 

 

 

 

 

 

 

 

161

 

Repurchased

 

 

 

 

 

 

 

 

(16

)

 

 

 

 

 

 

 

 

 

 

 

(16

)

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

719

 

 

 

 

 

 

 

 

 

 

 

 

719

 

Dividends ($2.095/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(28,868

)

 

 

 

 

 

(28,868

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

17,551

 

 

 

 

 

 

 

 

 

17,551

 

Unrealized net gain on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,259

 

 

 

3,259

 

Subtotal - comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17,551

 

 

 

 

 

 

 

3,259

 

 

 

20,810

 

September 30, 2021

 

 

13,784

 

 

$

138

 

 

$

268,232

 

 

$

698,278

 

 

$

(814,281

)

 

$

(556

)

 

$

151,811

 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Three Months Ended September 30, 2021

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

July 1, 2021

 

 

13,783

 

 

$

138

 

 

$

267,951

 

 

$

692,934

 

 

$

(804,632

)

 

$

(1,027

)

 

$

155,364

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued

 

 

1

 

 

 

 

 

 

55

 

 

 

 

 

 

 

 

 

 

 

 

55

 

Repurchased

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

226

 

 

 

 

 

 

 

 

 

 

 

 

226

 

Dividends ($.70/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,649

)

 

 

 

 

 

(9,649

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

5,344

 

 

 

 

 

 

 

 

 

5,344

 

Unrealized net gain on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

471

 

 

 

471

 

Subtotal - comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,344

 

 

 

 

 

 

 

471

 

 

 

5,815

 

September 30, 2021

 

 

13,784

 

 

$

138

 

 

$

268,232

 

 

$

698,278

 

 

$

(814,281

)

 

$

(556

)

 

$

151,811

 

See accompanying notes to these condensed consolidated financial statements.


7


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Nine Months Ended September 30, 2020

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

January 1, 2020

 

 

13,757

 

 

$

138

 

 

$

266,723

 

 

$

661,280

 

 

$

(747,417

)

 

$

1,010

 

 

$

181,734

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued, net

 

 

14

 

 

 

 

 

 

(317

)

 

 

 

 

 

 

 

 

 

 

 

(317

)

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

665

 

 

 

 

 

 

 

 

 

 

 

 

665

 

Dividends ($2.065/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(28,426

)

 

 

 

 

 

(28,426

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

14,447

 

 

 

 

 

 

 

 

 

14,447

 

Unrealized loss on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5,709

)

 

 

(5,709

)

Subtotal - comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

14,447

 

 

 

 

 

 

 

(5,709

)

 

 

8,738

 

September 30, 2020

 

 

13,771

 

 

$

138

 

 

$

267,071

 

 

$

675,727

 

 

$

(775,843

)

 

$

(4,699

)

 

$

162,394

 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Changes in Equity

For the Three Months Ended September 30, 2020

(amounts in thousands)

(unaudited)

 

 

 

Common Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital in

 

 

 

 

 

 

 

 

 

 

Accumulated other

 

 

 

 

 

 

 

Number

 

 

 

 

 

 

excess of

 

 

Cumulative

 

 

Cumulative

 

 

comprehensive

 

 

Total

 

 

 

of Shares

 

 

Amount

 

 

par value

 

 

net income

 

 

dividends

 

 

income/(loss)

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

July 1, 2020

 

 

13,770

 

 

$

138

 

 

$

266,843

 

 

$

670,534

 

 

$

(766,342

)

 

$

(4,933

)

 

$

166,240

 

Shares of Beneficial Interest:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Issued

 

 

1

 

 

 

 

 

 

(20

)

 

 

 

 

 

 

 

 

 

 

 

(20

)

Restricted stock-based compensation expense

 

 

 

 

 

 

 

 

248

 

 

 

 

 

 

 

 

 

 

 

 

248

 

Dividends ($.69/share)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,501

)

 

 

 

 

 

(9,501

)

Comprehensive income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

 

 

 

 

5,193

 

 

 

 

 

 

 

 

 

5,193

 

Unrealized gain on cash flow hedges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

234

 

 

 

234

 

Subtotal - comprehensive income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,193

 

 

 

 

 

 

 

234

 

 

 

5,427

 

September 30, 2020

 

 

13,771

 

 

$

138

 

 

$

267,071

 

 

$

675,727

 

 

$

(775,843

)

 

$

(4,699

)

 

$

162,394

 

See accompanying notes to these condensed consolidated financial statements.

 

 

8


 

 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

(unaudited)

 

 

 

Nine months ended September 30,

 

 

 

2021

 

 

2020

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

17,551

 

 

$

14,447

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

20,551

 

 

 

19,160

 

Amortization related to above/below market leases, net

 

 

(139

)

 

 

(140

)

Amortization of debt premium

 

 

(38

)

 

 

(39

)

Amortization of deferred financing costs

 

 

609

 

 

 

549

 

Stock-based compensation expense

 

 

719

 

 

 

665

 

Gain on sale of real estate assets

 

 

(1,304

)

 

 

-

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Lease receivable

 

 

(457

)

 

 

27

 

Accrued expenses and other liabilities

 

 

201

 

 

 

49

 

Tenant reserves, deposits and deferred and prepaid rents

 

 

272

 

 

 

(186

)

Accrued interest

 

 

1

 

 

 

159

 

Leasing costs paid

 

 

(1,250

)

 

 

(745

)

Other, net

 

 

(522

)

 

 

(1,171

)

Net cash provided by operating activities

 

 

36,194

 

 

 

32,775

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Investments in LLCs

 

 

(16,138

)

 

 

(3,204

)

Cash distributions from LLCs

 

 

-

 

 

 

5,196

 

Advance made to LLC

 

 

(3,500

)

 

 

-

 

Additions to real estate investments, net

 

 

(11,537

)

 

 

(18,784

)

Deposit on real estate assets

 

 

(200

)

 

 

-

 

Net cash paid for acquisition of property

 

 

(12,989

)

 

 

-

 

Cash proceeds received from sale of property, net

 

 

3,209

 

 

 

-

 

Net cash used in investing activities

 

 

(41,155

)

 

 

(16,792

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net borrowings on line of credit

 

 

40,600

 

 

 

14,150

 

Repayments of mortgage notes payable

 

 

(1,550

)

 

 

(1,406

)

Financing costs paid

 

 

(1,813

)

 

 

(372

)

Dividends paid

 

 

(28,830

)

 

 

(28,411

)

Issuance of shares of beneficial interest, net

 

 

159

 

 

 

266

 

Net cash provided by/(used in) financing activities

 

 

8,566

 

 

 

(15,773

)

Increase in cash and cash equivalents

 

 

3,605

 

 

 

210

 

Cash and cash equivalents, beginning of period

 

 

5,742

 

 

 

6,110

 

Cash and cash equivalents, end of period

 

$

9,347

 

 

$

6,320

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

5,995

 

 

$

5,620

 

Invoices accrued for construction and improvements

 

$

151

 

 

$

5,660

 

 

See accompanying notes to these condensed consolidated financial statements.

 

9


 

 

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2021

(unaudited)

 

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of September 30, 2021, we had investments in five jointly-owned LLCs/LPs (subsequent to September 30, 2021, we purchased the 5% third-party minority ownership interest in one of the jointly-owned LPs, as discussed in Note 5). We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.  

The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

 

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the three hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% and 23% of our consolidated revenues for the three months ended September 30, 2021 and 2020, respectively, and approximately 22% of our consolidated revenues for each of the nine months ended September 30, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have nineteen medical office buildings (“MOBs”), general office buildings or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and approximately 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and

10


 

conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

The table below details the existing lease terms and renewal options for our three hospitals operated by wholly-owned subsidiaries of UHS:  

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(c.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  

(c.)

UHS has notified us of their intent to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled termination of the current lease term on December 31, 2021. UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  See below for additional disclosure. 

 

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).  

 

Subsequent to September 30, 2021, we purchased the 5% minority ownership interest held by a third-party member in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for approximately $3.1 million. The MOB is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS. A third-party appraisal was completed to determine the fair value of the property.  As a result of this minority ownership purchase during the fourth quarter of 2021, we subsequently own 100% of the LP and we will therefore begin consolidating this LP effective with the purchase date.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  Please see Note 5 for additional disclosure surrounding this transaction.

 

In May, 2021, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million.  The building is 100% leased under the terms of a triple net lease by a wholly-owned subsidiary of UHS.  The initial lease is scheduled to expire on August 31, 2027 and has two five-year renewal options.  As discussed in Note 4, the acquisition of this office building is part of an anticipated series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.

 

In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.    

11


 

In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020, at which time the hospital lease commenced. Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale.

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  

 

We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are estimated to be approximately $508,000 during each of the years ended 2021 through 2025, and an aggregate of $29.0 million thereafter. See Note 7 for additional lease accounting disclosure.

 

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of September 30, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

 

Advisory Agreement:   UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory.

Our advisory fee for the three and nine months ended September 30, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended September 30, 2021 and 2020, respectively, and were based upon average invested real estate assets of $641 million and $594 million, respectively. Advisory fees incurred and paid (or payable) to UHS were approximately $3.3 million and $3.1 million for the nine months ended September 30, 2021 and 2020, and were based upon average invested real estate assets of $623 million and $587 million, respectively.   

 

Share Ownership: As of September 30, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

12


 

(3) Dividends and Equity Issuance Program

Dividends and dividend equivalents:

During the third quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.70 per share. We declared and paid dividends of approximately $9.5 million, or $.69 per share, during the third quarter of 2020.  During the nine-month period ended September 30, 2021 we declared and paid dividends of approximately $28.8 million, or $2.095 per share.  During the nine-month period ended September 30, 2020, we declared and paid dividends of approximately $28.4 million, or $2.065 per share. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first nine months of 2021 and will be paid upon vesting of the restricted stock.

Equity Issuance Program:

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020.

No shares were issued pursuant to this ATM equity program during the first nine months of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of September 30, 2021, we have paid or incurred approximately $508,000 in various fees and expenses related to the commencement of our ATM program.

(4) Acquisitions and Divestitures    

During the second quarter of 2021 and during the fourth quarter of 2021, we completed three transactions as described below utilizing qualified third-party intermediaries, as part of a series of anticipated tax-deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.

Subsequent to September 30, 2021:

In July, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we entered into an agreement to sell the Auburn Medical Office Building II.  On November 1, 2021 we settled on the sale of the Auburn Medical Office Building II, a multi-tenant MOB located in Auburn, Washington to a non-related party for a sale price of approximately $25.1 million.  The gain on this divestiture will be included in our consolidated statement of income for the three and twelve-month periods ended December 31, 2021.  The assets and liabilities related to this property are included in “Assets of property held for sale” or “Liabilities of property held for sale” on our consolidated balance sheet as of September 30, 2021.

Nine Months Ended September 30, 2021:

Acquisition:

In May, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million. The building, which has approximately 44,000 rentable square feet, is 100% leased under the terms of a triple net lease with a wholly-owned subsidiary of UHS.  The lease on this building is scheduled to expire on August 31, 2027 and has two five-year renewal options.

Divestiture:

In June, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we sold the Children’s Clinic at Springdale, a medical office building located in Springdale, AR for a sale price of approximately $3.2 million, net of closing costs. This divestiture resulted in a gain of approximately $1.3 million which is included in our consolidated statement of income for the nine-month period ended September 30, 2021.  

 

13


 

 

Nine Months Ended September 30, 2020:    

Acquisitions:

There were no acquisitions during the first nine months of 2020.  

Divestitures:    

There were no dispositions during the first nine months of 2020.

(5) Summarized Financial Information of Equity Affiliates

In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities.

At September 30, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.  

 

Subsequent to September 30, 2021, we purchased the third-party 5% ownership interest in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for a purchase price of approximately $3.1 million.  We formerly held a non-controlling majority ownership interest in this LP.  As a result of our purchase of the minority ownership interest, we now hold 100% of the ownership interest in this LP and we will begin accounting for this LP on a consolidated basis effective with the minority ownership interest purchase date. The property’s assets and liabilities will be recorded at the carrying amount of its previously held interest, plus the incremental cost which will be allocated based upon relative fair values.  A third-party appraisal was completed to determine the fair value of the property.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  

The following property table represents the five LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of September 30, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP.

14


 

(c.)

During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

(d.)

Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Below are the condensed combined statements of income (unaudited) for the five LLCs/LPs accounted for under the equity method at September 30, 2021 and the four LLCs/LPs accounted for under the equity method as September 30, 2020 (the 2020 periods do not include the newly constructed Texoma Medical Plaza II that was substantially completed in December, 2020).     

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

(amounts in thousands)

 

Revenues

 

$

2,736

 

 

$

2,624

 

 

$

8,373

 

 

$

7,637

 

Operating expenses

 

 

1,184

 

 

 

1,047

 

 

 

3,356

 

 

 

3,094

 

Depreciation and amortization

 

 

627

 

 

 

444

 

 

 

1,684

 

 

 

1,333

 

Interest, net

 

 

388

 

 

 

315

 

 

 

1,260

 

 

 

949

 

Net income

 

$

537

 

 

$

818

 

 

$

2,073

 

 

$

2,261

 

Our share of net income

 

$

303

 

 

$

517

 

 

$

1,341

 

 

$

1,371

 

   

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of September 30, 2021 and December 31, 2020:     

 

 

September 30,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

42,789

 

 

$

42,374

 

Other assets (a.)

 

 

9,484

 

 

 

8,818

 

Total assets

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

6,966

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

22,133

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

19,674

 

 

 

2,055

 

Total liabilities and equity

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in and advances to LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

23,123

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,896

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

21,227

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.  

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.

15


 

 

As of September 30, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

9/30/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

February, 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

-

 

 

 

13,372

 

 

September, 2021

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

13,075

 

 

 

12,336

 

 

June, 2025

Brunswick Associates (2.80% fixed rate mortgage loan)

 

 

9,058

 

 

 

9,250

 

 

December, 2030

 

 

$

22,133

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity

 

(b.)

Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

The minority partner in Grayson Properties, LP, as the Offering Member, made an offer to sell its entire 5% ownership interest to us at a stipulated price, and we agreed to purchase the ownership interest at the stipulated price of approximately $3.1 million. The transaction was completed during the fourth quarter of 2021, as discussed above.

 

(6) Recent Accounting Pronouncements

 

Accounting for Lease Concessions Granted in Connection with COVID-19

On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, Leases, which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.

      

Based on the Q&A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three and nine months ended September 30, 2021 or the year ended December 31, 2020.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives

16


 

and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.

 

(7) Lease Accounting

 

We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.

As Lessor:

We lease our operating properties to customers under agreements that are classified as operating leases. We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease.  We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and nine months ended September 30, 2021 and 2020.  

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and nine month periods ended September 30, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

$

5,392

 

 

$

4,402

 

 

$

15,820

 

 

$

12,940

 

Bonus rents

 

1,828

 

 

 

1,680

 

 

 

5,171

 

 

 

4,477

 

Tenant reimbursements

 

354

 

 

 

299

 

 

 

980

 

 

 

826

 

Lease revenue - UHS facilities

$

7,574

 

 

$

6,381

 

 

$

21,971

 

 

$

18,243

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

 

10,421

 

 

 

10,390

 

 

 

31,425

 

 

 

31,155

 

Tenant reimbursements

 

2,694

 

 

 

2,451

 

 

 

7,899

 

 

 

7,371

 

Lease revenue - Non-related parties

$

13,115

 

 

$

12,841

 

 

$

39,324

 

 

$

38,526

 

 

Disclosures Related to Certain Facilities:  

Wellington Regional Medical Center:

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to Wellington Regional Medical Center.  The current lease on this facility is scheduled to expire on December 31, 2021.  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  

17


 

Southwest Healthcare System, Inland Valley Campus:

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).

PeaceHealth Medical Clinic:

The existing lease on the PeaceHealth Medical Clinic, an MOB located in Bellingham, Washington was scheduled to expire on December 31, 2021.  In July, 2021, the lease was renewed for an additional seven year term, extending the scheduled expiration date to January 31, 2029.  The tenant also has two additional five-year renewal terms.  Additionally, the tenant has the right of first offer to purchase the property if the property is marketed by us; and the tenant has an option to purchase the property at the end of the lease term at the then fair market value.  Pursuant to the terms of the lease on the PeaceHealth Medical Clinic, we earned $2.1 million of lease revenue during the nine-month period ended September 30, 2021 and $2.8 million of lease revenue during the year ended December 31, 2020.

Kindred Hospital Chicago Central:

As previously disclosed, the existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility notified us that they do not intend to renew the lease upon its scheduled expiration. We are marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $1.2 million of lease revenue during the nine-month period ended September 30, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  

Vacancies - Evansville, Indiana and Corpus Christi, Texas:    

The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  

We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted.

 As Lessee:

We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments. A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similarly to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. As of September 30, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the nine months ended September 30, 2021.

 

18


 

 

(8) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On July 2, 2021, we entered into an amended and restated revolving credit agreement (“Credit Agreement”) to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020 (“Prior Credit Agreement”). Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million.  The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trust’s wholly-owned subsidiaries.

Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans. The initial applicable margin is 1.25% for LIBOR loans and 0.25% for Base Rate loans. The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. The Trust will also pay a quarterly commitment fee ranging from 0.15% to 0.35% (depending on the Trust’s ratio of debt to asset value) of the average daily unused portion of the revolving credit commitments.  The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods.

The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At September 30, 2021, the applicable margin over the LIBOR rate was 1.25%, the margin over the Base Rate was 0.25% and the facility fee was 0.25%.  

At September 30, 2021, we had $276.8 million of outstanding borrowings and $3.6 million of letters of credit outstanding under our Credit Agreement. We had $94.6 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our Prior Credit Agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at September 30, 2021 and were in compliance with all of the covenants in the Prior Credit Agreement at December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

19


 

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):

 

 

 

Covenant

 

September 30,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

141,419

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.6

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.1

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

47.2

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan (b.)

 

$

5,268

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,337

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,395

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,458

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,866

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,494

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,530

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,333

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

57,681

 

 

 

 

 

 

 

     Less net financing fees

 

 

(387

)

 

 

 

 

 

 

     Plus net debt premium

 

 

103

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

57,397

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

 

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of September 30, 2021 had a combined fair value of approximately $60.3 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

Financial Instruments:

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

20


 

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At September 30, 2021, the fair value of our interest rate swaps was a net liability of $556,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the third quarter of 2021, we paid or accrued approximately $324,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first nine months of 2021, we paid or accrued approximately $945,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. From inception of the swap agreements through September 30, 2021 we paid or accrued approximately $1.6 million in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.8 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.  We do not expect any gains or losses on our interest rate swaps to be reclassified to earnings in the next twelve months.

 

(9) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

 

 

21


 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, behavioral health care hospitals, specialty hospitals, free-standing emergency departments, childcare centers and medical/office buildings. As of November 1, 2021, we have seventy-one real estate investments or commitments located in twenty states consisting of:  

 

seven hospital facilities consisting of three acute care, one behavioral health care, and three specialty hospitals (two of which are currently vacant);

 

four free-standing emergency departments (“FEDs”);

 

fifty-six medical or general office buildings, including four owned by unconsolidated limited liability companies (“LLCs”)/limited liability partnerships (“LPs”), and;

 

four preschool and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in our Annual Report on Form 10-K for the year ended December 31, 2020, this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. This Quarterly Report contains “forward-looking statements” that reflect our current estimates, expectations and projections about our future results, performance, prospects and opportunities. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense, identify forward-looking statements. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks described elsewhere herein and in our Annual Report on Form 10-K for the year ended December 31, 2020 in Item 1A Risk Factors and in Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements and in Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements and Risk Factors, as included herein. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:  

 

Future operations and financial results of our tenants, and in turn ours, will likely be materially impacted by numerous factors and future developments related to COVID-19.   Such factors and developments include, but are not limited to, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated by the operators of our hospitals and other healthcare facilities; measures our tenants are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation, including travel bans and restrictions, shelter-in-place or stay-at-home orders, quarantines, the promotion of social distancing, business shutdowns and limitations on business activity; vaccine requirements; changes in patient volumes at our tenants’ hospitals and other healthcare facilities due to patients’ general concerns related to the risk of contracting COVID-19 from interacting with the healthcare system; the impact of stimulus on the health care industry and our tenants; changes in patient volumes and payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings and layoffs); potential disruptions to clinical staffing and shortages and disruptions related to supplies required for our tenants’ employees and patients, including equipment, pharmaceuticals and medical supplies, particularly personal protective equipment, or PPE; potential increases to expenses incurred by our tenants related to staffing, supply chain or other expenditures; the impact of our indebtedness and the ability to refinance such indebtedness on acceptable terms; disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact our ability to access capital or increase associated borrowing costs; and changes in general economic conditions nationally and regionally in the markets our properties are located resulting from the COVID-19 pandemic, including higher sustained rates of unemployment and underemployment levels and reduced consumer spending and confidence.  There may be significant declines in future bonus rental revenue earned on our hospital properties leased to subsidiaries of UHS to the extent that each hospital continues to experience significant decline in patient volumes and

22


 

 

revenues. These factors may result in the inability or unwillingness on the part of some of our tenants to make timely payment of their rent to us at current levels or to seek to amend or terminate their leases which, in turn, would have an adverse effect on our occupancy levels and our revenue and cash flow and the value of our properties, and potentially, our ability to maintain our dividend at current levels.

 

 

Due to COVID-19 restrictions and its impact on the economy, we may experience a decrease in prospective tenants which could unfavorably impact the volume of new leases, as well as the renewal rate of existing leases. The COVID-19 pandemic could also impact our indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financing perspective; and changes in general economic conditions nationally and regionally in the markets our properties are located resulting from the COVID-19 pandemic. We are not able to fully quantify the impact that these factors will have on our financial results during 2021, but developments related to the COVID-19 pandemic are likely to have a material adverse impact on our future financial results.

 

 

The Centers for Medicare and Medicaid Services (“CMS”) issued an Interim Final Rule (“IFR”) effective November 5, 2021 mandating COVID-19 vaccinations for all applicable staff at all Medicare and Medicaid certified facilities. Facilities covered by this regulation must establish a policy ensuring all eligible staff have received the first dose of a two-dose COVID-19 vaccine or a one-dose COVID-19 vaccine prior to providing any care, treatment, or other services by December 5, 2021. All eligible staff must have received the necessary shots to be fully vaccinated – either two doses of Pfizer or Moderna or one dose of Johnson & Johnson – by January 4, 2022. The regulation also provides for exemptions based on recognized medical conditions or religious beliefs, observances, or practices. Facilities must develop a similar process or plan for permitting exemptions in alignment with federal law. If facilities fail to comply with the IFR by the deadlines established, they are subject to potential termination from the Medicare and Medicaid program for non-compliance.  In addition, the Occupational Safety and Health Administration also issued an Emergency Temporary Standard requiring all businesses with 100 or more employees to be vaccinated by January 4, 2022.  Those employees not vaccinated by that date will need to show a negative COVID-19 test weekly and wear a face mask in the workplace.  However, healthcare employees at healthcare facilities covered by the CMS IFR will not have the option of weekly COVID-19 testing in lieu of vaccination. Legal challenges to these rules are expected and we cannot predict at this time the potential viability or impact of such litigation.  No assurance can be given that implementation of this IFR will not have a material adverse effect on the staffing, patient volumes, labor costs or results of operations of our operators.

 

 

Recent legislation, including the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), the Paycheck Protection Program and Health Care Enhancement Act (“PPPHCE Act”) and the American Rescue Plan Act of 2021 (“ARPA”), has provided grant funding to hospitals and other healthcare providers to assist them during the COVID-19 pandemic.  There is a high degree of uncertainty surrounding the implementation of the CARES Act, the PPPHCE Act and ARPA, and the federal government may consider additional stimulus and relief efforts, but we are unable to predict whether additional stimulus measures will be enacted or their impact.  There can be no assurance as to the total amount of financial and other types of assistance our tenants will receive under the CARES Act, the PPPHCE Act and the ARPA, and it is difficult to predict the impact of such legislation on our tenants’ operations or how they will affect operations of our tenants’ competitors.  There can be no assurance as to whether our tenants would be required to repay any previously granted funding, due to noncompliance with grant terms or otherwise. Moreover, we are unable to assess the extent to which anticipated negative impacts on our tenants (and, in turn, us) arising from the COVID-19 pandemic will be offset by amounts or benefits received or to be received under the CARES Act, the PPPHCE Act and the ARPA.

 

A substantial portion of our revenues are dependent upon one operator, UHS, which comprised approximately 37% and 34% of our consolidated revenues for the three-month periods ended September 30, 2021 and 2020, respectively and approximately 36% and 33% of our consolidated revenues for the nine-month periods ended September 30, 2021 and 2020, respectively.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended

23


 

 

September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).     

 

In addition, we cannot assure you that subsidiaries of UHS will renew the leases on the hospital facilities and free-standing emergency departments, upon the scheduled expirations of the existing lease terms. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities and FEDs, and do not enter into a substitution arrangement upon expiration of the lease terms or otherwise, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases. Please see Note 7 to the condensed consolidated financial statements - Lease Accounting, for additional information related to the planned transaction with a wholly-owned subsidiary of UHS in connection with Southwest Healthcare System, Inland Valley Campus.

 

In certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties.

 

A number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators.

 

The potential indirect impact of the Tax Cuts and Jobs Act of 2017, signed into law on December 22, 2017, which makes significant changes to corporate and individual tax rates and calculation of taxes, which could potentially impact our tenants and jurisdictions, both positively and negatively, in which we do business, as well as the overall investment thesis for REITs.

 

A subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest.

 

Lost revenues resulting from the exercise of purchase options, lease expirations and renewals and other transactions (see Note 7 to the condensed consolidated financial statements – Lease Accounting for additional disclosure related to lease expirations and subsequent vacancies that occurred during the second and third quarters of 2019 on two hospital facilities and the notice provided by Kindred Healthcare, lessee of one of our other specialty hospitals that they do not intend to renew the lease on its facility which expires on December 31, 2021).

 

Potential unfavorable tax consequences and reduced income resulting from an inability to complete, within the statutory timeframes, our anticipated tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code, as described in Note 4 to the condensed consolidated financial statements – Acquisitions and Divestitures.

 

Our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business.

 

The outcome and effects of known and unknown litigation, government investigations, and liabilities and other claims asserted against us, UHS or the other operators of our facilities. UHS and its subsidiaries are subject to legal actions, purported shareholder class actions and shareholder derivative cases, governmental investigations and regulatory actions and the effects of adverse publicity relating to such matters. Since UHS comprised approximately 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and 36% and 33% of our consolidated revenues during the nine-month period ended September 30, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain and review the disclosures contained in the Legal Proceedings section of Universal Health Services, Inc.’s Forms 10-Q and 10-K, as publicly filed with the Securities and Exchange Commission. Those filings are the sole responsibility of UHS and are not incorporated by reference herein.

 

Failure of UHS or the other operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property.

 

The potential unfavorable impact on our business of the deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities.

 

A deterioration in general economic conditions which could result in increases in the number of people unemployed and/or insured. Under these circumstances, the operators of our facilities may experience declines in patient volumes which could result in decreased occupancy rates at our medical office buildings.

24


 

 

A worsening of the economic and employment conditions in the United States would likely materially affect the business of our operators, including UHS, which would likely unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties.

 

Real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets.

 

The impact of property values and results of operations of severe weather conditions, including the effects of hurricanes.

 

Government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs.

 

The issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed in the next bullet point below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians.

 

The Budget Control Act of 2011 imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the Budget Control Act of 2011. Recent legislation has suspended payment reductions through December 31, 2021 in exchange for extended cuts through 2030.  We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what other federal budget deficit reduction initiatives may be proposed by Congress going forward.  We also cannot predict the effect these enactments will have on the operators of our properties (including UHS), and thus, our business.

 

An increasing number of legislative initiatives have been passed into law that may result in major changes in the health care delivery system on a national or state level. Legislation has already been enacted that has eliminated the penalty for failing to maintain health coverage that was part of the original Patient Protection and Affordable Care Act (the “ACA”). President Biden is expected to undertake executive actions that will strengthen the ACA and may reverse the policies of the prior administration. To date, the Biden administration has issued executive orders implementing a special enrollment period permitting individuals to enroll in health plans outside of the annual open enrollment period and reexamining policies that may undermine the ACA or the Medicaid program. The ARPA’s expansion of subsidies to purchase coverage through an exchange is anticipated to increase exchange enrollment. The Trump Administration had directed the issuance of final rules: (i) enabling the formation of association health plans that would be exempt from certain ACA requirements such as the provision of essential health benefits; (ii) expanding the availability of short-term, limited duration health insurance, (iii) eliminating cost-sharing reduction payments to insurers that would otherwise offset deductibles and other out-of-pocket expenses for health plan enrollees at or below 250 percent of the federal poverty level; (iv) relaxing requirements for state innovation waivers that could reduce enrollment in the individual and small group markets and lead to additional enrollment in short-term, limited duration insurance and association health plans; and (v) incentivizing the use of health reimbursement arrangements by employers to permit employees to purchase health insurance in the individual market.  The uncertainty resulting from these Executive Branch policies had led to reduced Exchange enrollment in 2018, 2019 and 2020, and is expected to further worsen the individual and small group market risk pools in future years.  It is also anticipated that these policies, to the extent that they remain as implemented, may create additional cost and reimbursement pressures on hospitals, including ours. In addition, while attempts to repeal the entirety of the ACA have not been successful to date, a key provision of the ACA was eliminated as part of the Tax Cuts and Jobs Act and on December 14, 2018, a federal U.S. District Court Judge in Texas ruled the entire ACA is unconstitutional. That ruling was appealed and on December 18, 2019, the Fifth Circuit Court of Appeals voted 2-1 to strike down the ACA individual mandate as unconstitutional. The case was ultimately appealed to the United States Supreme Court, which decided in California v. Texas that the plaintiffs in the matter lacked standing to bring their constitutionality claims.  As a result, the Legislation will continue to remain law, in its entirety, likely for the foreseeable future.    

25


 

 

There can be no assurance that if any of the announced or proposed changes described above are implemented there will not be negative financial impact on the operators of our hospitals, which material effects may include a potential decrease in the market for health care services or a decrease in the ability of the operators of our hospitals to receive reimbursement for health care services provided which could result in a material adverse effect on the financial condition or results of operations of the operators of our properties, and, thus, our business.

 

Competition for properties include, but are not limited to, other REITs, private investors and firms, banks and other companies, including UHS.  In addition, we may face competition from other REITs for our tenants.

 

The operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 370-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 130-bed acute care hospital.

 

Changes in, or inadvertent violations of, tax laws and regulations and other factors that can affect REITs and our status as a REIT, including possible future changes to federal tax laws that could materially impact our ability to defer gains on divestitures through like-kind property exchanges.

 

 

The individual and collective impact of the changes made by the CARES Act on REITs and their security holders are uncertain and may not become evident for some period of time; it is also possible additional legislation could be enacted in the future as a result of the COVID-19 pandemic which may affect the holders of our securities.

 

Should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition.

 

Our ownership interest in four LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.  Please see Note 5 to the condensed consolidated financial statements – Summarized Financial Information of Equity Affiliates for additional disclosure related to a fourth quarter, 2021 transaction between us and the minority partner in Grayson Properties, LP.

 

Fluctuations in the value of our common stock.

 

Other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.  

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

26


 

Purchase Accounting for Acquisition of Investments in Real Estate:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, we account for our property acquisitions as acquisitions of assets, which requires the capitalization of acquisition costs to the underlying assets and prohibits the recognition of goodwill or bargain purchase gains. The fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate assumed loans, or loan discounts, in the case of below market assumed loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

 

In allocating the fair value of the identified intangible assets and liabilities of an acquired property, above-market and below-market in-place lease values are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) estimated fair market lease rates from the perspective of a market participant for the corresponding in-place leases, measured, for above-market leases, over a period equal to the remaining non-cancelable term of the lease and, for below-market leases, over a period equal to the initial term plus any below market fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values, also referred to as acquired lease obligations, are amortized as an increase to rental income over the initial terms of the respective leases.

Asset Impairment:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, we account for our property acquisitions as acquisitions of assets, which requires the capitalization of acquisition costs to the underlying assets and prohibits the recognition of goodwill or bargain purchase gains. The fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate assumed loans, or loan discounts, in the case of below market assumed loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

 

Federal Income Taxes:    No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified.  To qualify as a REIT, we must meet

27


 

certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to shareholders. As a REIT, we generally will not be subject to federal, state or local income tax on income that we distribute as dividends to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax was due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

Results of Operations

During the three-month period ended September 30, 2021, net income was $5.3 million, as compared to $5.2 million during the third quarter of 2020.  The $151,000 increase was attributable to:

 

$289,000 of other combined net increases including an aggregate net increase in income generated at various properties, including the income recorded in connection with the newly constructed Clive Behavioral Health facility;

 

$148,000 increase in bonus rentals earned on the three hospital facilities leased to subsidiaries of UHS, and;

 

$286,000 decrease resulting from an increase in interest expense, as discussed below in Interest Expense.

During the nine-month period ended September 30, 2021, net income was $17.6 million, as compared to $14.4 million during the nine-month period of 2020.  The $3.1 million increase was attributable to:

 

$1.3 million increase resulting from the gain recorded during the second quarter of 2021 related to the sale of a medical office building located in Springdale, AR;

 

$1.4 million combined net increase resulting from an aggregate net increase in income generated at various properties, including the income recorded in connection with the newly constructed Clive Behavioral Health facility;

 

$694,000 increase in bonus rentals earned on the three hospital facilities leased to subsidiaries of UHS, and;

 

$277,000 decrease resulting from an increase in interest expense, as discussed below in Interest Expense.

Total revenues increased $1.5 million, or 7.7%, during the three-month period ended September 30, 2021, as compared to the third quarter of 2020, and increased $4.6 million, or 7.9%, during the nine-month period ended September 30, 2021, as compared to the comparable period of 2020.  In addition to the increased revenues generated at various properties, the increases in each period of 2021, as compared to 2020, resulted primarily from the revenue recorded in connection with the Clive Behavioral Health facility located in Clive, Iowa, which was completed in December, 2020, and increased bonus rentals earned on the three hospital facilities leased to wholly-owned subsidiaries of UHS.

Included in our other operating expenses are expenses related to the consolidated medical office buildings and two vacant hospital facilities, which totaled $5.3 million and $4.8 million for the three-month periods ended September 30, 2021 and 2020, respectively, and $15.1 million and $14.2 million for the nine-month periods ended September 30, 2021 and 2020, respectively. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as lease revenue in our condensed consolidated statements of income. Included in our operating expenses for the three months ended September 30, 2021 and 2020, is $225,000 and $153,000, respectively, and $571,000 and $533,000 for the nine months ended September 30, 2021 and 2020, respectively, of aggregate operating expenses related to two vacant hospital facilities located in Corpus Christi, Texas, and Evansville, Indiana.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of gains, such as gains on transactions during the periods presented.  To the extent a REIT recognizes a gain or loss with respect to the sale of incidental assets, the REIT has the option to exclude or include such gains and losses in the calculation of FFO.  We have opted to exclude gains and

28


 

losses from sales of incidental assets in our calculation of FFO.  FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for the three and nine-month periods ended September 30, 2021 and 2020 (in thousands):

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Net income

 

$

5,344

 

 

$

5,193

 

 

$

17,551

 

 

$

14,447

 

Depreciation and amortization expense on consolidated

   investments

 

 

6,813

 

 

 

6,399

 

 

 

20,551

 

 

 

19,160

 

Depreciation and amortization expense on unconsolidated

   affiliates

 

 

460

 

 

 

290

 

 

 

1,196

 

 

 

869

 

Gain on sale of real estate assets

 

 

-

 

 

 

-

 

 

 

(1,304

)

 

 

-

 

Funds From Operations

 

$

12,617

 

 

$

11,882

 

 

$

37,994

 

 

$

34,476

 

Weighted average number of shares outstanding - Diluted

 

 

13,783

 

 

 

13,770

 

 

 

13,777

 

 

 

13,763

 

Funds From Operations per diluted share

 

$

0.92

 

 

$

0.86

 

 

$

2.76

 

 

$

2.50

 

Our FFO increased $735,000, or $.06 per diluted share, during the third quarter of 2021, as compared to the third quarter of 2020.  The net increase was primarily due to: (i) the increase in net income of $151,000, or $.01 per diluted share, as discussed above; (ii) a $584,000, or $.04 per diluted share, increase in depreciation and amortization expense on consolidated and unconsolidated affiliates, due primarily to the depreciation expense recorded on the Clive Behavioral Health facility which was completed in December, 2020.

Our FFO increased $3.5 million, or $.26 per diluted share, during the first nine months of 2021, as compared to the first nine months of 2020.  The net increase was primarily due to: (i) the increase in net income of $3.1 million, or $.22 per diluted share, as discussed above; (ii) a $1.7 million, or $.13 per diluted share, increase in depreciation and amortization expense on consolidated investments and unconsolidated affiliates, due primarily to the depreciation expense recorded on the Clive Behavioral Health facility which was completed in December, 2020, partially offset by the reduction for; (iii) the $1.3 million, or $.09 per diluted share, gain recorded during the first nine months of 2021 related to the sale of a medical office building, since we have historically excluded such gains from our calculation of FFO.  

 

Other Operating Results

Interest Expense:

As reflected in the schedule below, interest expense was $2.3 million and $2.0 million during the three-month periods ended September 30, 2021 and 2020, respectively and $6.6 million and $6.3 million during the nine-month periods ended September 30, 2021 and 2020, respectively (amounts in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months

Ended

September 30,

2021

 

 

Three Months

Ended

September 30,

2020

 

 

Nine Months

Ended

September 30,

2021

 

 

Nine Months

Ended

September 30,

2020

 

Revolving credit agreement

 

$

1,131

 

 

$

948

 

 

$

3,127

 

 

$

3,646

 

Mortgage interest

 

 

623

 

 

 

645

 

 

 

1,887

 

 

 

1,957

 

Interest rate swaps expense/(income), net (a.)

 

 

328

 

 

 

299

 

 

 

957

 

 

 

430

 

Amortization of financing fees

 

 

176

 

 

 

220

 

 

 

608

 

 

 

549

 

Amortization of fair value of debt

 

 

(13

)

 

 

(13

)

 

 

(39

)

 

 

(39

)

Capitalized interest on major projects

 

 

-

 

 

 

(128

)

 

 

-

 

 

 

(254

)

Other interest

 

 

5

 

 

 

(7

)

 

 

26

 

 

 

-

 

Interest expense, net

 

$

2,250

 

 

$

1,964

 

 

$

6,566

 

 

$

6,289

 

        

 

(a.)

Represents net interest paid by us/(to us) by the counterparties pursuant to three interest rate SWAPs with a combined notional amount of $140 million.

Interest expense increased by $286,000 during the three-month period ended September 30, 2021, as compared to the comparable quarter of 2020, due primarily to: (i) a $183,000 increase in the interest expense on our revolving credit agreement primarily resulting from an increase in our average outstanding borrowings ($259.8 million during the three months ended September 30, 2021 as compared to $220.1 million in the comparable quarter of 2020); (ii) a $29,000 net increase in interest rate swap expense; (iii) a

29


 

$128,000 increase in interest expense due to a decrease in capitalized interest on major projects (both newly constructed facilities were substantially completed in December, 2020), and; (iv) $54,000 of other combined net decreases in interest expense.

Interest expense increased by $277,000 during the nine-month period ended September 30, 2021, as compared to the comparable period of 2020, due primarily to: (i) a $519,000 decrease in the interest expense on our revolving credit agreement resulting from a decrease in our average cost of borrowings (1.35% during the nine months ended September 30, 2021 as compared to 1.95% during the comparable nine month period of 2020), partially offset by an increase in our average outstanding borrowings ($249.1 million during the nine-month period ended September 30, 2021 as compared to $216.3 million in the comparable 2020 nine-month period); (ii) a $527,000 net increase in interest rate swap expense; (iii) a $254,000 increase in interest expense due to a decrease in capitalized interest on major projects (both newly constructed facilities were substantially completed in December, 2020); (iv) a $59,000 increase resulting from increased amortization of financing fees, and; (v)  $44,000 of other combined net decreases in interest expense.

 

Disclosures Related to Certain Facilities

Please refer to Note 7 to the condensed consolidated financial statements - Lease Accounting, for additional information regarding certain of our hospital facilities including Wellington Regional Medical Center, Southwest Healthcare System, Inland Valley Campus; Evansville, Indiana; Corpus Christi, Texas; PeaceHealth Medical Clinic, and; Kindred Hospital Chicago Central.  

 

Liquidity and Capital Resources    

Net cash provided by operating activities

Net cash provided by operating activities was $36.2 million during the nine-month period ended September 30, 2021 as compared to $32.8 million during the comparable period of 2020. The $3.4 million net increase was attributable to:

 

a favorable change of $3.3 million due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization related to above/below market leases, amortization of debt premium, amortization of deferred financing costs, stock-based compensation and gain on sale of real estate assets), as discussed above;

 

an unfavorable change of $484,000 in lease receivable;

 

a favorable change of $458,000 in tenant reserves, deposits and deferred and prepaid rents;

 

an unfavorable change of $505,000 in leasing costs paid, and;

 

other combined net favorable changes of $643,000, resulting primarily from the timing of prepaid expense payments.

Net cash used in investing activities

Net cash used in investing activities was $41.2 million during the first nine months of 2021 as compared to $16.8 million during the first nine months of 2020.

During the nine-month period ended September 30, 2021 we funded: (i) $13.0 million, including transaction costs, on the acquisition of the Fire Mesa office building in May, 2021, as discussed in Note 4 to the consolidated financial statements–Acquisitions and Dispositions; (ii) $11.5 million in additions to real estate investments including construction costs related to the 100-bed behavioral health care hospital located in Clive, Iowa, that was substantially completed in late December, 2020, as well as tenant improvements at various MOBs; (iii) a $3.5 million member loan to an unconsolidated LP; (iv) $200,000 in a deposit on real estate assets, and; (v) $16.1 million in equity investments in unconsolidated LLCs. In addition, during the nine-months ended September 30, 2021, we received approximately $3.2 million of net cash proceeds from the sale of the Children’s Clinic of Springdale as discussed in Note 4 to the consolidated financial statements–Acquisitions and Dispositions.

During the nine-month period ended September 30, 2020 we funded: (i) $18.8 million in additions to real estate investments including $14.4 million of construction costs related to the Clive Behavioral Health facility, and tenant improvements at various MOBs, and; (ii) $3.2 million in equity investments in unconsolidated LLCs. In addition, during the nine-months ended September 30, 2020, we received $5.2 million of cash distributions from our unconsolidated LLCs, consisting of proceeds generated from a construction loan obtained by Grayson Properties II during the second quarter of 2020.

Net cash provided by/(used in) financing activities

Net cash provided by financing activities was $8.6 million during the nine months ended September 30, 2021, as compared to $15.8 million of cash used in financing activities during the nine months ended September 30, 2020.

30


 

During the nine-month period ended September 30, 2021, we paid: (i) $1.6 million on mortgage notes payable that are non-recourse to us; (ii) $1.8 million of financing costs, primarily related to the July 2, 2021 amended and restated revolving credit agreement, and; (iii) $28.8 million of dividends. Additionally, during the nine months ended September 30, 2021, we received: (i) $40.6 million of net borrowings on our revolving credit agreement, and; (ii) $159,000 of net cash from the issuance of shares of beneficial interest.

During the nine-month period ended September 30, 2020, we paid: (i) $1.4 million on mortgage notes payable that are non-recourse to us; (ii) $372,000 of financing costs related to the revolving credit agreement in place at that time, including amendment fees, and; (iii) $28.4 million of dividends.  Additionally, during the nine months ended September 30, 2020, we received: (i) $14.2 million of net borrowings on our revolving credit agreement, and; (ii) $266,000 of net cash from the issuance of shares of beneficial interest, as discussed below.

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. No shares were issued pursuant to this ATM equity program during the first nine months of 2021. Since inception pursuant to this ATM equity program, we have issued 2,704 shares at an average price of $101.30 per share which generated approximately $270,000 of net cash proceeds (net of compensation to BofA Securities, Inc. of approximately $4,000).  Additionally, we paid or incurred approximately $508,000 in various fees and expenses related to the commencement of our ATM program.  

Additional cash flow and dividends paid information for the nine-month periods ended September 30, 2021 and 2020:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $36.2 million and $32.8 million during the nine-month periods ended September 30, 2021 and 2020, respectively. As also indicated on our statement of cash flows, non-cash expenses including depreciation and amortization expense, amortization related to above/below market leases, amortization of debt premium, amortization of deferred financing costs and stock-based compensation expense, as well as the gain on sale of real estate assets are the primary differences between our net income and net cash provided by operating activities during each period.

We declared and paid dividends of $28.8 million and $28.4 million during the nine-month periods ended September 30, 2021 and 2020, respectively. During the first nine months of 2021, the $36.2 million of net cash provided by operating activities was approximately $7.4 million greater than the $28.8 million of dividends paid during the first nine months of 2021. During the first nine months of 2020, the $32.8 million of net cash provided by operating activities was approximately $4.4 million greater than the $28.4 million of dividends paid during the first nine months of 2020.  

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the nine months ended September 30, 2021 and 2020.  From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows, management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our $375 million revolving credit agreement (which had $94.6 million of available borrowing capacity, net of outstanding borrowings and letters of credit as of September 30, 2021); (ii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our consolidated and unconsolidated LLCs/LPs; (iii) the issuance of equity pursuant to our ATM program, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit agreement and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access

31


 

the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

Credit facilities and mortgage debt

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On July 2, 2021, we entered into an amended and restated revolving credit agreement (“Credit Agreement”) to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020 (“Prior Credit Agreement”). Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million.  The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trust’s wholly-owned subsidiaries.

Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans. The initial applicable margin is 1.25% for LIBOR loans and 0.25% for Base Rate loans. The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. The Trust will also pay a quarterly commitment fee ranging from 0.15% to 0.35% (depending on the Trust’s ratio of debt to asset value) of the average daily unused portion of the revolving credit commitments.  The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods.

The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At September 30, 2021, the applicable margin over the LIBOR rate was 1.25%, the margin over the Base Rate was 0.25% and the facility fee was 0.25%.  

At September 30, 2021, we had $276.8 million of outstanding borrowings and $3.6 million of letters of credit outstanding under our Credit Agreement. We had $94.6 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2021. There are no compensating balance requirements.  At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our Prior Credit Agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at September 30, 2021 and were in compliance with all of the covenants in the Prior Credit Agreement at December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

32


 

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):

 

 

Covenant

 

September 30,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

141,419

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.6

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.1

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

47.2

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan (b.)

 

$

5,268

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,337

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,395

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,458

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,866

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,494

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,530

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,333

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

57,681

 

 

 

 

 

 

 

     Less net financing fees

 

 

(387

)

 

 

 

 

 

 

     Plus net debt premium

 

 

103

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

57,397

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of September 30, 2021 had a combined fair value of approximately $60.3 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million.

Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

 

Off Balance Sheet Arrangements

As of September 30, 2021, we are party to certain off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments.  Our outstanding letters of credit at September 30, 2021 totaled $3.6 million related to Grayson Properties II.  As of December 31, 2020 we had off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments. Our outstanding letters of credit at December 31, 2020 totaled $5.6 million related to Grayson Properties II.

Acquisition and Divestiture Activity

Please see Note 4 to the consolidated financial statements for completed transactions.

33


 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes in the quantitative and qualitative disclosures during the first nine months of 2021, except for the additional disclosure below.  

Financial Instruments

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At September 30, 2021, the fair value of our interest rate swaps was a net liability of $556,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the third quarter of 2021, we paid or accrued approximately $324,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first nine months of 2021, we paid or accrued approximately $945,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps.  From inception of the swap agreements through September 30, 2021 we paid or accrued approximately $1.6 million in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.8 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.

The sensitivity analysis related to our fixed and variable rate debt assumes current market rates with all other variables held constant. As of September 30, 2021, the fair value and carrying value of our debt is approximately $337.1 million and $334.5 million, respectively. As of that date, the fair value exceeds the carrying value by approximately $2.6 million.

The table below presents information about our financial instruments that are sensitive to changes in interest rates. The interest rate swaps include the $50 million swap agreement entered into during the third quarter of 2019, the $35 million swap agreement entered into in January, 2020 and the $55 million swap agreement entered into in March, 2020. For debt obligations, the amounts of which are as of September 30, 2021, the table presents principal cash flows and related weighted average interest rates by contractual maturity dates.

 

 

 

Maturity Date, Year Ending December 31

 

(Dollars in thousands)

 

2021

 

 

2022

 

 

2023

 

 

2024

 

 

2025

 

 

Thereafter

 

 

Total

 

Long-term debt:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fixed rate:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Debt(a)

 

$

529

 

 

$

12,197

 

 

$

11,892

 

 

$

13,551

 

 

$

939

 

 

$

18,573

 

 

$

57,681

 

Average interest rates

 

 

4.3

%

 

 

4.4

%

 

 

4.4

%

 

 

4.4

%

 

 

4.3

%

 

 

4.3

%

 

 

4.3

%

Variable rate:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Debt(b)

 

$

 

 

$

 

 

$

 

 

$

 

 

$

276,800

 

 

$

 

 

$

276,800

 

Average interest rates

 

 

 

 

 

 

 

 

 

 

1.3

%

 

 

 

 

1.3

%

Interest rate swaps:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notional amount(c)

 

$

 

 

$

 

 

$

 

 

$

85,000

 

 

$

 

 

$

55,000

 

 

$

140,000

 

Interest rates

 

 

 

 

 

 

 

 

1.320

%

 

 

 

 

0.565

%

 

 

1.070

%

34


 

 

 

(a)

Consists of non-recourse mortgage notes payable.

 

(b)

Includes $276.8 million of outstanding borrowings under the terms of our $375 million revolving credit agreement which has a maturity date of July 2, 2025.

 

(c)

Includes a $50 million interest rate swap that became effective on September 16, 2019, and a $35 million interest rate swap that became effective on January 15, 2020, both of which are scheduled to mature during 2024. Additionally, included is a $55 million interest rate swap that became effective on March 25, 2020, which is scheduled to mature in 2027.

As calculated based upon our variable rate debt outstanding as of September 30, 2021 that is subject to interest rate fluctuations, and giving effect to the above-mentioned interest rate swap, each 1% change in interest rates would impact our net income by approximately $1.4 million.

Item 4. Controls and Procedures

As of September 30, 2021, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first nine months of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

35


 

 

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2020 includes a listing of risk factors to be considered by investors in our securities.  There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 6. Exhibits

 

(a.)

Exhibits:

 

 

 

 

 

 

  10.1

 

Amended and Restated Credit Agreement, dated as of July 2, 2021 among Universal Health Realty Income Trust, the Lenders Party thereto and Wells Fargo Bank, National Association, as Administrative Agent, Bank of America, N.A., as Syndication Agent and Fifth Third Bank, N.A., JPMorgan Chase Bank, N.A. and Truist Bank as Co-Documentation Agents, Wells Fargo Securities, LLC and BOFA Securities, Inc., as Joint Lead Arrangers and Joint Bookrunners previously filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K dated July 2, 2021, is incorporated herein by reference.

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data file because iXBRL tags are embedded within the Inline XBRL document

 

 

 

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

   104

 

Cover Page Interactive Data file (formatted as Inline XBRL and contained in Exhibit 101)

 

 

36


 

 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date:  November 8, 2021

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Registrant)

 

 

 

 

 

/s/ Alan B. Miller 

 

 

Alan B. Miller,

 

 

Chairman of the Board,

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

/s/ Charles F. Boyle 

 

 

Charles F. Boyle, Vice President and Chief Financial Officer

(Principal Financial Officer)

 

37

EX-31.1 2 uht-ex311_8.htm EX-31.1 uht-ex311_8.htm

 

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2021

 

/s/ Alan B. Miller 

President and Chief Executive Officer

 

 

EX-31.2 3 uht-ex312_7.htm EX-31.2 uht-ex312_7.htm

 

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 8, 2021

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

 

 

EX-32.1 4 uht-ex321_6.htm EX-32.1 uht-ex321_6.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Alan B. Miller

President and Chief Executive Officer

November 8, 2021

 

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 uht-ex322_9.htm EX-32.2 uht-ex322_9.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

November 8, 2021

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.SCH 6 uht-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Changes in Equity link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100080 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Dividends and Equity Issuance Program link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Acquisitions and Divestitures link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Lease Accounting link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Lease Accounting (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Lease Accounting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 uht-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 uht-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 uht-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lease and other receivables. Lease receivable, other. Equity method investment summarized financial information assets property plant and equipment net. Equity method investment summarized financial information other assets. Equity Method Investment Summarized Financial Information Other Liabilities Equity Method Investment Summarized Financial Information Mortgage Notes Payable Equity method investment summarized financial information advance payment to loans to related party. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Income Statement [Abstract] Statement [Table] Statement [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Related-party principal tenant. UHS Facilities Universal Health Services Inc [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Other Product And Service Other [Member] Management Service Management Service [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Non related party. Non-Related Parties Non Related Party [Member] Statement [Line Items] Statement [Line Items] Revenues: Revenues [Abstract] Lease revenue Operating Lease Lease Income Other revenue Revenue From Contract With Customer Including Assessed Tax Revenues, Total Revenues Expenses: Costs And Expenses [Abstract] Depreciation and amortization Depreciation And Amortization Advisory fees to UHS Cost Of Goods And Services Sold Other operating expenses Other Cost And Expense Operating Costs and Expenses, Total Costs And Expenses Income before equity in income of unconsolidated limited liability companies ("LLCs"), gain on sale and interest expense Operating Income Loss Equity in income of unconsolidated LLCs Income Loss From Equity Method Investments Gain on sale of real estate assets Gain Loss On Disposition Of Assets Interest expense, net Interest Income Expense Net Net income Net Income Loss Basic earnings per share Earnings Per Share Basic Diluted earnings per share Earnings Per Share Diluted Weighted average number of shares outstanding - Basic Weighted Average Number Of Shares Outstanding Basic Weighted average number of shares outstanding - Diluted Weighted Average Number Of Diluted Shares Outstanding Bonus rental income. Universal health services hospital Inc. UHS Hospital Facilities Universal Health Services Hospital Inc [Member] Bonus rental Bonus Rental Income Statement Of Income And Comprehensive Income [Abstract] Net income Other comprehensive (loss)/gain: Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] Unrealized derivative gains/(loss) on cash flow hedges Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax Total other comprehensive gains/(loss): Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Total comprehensive income Comprehensive Income Net Of Tax Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches. Statement Of Financial Position [Abstract] Assets: Assets [Abstract] Real Estate Investments: Real Estate Investments [Abstract] Buildings and improvements and construction in progress Real Estate Investment Property At Cost Accumulated depreciation Real Estate Investment Property Accumulated Depreciation Real Estate Investment Property, Net, Total Real Estate Investment Property Net Land Land Net Real Estate Investments Real Estate Investments Investments in and advances to limited liability companies ("LLCs") Investments In And Advances To Affiliates At Fair Value Other Assets: Other Assets [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Lease and other receivables from UHS Lease And Other Receivables Lease receivable - other Lease Receivable Other Intangible assets (net of accumulated amortization of $17.7 million and $19.5 million, respectively) Intangible Assets Net Excluding Goodwill Right-of-use land assets, net Operating Lease Right Of Use Asset Deferred charges and other assets, net Deferred Costs And Other Assets Assets of property held for sale Assets Of Disposal Group Including Discontinued Operation Total Assets Assets Liabilities: Liabilities [Abstract] Line of credit borrowings Line Of Credit Mortgage notes payable, non-recourse to us, net Secured Debt Accrued interest Interest Payable Current And Noncurrent Accrued expenses and other liabilities Accrued Liabilities And Other Liabilities Ground lease liabilities, net Operating Lease Liability Tenant reserves, deposits and deferred and prepaid rents Tenant Reserves Deposits And Deferred And Prepaid Rents Liabilities of property held for sale Liabilities Of Disposal Group Including Discontinued Operation Total Liabilities Liabilities Equity: Stockholders Equity [Abstract] Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock Value Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,784,401; 2020 - 13,771,287 Common Stock Value Capital in excess of par value Additional Paid In Capital Common Stock Cumulative net income Retained Earnings Accumulated Deficit Cumulative dividends Cumulative Dividends Accumulated other comprehensive loss Accumulated Other Comprehensive Income Loss Net Of Tax Total Equity Stockholders Equity Total Liabilities and Equity Liabilities And Stockholders Equity Intangible assets, accumulated amortization Finite Lived Intangible Assets Accumulated Amortization Preferred shares of beneficial interest, par value Preferred Stock Par Or Stated Value Per Share Preferred shares of beneficial interest, shares authorized Preferred Stock Shares Authorized Preferred shares of beneficial interest, issued Preferred Stock Shares Issued Preferred shares of beneficial interest, outstanding Preferred Stock Shares Outstanding Common shares, par value Common Stock Par Or Stated Value Per Share Common shares, shares authorized Common Stock Shares Authorized Common shares, issued Common Stock Shares Issued Common shares, outstanding Common Stock Shares Outstanding Shares of beneficial interest. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Capital in excess of par value Additional Paid In Capital [Member] Cumulative net income Retained Earnings [Member] Cumulative dividends. Cumulative dividends Cumulative Dividends [Member] Accumulated other comprehensive income/(loss) Accumulated Other Comprehensive Income [Member] Balance Stockholders Equity Including Portion Attributable To Noncontrolling Interest Balance, Shares Shares Outstanding Shares of Beneficial Interest: Shares Of Beneficial Interest [Abstract] Issued, net Stock Issued During Period Value New Issues Issued (in shares) Stock Issued During Period Shares New Issues Repurchased Stock Repurchased During Period Value Repurchased (in shares) Stock Repurchased During Period Shares Restricted stock-based compensation expense Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition Dividends Dividends Comprehensive income: Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest [Abstract] Net income Unrealized net gain (loss) on cash flow hedges Subtotal - comprehensive income Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest Balance Balance, Shares Dividends, per share. Dividend, per share Dividends Per Share Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents. Increase decrease in leasing costs. Equity investment distribution. Payments for deposit on real estate assets. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net income Profit Loss Adjustments to reconcile net income to net cash provided by operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization related to above/below market leases, net Amortization Of Above And Below Market Leases Amortization of debt premium Amortization Of Debt Discount Premium Amortization of deferred financing costs Amortization Of Financing Costs Stock-based compensation expense Share Based Compensation Gain on sale of real estate assets Changes in assets and liabilities: Increase Decrease In Operating Capital [Abstract] Lease receivable Increase Decrease In Leasing Receivables Accrued expenses and other liabilities Increase Decrease In Accrued Liabilities And Other Operating Liabilities Tenant reserves, deposits and deferred and prepaid rents Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents Accrued interest Increase Decrease In Accrued Interest Receivable Net Leasing costs paid Increase Decrease In Leasing Costs Other, net Increase Decrease In Other Operating Capital Net Net cash provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Investments in LLCs Payments To Acquire Investments Cash distributions from LLCs Cash Distributions In Excess Of Income From Limited Liability Companies Advance made to LLC Payments To Fund Longterm Loans To Related Parties Additions to real estate investments, net Real Estate Period Increase Decrease Deposit on real estate assets Payments For Deposit On Real Estate Assets Net cash paid for acquisition of property Payments To Acquire Property Plant And Equipment Cash proceeds received from sale of property, net Proceeds From Sale Of Real Estate Heldforinvestment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Net borrowings on line of credit Proceeds From Lines Of Credit Repayments of mortgage notes payable Repayments Of Secured Debt Financing costs paid Payments Of Financing Costs Dividends paid Payments Of Dividends Issuance of shares of beneficial interest, net Proceeds From Issuance Or Sale Of Equity Net cash provided by/(used in) financing activities Net Cash Provided By Used In Financing Activities Increase in cash and cash equivalents Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash and cash equivalents, end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Net Invoices accrued for construction and improvements Construction In Progress Expenditures Incurred But Not Yet Paid Organization Consolidation And Presentation Of Financial Statements [Abstract] General Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Related Party Transactions [Abstract] Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Related Party Transactions Disclosure [Text Block] Equity [Abstract] Dividends and Equity Issuance Program Stockholders Equity Note Disclosure [Text Block] Business Combinations [Abstract] Acquisitions and Divestitures Mergers Acquisitions And Dispositions Disclosures [Text Block] Equity Method Investments And Joint Ventures [Abstract] Summarized Financial Information of Equity Affiliates Equity Method Investments Disclosure [Text Block] Accounting Policies [Abstract] Recent Accounting Pronouncements New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Disclosures of leases. Leases [Abstract] Lease Accounting Disclosures Of Leases [Text Block] Debt and financial instruments disclosure. Debt Disclosure [Abstract] Debt and Financial Instruments Debt And Financial Instruments Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities Schedule Of Property Subject To Or Available For Operating Lease [Text Block] Limited Liability Companies Accounted for Under Equity Method Equity Method Investments [Text Block] Equity Method Investments Summarized Income Statement Information. Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Income Statement Information Table [Text Block] Equity Method Investments Summarized Combined Balance Sheet Information. Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block] Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block] Components of lessor lease revenue with UHS facilities and non-related parties. Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block] Schedule of Financial Covenants. Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement Schedule Of Financial Covenants Table [Text Block] Outstanding Mortgages, Excluding Net Debt Premium Schedule Of Debt Instruments [Text Block] Number of real estate properties including property under construction. Organization consolidation and presentation of financial statements. Organization consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Limited liability company or limited partner. Limited Liability Companies Limited Liability Company Or Limited Partner [Member] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Unconsolidated limited liabilities or limited partner. 4 Unconsolidated Limited Liability Companies / Limited Partner Unconsolidated Limited Liabilities Or Limited Partner [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Ownership Ownership [Axis] Ownership Ownership [Domain] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Grayson Properties Grayson Properties [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Non-controlling equity interest, ownership percentage Equity Method Investment Ownership Percentage Number of real estate investments Number Of Real Estate Properties Including Property Under Construction Minority ownership interest held by a third-party Minority Interest Ownership Percentage By Noncontrolling Owners Initial lease expiration period. Renewal option terms additional period. Number of renewal options. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Universal Health Services, Inc Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Revenue. Revenues Revenue [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Tenants. Tenants Tenants [Member] Lease Contractual Term Lease Contractual Term [Axis] Lease Contractual Term Lease Contractual Term [Domain] Base rents. Base Rents Base Rents [Member] Bonus rents. Bonus Rents Bonus Rents [Member] Major Property Class Major Property Class [Axis] Major Property Class Major Property Class [Domain] UHS-related hospital facility. Southwest Healthcare System, Inland Valley Campus Southwest Healthcare System Inland Valley Campus [Member] Fire Mesa office building located in Las Vegas. Fire Mesa Office Building [Member] Fire Mesa Office Building [Member] Grayson properties two LP. Grayson Properties Two L P Grayson Properties Two L P [Member] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] Denison, Texas. Denison Texas Denison Texas [Member] Universal Health Services, Inc and Catholic Health Initiatives. Universal Health Services Inc And Catholic Health Initiatives Universal Health Services Inc And Catholic Health Initiatives [Member] Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT Universal Health Services of Delaware Inc Universal Health Services Of Delaware Inc [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Initial lease terms Initial Lease Expiration Period Number of term renewal options Number Of Renewal Options Additional renewal terms Renewal Option Terms Additional Period Number of hospital facilities leased Number Of Real Estate Properties Number of leased properties for medical office buildings and free standing emergency departments. Percentage of revenues generated from leases and tenants Concentration Risk Percentage1 Number of medical office buildings and free standing emergency departments Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments Lease renewal, notice period. Period to purchase respective leased facilities after lease terms. Renewal option terms maximum additional period. Option to renew lease, notice period prior to termination date of current term Lease Renewal Notice Period Period to purchase respective leased facilities at same price after lease terms Period To Purchase Respective Leased Facilities After Lease Terms Renewal period of respective leased facilities at same price after lease terms Renewal Option Terms Maximum Additional Period Operating leases, number of renewal options at existing lease rates. Number of renewal options at existing lease rate Operating Leases Number Of Renewal Options At Existing Lease Rates Operating leases, annual future minimum payments receivable. Schedule Of Operating Leased Assets [Table] Schedule Of Operating Leased Assets [Table] UHS-related hospital facility. McAllen Medical Center Mc Allen Medical Center [Member] UHS-related hospital facility. Wellington Regional Medical Center Wellington Regional Medical Center [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Annual Minimum Rent Operating Leases Annual Future Minimum Payments Receivable Lease expiration, month and year. End of Lease Term Lease Expiration Month And Year Renewal Term (years) Lessor Operating Lease Renewal Term Operating leases, renewal options term at existing lease rate. Operating leases, renewal options at existing lease rate, expiration year. Operating leases, number of renewal options at fair market value lease rates. Operating leases, renewal options term at fair market value lease rates. Operating leases, renewal options at fair market value lease rates, expiration year. Number of renewal option at existing lease rate Renewal option term at existing lease rate Operating Leases Renewal Options Term At Existing Lease Rate Renewal option at existing lease rate expiration year Operating Leases Renewal Options At Existing Lease Rate Expiration Year Number of renewal options at fair market value lease rates Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates Renewal options term at fair market value lease rates Operating Leases Renewal Options Term At Fair Market Value Lease Rates Renewal options at fair market value lease rates expiration year Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year Lease expiration date Lease Expiration Date1 Ownership percentage upon completion of the minority ownership purchase Minority Interest Ownership Percentage By Parent Minority ownership interest Minority Interest Lease percentage. Payment to acquire business Payments To Acquire Businesses Gross Lease percentage Lease Percentage Master flex lease term. Percentage of rentable square feet. Master flex lease term Master Flex Lease Term Percentage of rentable square feet Percentage Of Rentable Square Feet Triple net lease agreement period. Renewal options term. Change in control of trust notice period, description. Triple net lease agreement period Triple Net Lease Agreement Period Renewal option term Renewal Options Term Project manager's aggregate fee Property Management Fee Revenue Change in control of trust notice, description Change In Control Of Trust Notice Period Description Number of ground leases. Operating lease remaining lease term. Lessee operating lease liability payments due after year four. Number of ground leases Number Of Ground Leases Remaining lease terms on ground leases Operating Lease Remaining Lease Term Aggregate lease payments for 2021 Lessee Operating Lease Liability Payments Remainder Of Fiscal Year Aggregate lease payments for 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months Aggregate lease payments for 2023 Lessee Operating Lease Liability Payments Due Year Two Aggregate lease payments for 2024 Lessee Operating Lease Liability Payments Due Year Three Aggregate lease payments for 2025 Lessee Operating Lease Liability Payments Due Year Four Aggregate lease payments for thereafter Lessee Operating Lease Liability Payments Due After Year Four Annual advisory fees as percentage of average invested real estate assets. Average invested real estate assets. Annual advisory fee as percentage of average invested real estate assets Annual Advisory Fees As Percentage Of Average Invested Real Estate Assets Advisory fee Cost, Product and Service [Extensible List] Type Of Cost Good Or Service Extensible List Average invested real estate assets Average Invested Real Estate Assets Percentage of ownership interest related parties. Percentage ownership of outstanding shares Percentage Of Ownership Interest Related Parties Dividends and equity issuance. Dividends and equity issuance. Dividends And Equity Issuance [Table] Dividends And Equity Issuance [Table] Investment Type Investment Type [Axis] Investments Investment Type Categorization [Member] Shelf registration. At-The-Market Equity Issuance Program (ATM) At Market A T M Programs [Member] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Other Expenses Other Expense [Member] Dividends and Equity Issuance [Line Items] Dividends And Equity Issuance [Line Items] Dividends declared and paid Declared and paid dividends, per share Common Stock Dividends Per Share Cash Paid Aggregate sales of threshold amount. Aggregate sales of threshold amount Aggregate Sales Of Threshold Amount Shares issued average price per share. Payments for stock issuance other fees and expenses. Share issued Average sale price per share Shares Issued Average Price Per Share Net cash proceeds from stock issued Proceeds From Issuance Of Common Stock Payment of stock issuance cost Payment Of Financing And Stock Issuance Costs Payments for stock issuance Payments For Stock Issuance Other Fees And Expenses Business acquisitions and dispositions. Business acquisitions and dispositions. Business Acquisitions And Dispositions [Table] Business Acquisitions And Dispositions [Table] Disposal Group Name Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis] Disposal Group Name Disposal Groups Including Discontinued Operations Name [Domain] Auburn Medical Office Building II. Auburn Medical Office Building II Auburn Medical Office Building I I [Member] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Medical office buildings. Medical Office Buildings Medical Office Buildings [Member] Business Acquisitions And Dispositions [Line Items] Business Acquisitions And Dispositions [Line Items] Sale price Disposal Group Including Discontinued Operation Consideration Percentage of building area leased. Total purchase price Business Combination Consideration Transferred1 Percentage of building area leased Percentage Of Building Area Leased Rentable square feet Net Rentable Area Disposal group including discontinued operation consideration net of closing costs. Sale price net of closing costs Disposal Group Including Discontinued Operation Consideration Net Of Closing Costs Number of acquisitions Number Of Businesses Acquired Number of businesses disposed. Number of dispositions Number Of Businesses Disposed Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Real Estate Property Ownership Real Estate Properties [Axis] Real Estate Properties Real Estate Properties [Domain] Schedule Of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Number of real estate investments Purchase price Payments To Acquire Additional Interest In Subsidiaries Property owned by limited liability or limited partner company. Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Equity Method Investments Equity Method Investments [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Suburban Properties Suburban Properties [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest Brunswick Associates Brunswick Associates [Member] Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest FTX MOB Phase II limited partnership F T X Mob Phase Two L P [Member] Grayson Properties II LP Ownership Property Owned by LLC/LP Property Owned By Limited Liability Or Limited Partner Company Repayment of loan. Member loan used to repay mortgage loan. Commitments to invest. Construction loan outstanding balance. Third-party term loan Long Term Loans Payable Repayment of loan Repayment Of Loan Member loan used to repay mortgage loan Member Loan Used To Repay Mortgage Loan Commitment to investment Investment Commitments Construction loan Construction Loan Construction loan outstanding balance Construction Loan Outstanding Balance Equity method investment, summarized financial information, operating expenses. Equity method investment summarized financial information depreciation and amortization. Equity method investment summarized financial information interest expense. Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Equity Method Investment Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee or Group of Investees Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member] Revenues Operating expenses Equity Method Investment Summarized Financial Information Operating Expenses Depreciation and amortization Equity Method Investment Summarized Financial Information Depreciation And Amortization Interest, net Equity Method Investment Summarized Financial Information Interest Expense Net income Our share of net income Equity method investments accrued expenses and other liabilities. Net property, including construction in progress Equity Method Investment Summarized Financial Information Assets Property Plant And Equipment Net Other assets Equity Method Investment Summarized Financial Information Other Assets Other liabilities Equity Method Investment Summarized Financial Information Other Liabilities Mortgage notes payable, non-recourse to us Equity Method Investment Summarized Financial Information Mortgage Notes Payable Advances payable to us Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party Equity Investments in LLCs before amounts included in accrued expenses and other liabilities Amounts included in accrued expenses and other liabilities Equity Method Investments Accrued Expenses And Other Liabilities Our share of equity in LLCs, net Equity Method Investments Debt instrument, maturity, month and year. Right-of-use land assets Right-of-use land liabilities Debt Instrument Maturity Date Debt Instrument Maturity Month And Year Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest FTX MOB Phase II F T X Mob Phase Two [Member] Mortgage Loan Balance Number of trading period. Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member Number Of Trading Period Leases Disclosure [Line Items] Leases Disclosure [Table] Leases Disclosure [Table] Leases Disclosure [Table] Tenant reimbursements. Tenant Reimbursements Tenant Reimbursements [Member] Leases Disclosure [Line Items] Leases Disclosure [Line Items] Peace Health Medical Clinic Bellingham, WA. PeaceHealth Medical Clinic Bellingham WA Peace Health Medical Clinic Bellingham W A [Member] Kindred Chicago Central Hospital Central Chicago, Illinois. Kindred Chicago Central Hospital Central Chicago, Illinois Kindred Chicago Central Hospital Central Chicago Illinois [Member] Evansville Rehabilitation Hospital Evansville, Indiana. Evansville Rehabilitation Hospital Evansville, Indiana Evansville Rehabilitation Hospital Evansville Indiana [Member] Corpus Christi Corpus Christi, Texas. Corpus Christi Corpus Christi Texas Corpus Christi Corpus Christi Texas [Member] Extended lease expiration date. Number of additional lease term. Lease, Renewal Term Lessee Operating Lease Renewal Term Extended Lease Expiration Date Extended Lease Expiration Date Number of Additional Lease Term Number Of Additional Lease Term Number of bed in specialty hospital. Number of beds in specialty hospital Number Of Bed In Specialty Hospital Number of ground leases for land. Lessee in connection with ground leases for land Number Of Ground Leases For Land Ground lease liabilities Line of credit facility expiration year and month. Line of credit increase in borrowing capacity. Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Debt Instrument [Table] Debt Instrument [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Revolving credit agreement. Credit Agreement Revolving Credit Agreement [Member] Short-term Debt, Type Short Term Debt Type [Axis] Short-term Debt, Type Short Term Debt Type [Domain] Letters of Credit Letter Of Credit [Member] Financial Instrument Financial Instrument [Axis] Financial Instruments Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain] Swingline/Short-Term Loans Short Term Debt [Member] Revolving A facility. Revolving A Facility Revolving A Facility [Member] Variable Rate Variable Rate [Axis] Variable Rate Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate L I B O R [Member] Base Rate Base Rate [Member] Federal funds effective rate. Federal Funds Effective Rate Federal Funds Effective Rate [Member] Revolving B facility. Revolving B Facility Revolving B Facility [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 2 Fair Value Inputs Level2 [Member] Derivative Instrument Derivative Instrument Risk [Axis] Derivative Contract Derivative Contract Type [Domain] Interest Rate Swap Interest Rate Swap [Member] Hedging Relationship Derivative Instruments Gain Loss By Hedging Relationship [Axis] Hedging Relationship Hedging Relationship [Domain] Cash Flow Hedge Cash Flow Hedging [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Outstanding borrowing Line Of Credit Facility Maximum Borrowing Capacity Unsecured revolving amended credit agreement terminated date Line Of Credit Facility Expiration Year And Month Proceeds from lines of credit Increase in borrowing capacity Line Of Credit Increase In Borrowing Capacity Margin on base rate. Credit facility, Interest Rate Terms Debt Instrument Interest Rate Terms Margin points added to the reference rate Debt Instrument Basis Spread On Variable Rate1 Margin points added to the base rate Margin On Base Rate Base rate description Debt Instrument Description Of Variable Rate Basis Facility fee payable on commitment Line Of Credit Facility Commitment Fee Percentage Number of extension options. Number of additional six month extension options Number Of Extension Options Outstanding borrowings under revolving credit agreement Letters of credit outstanding Letters Of Credit Outstanding Amount Available borrowing capacity Line Of Credit Facility Remaining Borrowing Capacity Compensating balance Compensating Balance Amount Debt instrument covenant unencumbered leverage ratio. Debt instrument covenant fixed charge coverage ratio. Debt instrument covenant tangible net worth. Debt instrument covenant leverage ratio. Debt instrument covenant compliance secured leverage ratio. Covenant, Tangible net worth Debt Instrument Covenant Tangible Net Worth Covenant, Total leverage Debt Instrument Covenant Leverage Ratio Covenant, Secured leverage Debt Instrument Covenant Compliance Secured Leverage Ratio Covenant, Unencumbered leverage Debt Instrument Covenant Unencumbered Leverage Ratio Covenant, Fixed charge coverage Debt Instrument Covenant Fixed Charge Coverage Ratio Tangible net worth. Leverage ratio. Secured leverage ratio. Unencumbered leverage ratio. Fixed charge coverage ratio. Tangible net worth Tangible Net Worth Total leverage Leverage Ratio Secured leverage Secured Leverage Ratio Unencumbered leverage Unencumbered Leverage Ratio Fixed charge coverage Fixed Charge Coverage Ratio SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type Mortgage Loans On Real Estate Loan Type [Axis] SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type Mortgage Loans On Real Estate Loan Type [Domain] Seven hundred shadow lane and goldring medical office building fixed rate mortgage loan. Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan [Member] BRB medical office building fixed rate mortgage loan. BRB Medical Office Building Fixed Rate Mortgage Loan B R B Medical Office Building Fixed Rate Mortgage Loan [Member] Desert valley medical center fixed rate mortgage loan. Desert Valley Medical Center Fixed Rate Mortgage Loan Desert Valley Medical Center Fixed Rate Mortgage Loan [Member] Two seven zero four north Tenaya way fixed rate mortgage loan. 2704 North Tenaya Way Fixed Rate Mortgage Loan Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member] Summerlin hospital medical office building three fixed rate mortgage loan. Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member] Debt Instrument 100% consolidated Tuscan Professional Building Fixed Rate Mortgage Loan Tuscany Professional Building Fixed Rate Mortgage Loan [Member] Phoenix children's east valley care center fixed rate mortgage loan. Phoenix Children’s East Valley Care Center Fixed Rate Mortgage Loan Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member] Rosenberg children's medical plaza fixed rate mortgage loan. Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member] Outstanding Balance Non Recourse Debt Debt Instrument Interest Rate Stated Percentage Debt Instrument Interest Rate Stated Percentage Financing fees net. Less net financing fees Financing Fees Net Plus net debt premium Debt Instrument Unamortized Premium Total mortgages notes payable, non-recourse to us, net Mortgage debt. Mortgage loan fair value Long Term Debt Fair Value Mortgage debt Mortgage Debt Number of interest rate cap agreements Derivative Number Of Instruments Held Derivative instruments, fixed rate Derivative Fixed Interest Rate Notional amount Derivative Notional Amount Expiration date of interest rate Derivative Maturity Dates Derivative interest rate cap, net payment received or accrued from counter parties. Derivative interest rate cap payment received or accrued from counter parties. Derivative interest rate cap payment offset due to counter parties. Liability derivatives, fair value Derivative Fair Value Of Derivative Liability Derivative interest rate cap, net payment received or accrued from counterparties Derivative Interest Rate Cap Net Payment Received Or Accrued From Counter Parties Derivative interest rate cap, payment received or accrued from counterparties Derivative Interest Rate Cap Payment Received Or Accrued From Counter Parties Derivative interest rate cap, offset due to counterparties Derivative Interest Rate Cap Payment Offset Due To Counter Parties Number of reportable segments Number Of Reportable Segments EX-101.PRE 10 uht-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 uht-10q_20210930_htm.xml IDEA: XBRL DOCUMENT 0000798783 2021-01-01 2021-09-30 0000798783 2021-10-31 0000798783 uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember 2020-01-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2021-07-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2020-07-01 2020-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-09-30 0000798783 us-gaap:ProductAndServiceOtherMember 2020-01-01 2020-09-30 0000798783 2021-07-01 2021-09-30 0000798783 2020-07-01 2020-09-30 0000798783 2020-01-01 2020-09-30 0000798783 us-gaap:ManagementServiceMember 2021-07-01 2021-09-30 0000798783 us-gaap:ManagementServiceMember 2020-07-01 2020-09-30 0000798783 us-gaap:ManagementServiceMember 2021-01-01 2021-09-30 0000798783 us-gaap:ManagementServiceMember 2020-01-01 2020-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesHospitalIncMember 2020-01-01 2020-09-30 0000798783 2021-09-30 0000798783 2020-12-31 0000798783 us-gaap:CommonStockMember 2020-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000798783 us-gaap:RetainedEarningsMember 2020-12-31 0000798783 uht:CumulativeDividendsMember 2020-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000798783 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-01-01 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000798783 us-gaap:CommonStockMember 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000798783 us-gaap:CommonStockMember 2021-06-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000798783 us-gaap:RetainedEarningsMember 2021-06-30 0000798783 uht:CumulativeDividendsMember 2021-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000798783 2021-06-30 0000798783 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000798783 uht:CumulativeDividendsMember 2021-07-01 2021-09-30 0000798783 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000798783 us-gaap:CommonStockMember 2019-12-31 0000798783 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000798783 us-gaap:RetainedEarningsMember 2019-12-31 0000798783 uht:CumulativeDividendsMember 2019-12-31 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000798783 2019-12-31 0000798783 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-01-01 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000798783 us-gaap:CommonStockMember 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000798783 2020-09-30 0000798783 us-gaap:CommonStockMember 2020-06-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000798783 us-gaap:RetainedEarningsMember 2020-06-30 0000798783 uht:CumulativeDividendsMember 2020-06-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000798783 2020-06-30 0000798783 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0000798783 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000798783 uht:CumulativeDividendsMember 2020-07-01 2020-09-30 0000798783 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000798783 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000798783 srt:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-09-30 0000798783 srt:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2021-09-30 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:SubsequentEventMember 2021-11-08 0000798783 srt:MinimumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:TenantsMember uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-09-30 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 srt:MinimumMember uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember uht:WellingtonRegionalMedicalCenterMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 srt:MinimumMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:BaseRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:BaseRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:BonusRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:BonusRentsMember uht:SouthwestHealthcareSystemInlandValleyCampusMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-12-31 0000798783 uht:FireMesaOfficeBuildingMember 2021-05-01 2021-05-31 0000798783 uht:GraysonPropertiesTwoLPMember uht:DenisonTexasMember 2019-09-30 0000798783 uht:UniversalHealthServicesIncMember 2019-09-01 2019-09-30 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-01 2019-07-31 0000798783 uht:UniversalHealthServicesIncAndCatholicHealthInitiativesMember 2019-07-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-07-01 2021-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-07-01 2020-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2021-01-01 2021-09-30 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2020-01-01 2020-09-30 0000798783 uht:UniversalHealthServicesIncMember 2020-12-31 0000798783 uht:AtMarketATMProgramsMember 2020-06-30 0000798783 uht:AtMarketATMProgramsMember 2021-01-01 2021-09-30 0000798783 uht:AtMarketATMProgramsMember 2020-04-01 2020-06-30 0000798783 us-gaap:OtherExpenseMember uht:AtMarketATMProgramsMember 2021-01-01 2021-09-30 0000798783 uht:AuburnMedicalOfficeBuildingIIMember us-gaap:SubsequentEventMember 2021-11-01 0000798783 uht:FireMesaOfficeBuildingMember uht:UniversalHealthServicesIncMember 2021-05-01 2021-05-31 0000798783 uht:UniversalHealthServicesIncMember 2021-05-31 0000798783 uht:MedicalOfficeBuildingsMember 2021-06-01 2021-06-30 0000798783 uht:MedicalOfficeBuildingsMember 2021-01-01 2021-09-30 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:SubsequentEventMember 2021-10-01 2021-11-08 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:BrunswickAssociatesMember 2021-09-30 0000798783 uht:GraysonPropertiesMember 2021-07-01 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember 2021-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-03-31 0000798783 uht:GraysonPropertiesTwoLPMember srt:MaximumMember uht:DenisonTexasMember 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-07-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-07-01 2020-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-01-01 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-01-01 2020-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember 2020-12-31 0000798783 uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoLPMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 us-gaap:EquityMethodInvestmentsMember 2021-09-30 0000798783 uht:FTXMobPhaseTwoMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0000798783 uht:FTXMobPhaseTwoMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2021-01-01 2021-09-30 0000798783 uht:GraysonPropertiesTwoLPMember 2021-09-30 0000798783 uht:FTXMobPhaseTwoLPMember 2021-09-30 0000798783 srt:MinimumMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember 2021-01-01 2021-09-30 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:BaseRentsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:BonusRentsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2021-07-01 2021-09-30 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2020-07-01 2020-09-30 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2021-01-01 2021-09-30 0000798783 uht:TenantReimbursementsMember uht:UniversalHealthServicesIncMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:BaseRentsMember 2020-01-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-07-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-07-01 2020-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2021-01-01 2021-09-30 0000798783 uht:NonRelatedPartyMember uht:TenantReimbursementsMember 2020-01-01 2020-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2021-01-01 2021-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2021-09-30 0000798783 uht:PeaceHealthMedicalClinicBellinghamWAMember 2020-01-01 2020-12-31 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2021-01-01 2021-09-30 0000798783 uht:KindredChicagoCentralHospitalCentralChicagoIllinoisMember 2020-01-01 2020-12-31 0000798783 uht:EvansvilleRehabilitationHospitalEvansvilleIndianaMember 2021-01-01 2021-09-30 0000798783 uht:CorpusChristiCorpusChristiTexasMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 2021-07-02 0000798783 uht:RevolvingCreditAgreementMember 2021-07-02 0000798783 uht:RevolvingAFacilityMember 2021-01-01 2021-09-30 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2018-03-27 0000798783 us-gaap:BaseRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember uht:FederalFundsEffectiveRateMember 2018-03-27 2018-03-27 0000798783 srt:MinimumMember uht:RevolvingAFacilityMember 2018-03-27 2018-03-27 0000798783 srt:MaximumMember uht:RevolvingAFacilityMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingBFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingBFacilityMember us-gaap:BaseRateMember 2021-01-01 2021-09-30 0000798783 uht:RevolvingBFacilityMember 2021-01-01 2021-09-30 0000798783 srt:MaximumMember 2021-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-09-30 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:BRBMedicalOfficeBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:DesertValleyMedicalCenterFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2021-01-01 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-03-01 2020-03-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2020-01-01 2020-01-31 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-09-30 0000798783 us-gaap:InterestRateSwapMember 2021-01-01 2021-09-30 0000798783 us-gaap:FairValueInputsLevel2Member 2021-01-01 2021-09-30 0000798783 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member 2021-07-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:Hospital uht:RenewalOption uht:Lease utr:sqft uht:Acquisition uht:Disposition uht:Bed uht:Land uht:Option uht:Derivative uht:Segment false Q3 0000798783 --12-31 3 1 2 2 http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember http://fasb.org/us-gaap/2021-01-31#ManagementServiceMember 0.0050 1 1 1 3 1 2 2 P5Y P5Y 0.0050 1 1 1 P5Y P10Y P10Y 125000000 0.60 0.30 0.60 0.0150 10-Q true 2021-09-30 2021 false 1-9321 UNIVERSAL HEALTH REALTY INCOME TRUST MD 23-6858580 UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA PA 19406 610 265-0688 Shares of beneficial interest, $0.01 par value UHT NYSE Yes Yes Large Accelerated Filer false false false 13784412 7574000 6381000 21971000 18243000 13115000 12841000 39324000 38526000 236000 232000 669000 667000 280000 238000 816000 744000 21205000 19692000 62780000 58180000 6813000 6399000 20551000 19160000 1121000 1039000 3272000 3082000 5980000 5614000 17485000 16573000 13914000 13052000 41308000 38815000 7291000 6640000 21472000 19365000 303000 517000 1341000 1371000 1304000 -2250000 -1964000 -6566000 -6289000 5344000 5193000 17551000 14447000 0.39 0.38 1.28 1.05 0.39 0.38 1.27 1.05 13762 13748 13755 13741 13783 13770 13777 13763 1828000 1680000 5171000 4477000 5344000 5193000 17551000 14447000 471000 234000 3259000 -5709000 471000 234000 3259000 -5709000 5815000 5427000 20810000 8738000 610338000 605292000 230827000 216648000 379511000 388644000 56947000 55157000 436458000 443801000 23123000 4278000 9347000 5742000 4246000 3199000 6841000 7504000 17700000 19500000 10392000 11742000 8891000 8914000 11012000 8829000 7371000 517681000 494009000 276800000 236200000 57397000 58895000 352000 351000 11261000 19802000 8891000 8914000 11092000 10842000 77000 365870000 335004000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13784401 13784401 13771287 13771287 138000 138000 268232000 267368000 698278000 680727000 814281000 785413000 -556000 -3815000 151811000 159005000 517681000 494009000 13771 138000 267368000 680727000 -785413000 -3815000 159005000 13 161000 161000 16000 16000 719000 719000 2.095 28868000 28868000 17551000 17551000 3259000 3259000 17551000 3259000 20810000 13784 138000 268232000 698278000 -814281000 -556000 151811000 13783 138000 267951000 692934000 -804632000 -1027000 155364000 1 55000 55000 226000 226000 0.70 9649000 9649000 5344000 5344000 471000 471000 5344000 471000 5815000 13784 138000 268232000 698278000 -814281000 -556000 151811000 13757 138000 266723000 661280000 -747417000 1010000 181734000 14 -317000 -317000 665000 665000 2.065 28426000 28426000 14447000 14447000 -5709000 -5709000 14447000 -5709000 8738000 13771 138000 267071000 675727000 -775843000 -4699000 162394000 13770 138000 266843000 670534000 -766342000 -4933000 166240000 1 -20000 -20000 248000 248000 0.69 9501000 9501000 5193000 5193000 234000 234000 5193000 234000 5427000 13771 138000 267071000 675727000 -775843000 -4699000 162394000 17551000 14447000 20551000 19160000 -139000 -140000 -38000 -39000 609000 549000 719000 665000 1304000 457000 -27000 201000 49000 272000 -186000 -1000 -159000 1250000 745000 522000 1171000 36194000 32775000 16138000 3204000 5196000 3500000 -11537000 -18784000 200000 12989000 3209000 -41155000 -16792000 40600000 14150000 1550000 1406000 1813000 372000 28830000 28411000 159000 266000 8566000 -15773000 3605000 210000 5742000 6110000 9347000 6320000 5995000 5620000 151000 5660000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) General</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of September 30, 2021, we had investments in five jointly-owned LLCs/LPs (subsequent to September 30, 2021, we purchased the 5% third-party minority ownership interest in one of the jointly-owned LPs, as discussed in Note 5). We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.   </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. </p> 0.33 0.95 5 0.05 <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases:<span style="font-style:normal;"> We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined revenues generated from the leases on the three hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% and 23% of our consolidated revenues for the three months ended September 30, 2021 and 2020, respectively, and approximately 22% of our consolidated revenues for each of the nine months ended September 30, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have nineteen medical office buildings (“MOBs”), general office buildings or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and approximately 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditions of any third-party offer, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (ii) renew the lease on the respective leased facility at the end of, and for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180 days</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after, the lease term at the same terms and conditions pursuant to any third-party offer.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our <span style="-sec-ix-hidden:F_000411">three</span> hospitals operated by wholly-owned subsidiaries of UHS:  </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Hospital Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000418">5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000419">10</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000420">10</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000421_2">one</span> 5-year renewal option at the existing lease rate (through 2031).  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000424_2">two</span> 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has notified us of their intent to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled termination of the current lease term on December 31, 2021. UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  See below for additional disclosure. </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UHS has <span style="-sec-ix-hidden:F_000428_2">two</span> 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  <span style="Background-color:#FFFFFF;color:#000000;">As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right </span>to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. <span style="Background-color:#FFFFFF;">The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021</span><span style="Background-color:#FFFFFF;font-size:12pt;">.</span><span style="Background-color:#FFFFFF;"> Pursuant to the terms of the lease on </span><span style="Background-color:#FFFFFF;color:#000000;">the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).</span>  </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2021, we purchased the 5% minority ownership interest held by a third-party member in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for approximately $3.1 million. The MOB is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS. A third-party appraisal was completed to determine the fair value of the property.  As a result of this minority ownership purchase during the fourth quarter of 2021, we subsequently own 100% of the LP and we will therefore begin consolidating this LP effective with the purchase date.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  Please see Note 5 for additional disclosure surrounding this transaction.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May, 2021, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million.  The building is 100% leased under the terms of a triple net lease by a wholly-owned subsidiary of UHS.  The initial lease is scheduled to expire on August 31, 2027 and has two five-year renewal options.  As discussed in Note 4, the acquisition of this office building is part of an anticipated series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.     </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020, at which time the hospital lease commenced. Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are estimated to be approximately $508,000 during each of the years ended 2021 through 2025, and an aggregate of $29.0 million thereafter. <span style="color:#000000;">See Note 7 for additional lease accounting disclosure.</span> <span style="color:#FF0000;font-size:14pt;"> </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Officers and Employees:<span style="font-style:normal;"> Our officers are all employees of a wholly-owned subsidiary of UHS and although as of September 30, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advisory Agreement:   <span style="font-style:normal;">UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our advisory fee for the three and nine months ended September 30, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended September 30, 2021 and 2020, respectively, and were based upon average invested real estate assets of $641 million and $594 million, respectively. Advisory fees incurred and paid (or payable) to UHS were approximately $3.3 million and $3.1 million for the nine months ended September 30, 2021 and 2020, and were based upon average invested real estate assets of $623 million and $587 million, respectively.   </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Ownership:<span style="font-style:normal;"> As of September 30, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SEC reporting requirements of UHS:<span style="font-style:normal;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein</span>.</p> P13Y P15Y 6 P5Y 3 0.22 0.23 0.22 0.22 19 0.37 0.34 0.36 0.33 P90D P180D P180D The table below details the existing lease terms and renewal options for our <span style="-sec-ix-hidden:F_000411">three</span> hospitals operated by wholly-owned subsidiaries of UHS: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Hospital Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2026</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000418">5</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000419">10</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000420">10</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000421_2">one</span> 5-year renewal option at the existing lease rate (through 2031).  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has <span style="-sec-ix-hidden:F_000424_2">two</span> 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has notified us of their intent to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled termination of the current lease term on December 31, 2021. UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  See below for additional disclosure. </p></td></tr></table></div> 5485000 2026-12 3030000 2021-12 2648000 2021-12 P5Y 2031 P5Y 2022 2031 P5Y 2022 2031 2021-12-31 3400000 2000000.0 1400000 4400000 2600000 1800000 0.05 3100000 1 12900000 1 2027-08-31 0.95 P10Y 0.50 P20Y 5 P10Y 750000 P270D P270D upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right) 12 P28Y P78Y 508000 508000 508000 508000 508000 29000000.0 0.0070 0.0070 0.0070 0.0070 1100000 1000000.0 641000000 594000000 3300000 3100000 623000000 587000000 0.057 0.057 0.37 0.34 0.36 0.33 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) Dividends and Equity Issuance Program</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends and dividend equivalents:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.70 per share. We declared and paid dividends of approximately $9.5 million, or $.69 per share, during the third quarter of 2020.  During the nine-month period ended September 30, 2021 we declared and paid dividends of approximately $28.8 million, or $2.095 per share.  During the nine-month period ended September 30, 2020, we declared and paid dividends of approximately $28.4 million, or $2.065 per share. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first nine months of 2021 and will be paid upon vesting of the restricted stock.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Issuance Program:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:7pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No shares were issued pursuant to this ATM equity program during the first nine months of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of September 30, 2021, we have paid or incurred approximately $508,000 in various fees and expenses related to the commencement of our ATM program. </p> 9600000 0.70 9500000 0.69 28800000 2.095 28400000 2.065 100000000 0 2704 101.30 270000 4000 508000 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) Acquisitions and Divestitures    </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2021 and during the fourth quarter of 2021, we completed three transactions as described below utilizing qualified third-party intermediaries, as part of a series of anticipated tax-deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code. </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2021:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we entered into an agreement to sell the Auburn Medical Office Building II.  On November 1, 2021 we settled on the sale of the Auburn Medical Office Building II, a multi-tenant MOB located in Auburn, Washington to a non-related party for a sale price of approximately $25.1 million.  The gain on this divestiture will be included in our consolidated statement of income for the three and twelve-month periods ended December 31, 2021.  The assets and liabilities related to this property are included in “Assets of property held for sale” or “Liabilities of property held for sale” on our consolidated balance sheet as of September 30, 2021.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30, 2021:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisition:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million. The building, which has approximately 44,000 rentable square feet, is 100% leased under the terms of a triple net lease with a wholly-owned subsidiary of UHS.  The lease on this building is scheduled to expire on August 31, 2027 and has two <span style="-sec-ix-hidden:F_000505">five-year</span> renewal options. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Divestiture:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we sold the Children’s Clinic at Springdale, a medical office building located in Springdale, AR for a sale price of approximately $3.2 million, net of closing costs. This divestiture resulted in a gain of approximately $1.3 million which is included in our consolidated statement of income for the nine-month period ended September 30, 2021.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30, 2020:    </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no acquisitions during the first nine months of 2020.<span style="color:#FF0000;">  </span> </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Divestitures:    </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no dispositions during the first nine months of 2020.</p> 25100000 12900000 44000 1 2 3200000 1300000 0 0 <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) Summarized Financial Information of Equity Affiliates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.  </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subsequent to September 30, 2021, we purchased the third-party 5% ownership interest in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for a purchase price of approximately $3.1 million.  We formerly held a non-controlling majority ownership interest in this LP.  As a result of our purchase of the minority ownership interest, we now hold 100% of the ownership interest in this LP and we will begin accounting for this LP on a consolidated basis effective with the minority ownership interest purchase date. The property’s assets and liabilities will be recorded at the carrying amount of its previously held interest, plus the incremental cost which will be allocated based upon relative fair values.  A third-party appraisal was completed to determine the fair value of the property.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of September 30, 2021:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)(e.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (d.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza II</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">his LP</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> paid off its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mortgage</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, upon maturity,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilizing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pro rata </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity contributions from the limited partners as well as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million member loan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the LP</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funded utilizing borrowings from our revolving credit agreement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The LLC is the lessee with a third-party lessor under a ground lease for land.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">These LPs are the lessees with UHS-related parties for the land related to these properties.</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the five LLCs/LPs accounted for under the equity method at September 30, 2021 and the four LLCs/LPs accounted for under the equity method as September 30, 2020 (the 2020 periods do not include the newly constructed Texoma Medical Plaza II that was substantially completed in December, 2020).      </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="8" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,184</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,047</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,094</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,073</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,261</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of September 30, 2021 and December 31, 2020:     </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,484</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,818</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities (a.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,674</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in and advances to LLCs before amounts included in</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   accrued expenses and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,227</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.   </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.<br/></span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9/30/2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2021</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan) (c.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (3.70% fixed rate construction loan) (d.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,075</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,336</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (2.80% fixed rate mortgage loan)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,058</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,250</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2030</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.</span><span style="color:#000000;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The minority partner in Grayson Properties, LP, as the Offering Member, made an offer to sell its entire 5% ownership interest to us at a stipulated price, and we agreed to purchase the ownership interest at the stipulated price of approximately $3.1 million. The transaction was completed during the fourth quarter of 2021, as discussed above. </p> 0.33 0.95 5 0.05 3100000 1 <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following property table represents the five LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of September 30, 2021:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)(e.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (d.)(f.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza II</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"/><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2021, t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">his LP</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> paid off its </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mortgage</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, upon maturity,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilizing </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pro rata </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equity contributions from the limited partners as well as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million member loan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the LP</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funded utilizing borrowings from our revolving credit agreement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021. </p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The LLC is the lessee with a third-party lessor under a ground lease for land.</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:4.54%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">These LPs are the lessees with UHS-related parties for the land related to these properties.</p></td></tr></table></div> 0.33 St. Matthews Medical Plaza II 0.74 Mid Coast Hospital MOB 0.95 Texoma Medical Plaza 0.95 Forney Medical Plaza II 0.95 Texoma Medical Plaza II 9100000 13200000 0.05 3100000 1 4700000 3500000 4800000 13100000 13100000 Below are the condensed combined statements of income (unaudited) for the five LLCs/LPs accounted for under the equity method at September 30, 2021 and the four LLCs/LPs accounted for under the equity method as September 30, 2020 (the 2020 periods do not include the newly constructed Texoma Medical Plaza II that was substantially completed in December, 2020).      <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="8" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.94%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.66%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,736</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,624</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,373</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,184</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,047</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,356</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,094</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.08%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">444</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">388</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">315</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,260</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">537</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,073</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,261</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.08%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">303</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">    </p> 2736000 2624000 8373000 7637000 1184000 1047000 3356000 3094000 627000 444000 1684000 1333000 388000 315000 1260000 949000 537000 818000 2073000 2261000 303000 517000 1341000 1371000 <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of September 30, 2021 and December 31, 2020:     </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,789</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,374</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,484</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,818</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities (a.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,966</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,133</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Advances payable to us (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,500</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,674</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,055</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,273</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,192</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in and advances to LLCs before amounts included in</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.74%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   accrued expenses and other liabilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,123</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   Amounts included in accrued expenses and other liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,896</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,020</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.74%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,227</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.   </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.<br/></span></p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 42789000 42374000 9484000 8818000 52273000 51192000 6966000 9402000 22133000 39735000 3500000 19674000 2055000 52273000 51192000 23123000 4278000 1896000 3020000 21227000 1258000 4300000 4300000 4300000 4300000 2023-03 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of LLC/LP</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9/30/2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,777</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%; border-top:solid 0.75pt #000000;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February, 2021</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan) (c.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,372</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.96%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties II (3.70% fixed rate construction loan) (d.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,075</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,336</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (2.80% fixed rate mortgage loan)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,058</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,250</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2030</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.96%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,133</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.16%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.</span><span style="color:#000000;"> </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:0.46%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.07%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="color:#000000;">This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.</span></p></td></tr></table></div> 4777000 2021-02 13372000 2021-09 13075000 12336000 2025-06 9058000 9250000 2030-12 22133000 39735000 3500000 13100000 P60D P90D 0.05 3100000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) Recent Accounting Pronouncements</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Accounting for Lease Concessions Granted in Connection with COVID-19</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&amp;A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, </span><span style="font-style:italic;Background-color:#FFFFFF;">Leases, </span><span style="Background-color:#FFFFFF;">which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">      </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Based on the Q&amp;A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three and nine months ended September 30, 2021 or the year ended December 31, 2020.</span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Reference Rate Reform</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) Lease Accounting</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:inherit;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">As Lessor:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We lease our operating properties to customers under agreements that are classified as operating leases. <span style="color:#000000;">We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease. </span> We<span style="font-family:inherit;"> have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and nine months ended September 30, 2021 and 2020.  </span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and nine month periods ended September 30, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UHS facilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,392</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,820</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus rents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - UHS facilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,574</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,381</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,971</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-related parties:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,390</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,425</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,899</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - Non-related parties</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,115</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,841</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disclosures Related to Certain Facilities:   </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to Wellington Regional Medical Center.  The current lease on this facility is scheduled to expire on December 31, 2021.  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  <span style="Background-color:#FFFFFF;color:#000000;">As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right </span>to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. <span style="Background-color:#FFFFFF;">The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021</span><span style="Background-color:#FFFFFF;font-size:12pt;">.</span><span style="Background-color:#FFFFFF;"> Pursuant to the terms of the lease on </span><span style="Background-color:#FFFFFF;color:#000000;">the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $<span>1.4 million</span> in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PeaceHealth Medical Clinic:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The existing lease on the PeaceHealth Medical Clinic, an MOB located in Bellingham, Washington was scheduled to expire on December 31, 2021.  In July, 2021, the lease was renewed for an additional seven year term, extending the scheduled expiration date to January 31, 2029.  The tenant also has two additional <span style="-sec-ix-hidden:F_000651">five-year</span> renewal terms.  Additionally, the tenant has the right of first offer to purchase the property if the property is marketed by us; and the tenant has an option to purchase the property at the end of the lease term at the then fair market value.  Pursuant to the terms of the lease on the PeaceHealth Medical Clinic, we earned $2.1 million of lease revenue during the nine-month period ended September 30, 2021 and $2.8 million of lease revenue during the year ended December 31, 2020.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kindred Hospital Chicago Central:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously disclosed, the existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility notified us that they do not intend to renew the lease upon its scheduled expiration. We are marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $1.2 million of lease revenue during the nine-month period ended September 30, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Vacancies - Evansville, Indiana and Corpus Christi, Texas:<span style="color:#FF0000;">    </span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <span style="font-style:italic;font-family:inherit;">As Lessee:</span></p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments.<span style="color:#000000;font-size:9pt;font-family:Arial;"> </span>A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similarly to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. <span style="color:#000000;font-family:Times New Roman;">As of September 30, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. </span><span style="font-family:Times New Roman;">There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the nine months ended September 30, 2021.</span></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and nine month periods ended September 30, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">UHS facilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,392</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,402</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,820</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,940</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bonus rents</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,828</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,680</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,171</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,477</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">354</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">826</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - UHS facilities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,574</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,381</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,971</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,243</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-related parties:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base rents</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,421</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,390</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,425</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.56%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,155</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant reimbursements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,694</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,451</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,899</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,371</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease revenue - Non-related parties</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,115</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,841</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,324</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.56%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,526</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 5392000 4402000 15820000 12940000 1828000 1680000 5171000 4477000 354000 299000 980000 826000 7574000 6381000 21971000 18243000 10421000 10390000 31425000 31155000 2694000 2451000 7899000 7371000 13115000 12841000 39324000 38526000 P5Y 2022 2031 2021-12-31 P5Y 2022 2031 2021-12-31 2021-12-31 3400000 2000000.0 1400000 1400000 4400000 2600000 2600000 1800000 1800000 2021-12-31 P7Y 2029-01-31 2 2100000 2800000 95 2021-12-31 1200000 1600000 2019-05-31 2019-06-01 14 8900000 8900000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) Debt and Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 2, 2021, we entered into an amended and restated revolving credit agreement (“Credit Agreement”) to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020 (“Prior Credit Agreement”). Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million.  The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trust’s wholly-owned subsidiaries.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans. The initial applicable margin is 1.25% for LIBOR loans and 0.25% for Base Rate loans. The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus <span style="-sec-ix-hidden:F_000680_2">1/2</span> of 1% and (c) one month LIBOR plus 1%. The Trust will also pay a quarterly commitment fee ranging from 0.15% to 0.35% (depending on the Trust’s ratio of debt to asset value) of the average daily unused portion of the revolving credit commitments.  The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At September 30, 2021, the applicable margin over the LIBOR rate was </span>1.25<span style="Background-color:#FFFFFF;">%, the margin over the Base Rate was </span>0.25<span style="Background-color:#FFFFFF;">% and the facility fee was 0.25%.</span>   </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2021, we had $276.8 million of outstanding borrowings and $3.6 million of letters of credit outstanding under our Credit Agreement. We had $94.6 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our Prior Credit Agreement and $108.2 million of available borrowing capacity. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at September 30, 2021 and were in compliance with all of the covenants in the Prior Credit Agreement at December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">&gt; =$125,000</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000694">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000695">&lt; 30%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000696">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000697">&gt; 1.50x</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Facility Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="font-family:Calibri;"> </span>thousands) (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,268</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,395</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,458</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,866</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,494</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children's Medical Plaza fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2033</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,681</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Less net financing fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(387</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Plus net debt premium</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,397</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.</span></p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of September 30, 2021 had a combined fair value of approximately $60.3 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Instruments:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we entered into <span style="-sec-ix-hidden:F_000739_2">an</span> interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, we entered into <span style="-sec-ix-hidden:F_000746_2">an</span> interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2019, we entered into <span style="-sec-ix-hidden:F_000753_2">an</span> interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR. </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At September 30, 2021, the fair value of our interest rate swaps was a net liability of $556,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the third quarter of 2021, we paid or accrued approximately $324,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first nine months of 2021, we paid or accrued approximately $945,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. From inception of the swap agreements through September 30, 2021 we paid or accrued approximately $1.6 million in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.8 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.  We do not expect any gains or losses on our interest rate swaps to be reclassified to earnings in the next twelve months.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> 350000000 375000000 350000000 2025-07-02 375000000 40000000 30000000 50000000 Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans. 0.0110 0.0135 0.0010 0.0035 0.0125 0.0025 the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. 0.01 0.0015 0.0035 2 0.0125 0.0025 0.0025 276800000 3600000 94600000 0 236200000 108200000 <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000693">&gt; =$125,000</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,419</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,263</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000694">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000695">&lt; 30%</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000696">&lt; 60%</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.58%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.74%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000697">&gt; 1.50x</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.9%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.58%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7x</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 141419000 147263000 0.456 0.448 0.081 0.086 0.472 0.414 0.048 0.047 <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Facility Name</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<span style="font-family:Calibri;"> </span>thousands) (a.)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan (b.)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,268</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2022</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,337</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2022</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,395</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2023</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,458</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   rate mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,866</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2024</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,494</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June, 2025</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children’s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   mortgage loan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children's Medical Plaza fixed rate mortgage loan</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,333</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.42</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2033</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,681</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Less net financing fees</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(387</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">     Plus net debt premium</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,397</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. </span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.33%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"> </p></td> <td style="width:4.58%;white-space:nowrap" valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b.)</span></p></td> <td valign="top"> <p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.</span></p></td></tr></table></div> 5268000 0.0454 2022-06 5337000 0.0427 2022-12 4395000 0.0362 2023-01 6458000 0.0495 2023-11 12866000 0.0403 2024-04 2494000 0.0556 2025-06 8530000 0.0395 2030-01 12333000 0.0442 2033-09 57681000 387000 103000 57397000 60300000 59200000 62000000.0 55000000 0.00565 2027-03-25 0.00565 0.00565 0.00565 35000000 0.014975 2024-09-16 0.014975 0.014975 0.014975 50000000 0.01144 2024-09-16 0.01144 0.01144 0.01144 556000 324000 945000 1600000 199000 1800000 <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(9) Segment Reporting</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.</p> 1 The LLC is the lessee with a third-party lessor under a ground lease for land. These LPs are the lessees with UHS-related parties for the land related to these properties. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively. UHS has one 5-year renewal option at the existing lease rate (through 2031).   UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.   This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP. During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021. Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023. This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023. This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021. Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement. Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS. Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement. XML 12 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2021
Oct. 31, 2021
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST  
Entity Central Index Key 0000798783  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Common Stock, Shares Outstanding   13,784,412
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 1-9321  
Entity Tax Identification Number 23-6858580  
Entity Address, Address Line One UNIVERSAL CORPORATE CENTER  
Entity Address, Address Line Two 367 SOUTH GULPH ROAD  
Entity Address, City or Town KING OF PRUSSIA  
Entity Address, State or Province PA  
Entity Address, Postal Zip Code 19406  
City Area Code 610  
Local Phone Number 265-0688  
Entity Interactive Data Current Yes  
Title of 12(b) Security Shares of beneficial interest, $0.01 par value  
Trading Symbol UHT  
Security Exchange Name NYSE  
Entity Incorporation, State or Country Code MD  
Document Quarterly Report true  
Document Transition Report false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Income - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenues:        
Revenues, Total $ 21,205 $ 19,692 $ 62,780 $ 58,180
Expenses:        
Depreciation and amortization 6,813 6,399 20,551 19,160
Other operating expenses 5,980 5,614 17,485 16,573
Costs and Expenses, Total 13,914 13,052 41,308 38,815
Income before equity in income of unconsolidated limited liability companies ("LLCs"), gain on sale and interest expense 7,291 6,640 21,472 19,365
Equity in income of unconsolidated LLCs 303 517 1,341 1,371
Gain on sale of real estate assets     1,304  
Interest expense, net (2,250) (1,964) (6,566) (6,289)
Net income $ 5,344 $ 5,193 $ 17,551 $ 14,447
Basic earnings per share $ 0.39 $ 0.38 $ 1.28 $ 1.05
Diluted earnings per share $ 0.39 $ 0.38 $ 1.27 $ 1.05
Weighted average number of shares outstanding - Basic 13,762 13,748 13,755 13,741
Weighted average number of shares outstanding - Diluted 13,783 13,770 13,777 13,763
Non-Related Parties        
Revenues:        
Lease revenue $ 13,115 $ 12,841 $ 39,324 $ 38,526
Other        
Revenues:        
Other revenue 280 238 816 744
Management Service        
Expenses:        
Advisory fees to UHS 1,121 1,039 3,272 3,082
UHS Facilities        
Revenues:        
Lease revenue [1] 7,574 6,381 21,971 18,243
UHS Facilities | Other        
Revenues:        
Other revenue $ 236 $ 232 $ 669 $ 667
[1] Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Income (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
UHS Hospital Facilities        
Bonus rental $ 1,828 $ 1,680 $ 5,171 $ 4,477
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]        
Net income $ 5,344 $ 5,193 $ 17,551 $ 14,447
Other comprehensive (loss)/gain:        
Unrealized derivative gains/(loss) on cash flow hedges 471 234 3,259 (5,709)
Total other comprehensive gains/(loss): 471 234 3,259 (5,709)
Total comprehensive income $ 5,815 $ 5,427 $ 20,810 $ 8,738
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Real Estate Investments:    
Buildings and improvements and construction in progress $ 610,338 $ 605,292
Accumulated depreciation (230,827) (216,648)
Real Estate Investment Property, Net, Total 379,511 388,644
Land 56,947 55,157
Net Real Estate Investments 436,458 443,801
Investments in and advances to limited liability companies ("LLCs") 23,123 4,278
Other Assets:    
Cash and cash equivalents 9,347 5,742
Lease and other receivables from UHS 4,246 3,199
Lease receivable - other 6,841 7,504
Intangible assets (net of accumulated amortization of $17.7 million and $19.5 million, respectively) 10,392 11,742
Right-of-use land assets, net 8,891 8,914
Deferred charges and other assets, net 11,012 8,829
Assets of property held for sale 7,371  
Total Assets 517,681 494,009
Liabilities:    
Line of credit borrowings 276,800 236,200
Mortgage notes payable, non-recourse to us, net 57,397 [1] 58,895
Accrued interest 352 351
Accrued expenses and other liabilities 11,261 19,802
Ground lease liabilities, net 8,891 8,914
Tenant reserves, deposits and deferred and prepaid rents 11,092 10,842
Liabilities of property held for sale 77  
Total Liabilities 365,870 335,004
Equity:    
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,784,401; 2020 - 13,771,287 138 138
Capital in excess of par value 268,232 267,368
Cumulative net income 698,278 680,727
Cumulative dividends (814,281) (785,413)
Accumulated other comprehensive loss (556) (3,815)
Total Equity 151,811 159,005
Total Liabilities and Equity $ 517,681 $ 494,009
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2021
Dec. 31, 2020
Statement Of Financial Position [Abstract]    
Intangible assets, accumulated amortization $ 17.7 $ 19.5
Preferred shares of beneficial interest, par value $ 0.01 $ 0.01
Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000
Preferred shares of beneficial interest, issued 0 0
Preferred shares of beneficial interest, outstanding 0 0
Common shares, par value $ 0.01 $ 0.01
Common shares, shares authorized 95,000,000 95,000,000
Common shares, issued 13,784,401 13,771,287
Common shares, outstanding 13,784,401 13,771,287
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Changes in Equity - USD ($)
$ in Thousands
Total
Common Stock
Capital in excess of par value
Cumulative net income
Cumulative dividends
Accumulated other comprehensive income/(loss)
Balance at Dec. 31, 2019 $ 181,734 $ 138 $ 266,723 $ 661,280 $ (747,417) $ 1,010
Balance, Shares at Dec. 31, 2019   13,757        
Shares of Beneficial Interest:            
Issued, net (317)   (317)      
Issued (in shares)   14        
Restricted stock-based compensation expense 665   665      
Dividends (28,426)       (28,426)  
Comprehensive income:            
Net income 14,447     14,447    
Unrealized net gain (loss) on cash flow hedges (5,709)         (5,709)
Subtotal - comprehensive income 8,738     14,447   (5,709)
Balance at Sep. 30, 2020 162,394 $ 138 267,071 675,727 (775,843) (4,699)
Balance, Shares at Sep. 30, 2020   13,771        
Balance at Jun. 30, 2020 166,240 $ 138 266,843 670,534 (766,342) (4,933)
Balance, Shares at Jun. 30, 2020   13,770        
Shares of Beneficial Interest:            
Issued, net (20)   (20)      
Issued (in shares)   1        
Restricted stock-based compensation expense 248   248      
Dividends (9,501)       (9,501)  
Comprehensive income:            
Net income 5,193     5,193    
Unrealized net gain (loss) on cash flow hedges 234         234
Subtotal - comprehensive income 5,427     5,193   234
Balance at Sep. 30, 2020 162,394 $ 138 267,071 675,727 (775,843) (4,699)
Balance, Shares at Sep. 30, 2020   13,771        
Balance at Dec. 31, 2020 159,005 $ 138 267,368 680,727 (785,413) (3,815)
Balance, Shares at Dec. 31, 2020   13,771        
Shares of Beneficial Interest:            
Issued, net 161   161      
Issued (in shares)   13        
Repurchased (16)   (16)      
Restricted stock-based compensation expense 719   719      
Dividends (28,868)       (28,868)  
Comprehensive income:            
Net income 17,551     17,551    
Unrealized net gain (loss) on cash flow hedges 3,259         3,259
Subtotal - comprehensive income 20,810     17,551   3,259
Balance at Sep. 30, 2021 151,811 $ 138 268,232 698,278 (814,281) (556)
Balance, Shares at Sep. 30, 2021   13,784        
Balance at Jun. 30, 2021 155,364 $ 138 267,951 692,934 (804,632) (1,027)
Balance, Shares at Jun. 30, 2021   13,783        
Shares of Beneficial Interest:            
Issued, net 55   55      
Issued (in shares)   1        
Restricted stock-based compensation expense 226   226      
Dividends (9,649)       (9,649)  
Comprehensive income:            
Net income 5,344     5,344    
Unrealized net gain (loss) on cash flow hedges 471         471
Subtotal - comprehensive income 5,815     5,344   471
Balance at Sep. 30, 2021 $ 151,811 $ 138 $ 268,232 $ 698,278 $ (814,281) $ (556)
Balance, Shares at Sep. 30, 2021   13,784        
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Changes in Equity (Parenthetical) - $ / shares
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Statement Of Stockholders Equity [Abstract]        
Dividend, per share $ 0.70 $ 0.69 $ 2.095 $ 2.065
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities:    
Net income $ 17,551 $ 14,447
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 20,551 19,160
Amortization related to above/below market leases, net (139) (140)
Amortization of debt premium (38) (39)
Amortization of deferred financing costs 609 549
Stock-based compensation expense 719 665
Gain on sale of real estate assets (1,304)  
Changes in assets and liabilities:    
Lease receivable (457) 27
Accrued expenses and other liabilities 201 49
Tenant reserves, deposits and deferred and prepaid rents 272 (186)
Accrued interest 1 159
Leasing costs paid (1,250) (745)
Other, net (522) (1,171)
Net cash provided by operating activities 36,194 32,775
Cash flows from investing activities:    
Investments in LLCs (16,138) (3,204)
Cash distributions from LLCs   5,196
Advance made to LLC (3,500)  
Additions to real estate investments, net (11,537) (18,784)
Deposit on real estate assets (200)  
Net cash paid for acquisition of property (12,989)  
Cash proceeds received from sale of property, net 3,209  
Net cash used in investing activities (41,155) (16,792)
Cash flows from financing activities:    
Net borrowings on line of credit 40,600 14,150
Repayments of mortgage notes payable (1,550) (1,406)
Financing costs paid (1,813) (372)
Dividends paid (28,830) (28,411)
Issuance of shares of beneficial interest, net 159 266
Net cash provided by/(used in) financing activities 8,566 (15,773)
Increase in cash and cash equivalents 3,605 210
Cash and cash equivalents, beginning of period 5,742 6,110
Cash and cash equivalents, end of period 9,347 6,320
Supplemental disclosures of cash flow information:    
Interest paid 5,995 5,620
Invoices accrued for construction and improvements $ 151 $ 5,660
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.21.2
General
9 Months Ended
Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
General

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2021. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of September 30, 2021, we had investments in five jointly-owned LLCs/LPs (subsequent to September 30, 2021, we purchased the 5% third-party minority ownership interest in one of the jointly-owned LPs, as discussed in Note 5). We currently account for our share of the income/loss from these investments by the equity method (see Note 5). These LLCs are included in our consolidated financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.  

The condensed consolidated financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2020.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties from certain subsidiaries of UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and renewal terms for each of the three hospital facilities leased to wholly-owned subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with wholly-owned subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the three hospital facilities leased to wholly-owned subsidiaries of UHS accounted for approximately 22% and 23% of our consolidated revenues for the three months ended September 30, 2021 and 2020, respectively, and approximately 22% of our consolidated revenues for each of the nine months ended September 30, 2021 and 2020. In addition to these three UHS hospital facilities, one of our hospital facilities is leased to a joint venture between a subsidiary of UHS and a third party, and we have nineteen medical office buildings (“MOBs”), general office buildings or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us that include tenants which are subsidiaries or joint ventures of UHS. The aggregate revenues generated from UHS-related tenants comprised approximately 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and approximately 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of the three hospitals with wholly-owned subsidiaries of UHS, as reflected below, UHS has the option, among other things, to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities from us at their appraised fair market value upon any of the following:  (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that UHS provides notice to us of their intent to offer a substitution property/properties in exchange for one (or more) of the three hospital facilities leased from us, should we be unable to reach an agreement with UHS on the properties to be substituted. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and

conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

The table below details the existing lease terms and renewal options for our three hospitals operated by wholly-owned subsidiaries of UHS:  

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(c.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  

(c.)

UHS has notified us of their intent to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled termination of the current lease term on December 31, 2021. UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  See below for additional disclosure. 

 

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).  

 

Subsequent to September 30, 2021, we purchased the 5% minority ownership interest held by a third-party member in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for approximately $3.1 million. The MOB is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS. A third-party appraisal was completed to determine the fair value of the property.  As a result of this minority ownership purchase during the fourth quarter of 2021, we subsequently own 100% of the LP and we will therefore begin consolidating this LP effective with the purchase date.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  Please see Note 5 for additional disclosure surrounding this transaction.

 

In May, 2021, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million.  The building is 100% leased under the terms of a triple net lease by a wholly-owned subsidiary of UHS.  The initial lease is scheduled to expire on August 31, 2027 and has two five-year renewal options.  As discussed in Note 4, the acquisition of this office building is part of an anticipated series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.

 

In September 2019, we entered into an agreement whereby we own a 95% non-controlling ownership interest in Grayson Properties II L.P., which developed, constructed, owns and operates the Texoma Medical Plaza II, an MOB located in Denison, Texas.  This MOB, which was substantially completed in December 2020, is located on the campus of Texoma Medical Center, a hospital that is owned and operated by a wholly-owned subsidiary of UHS.  A 10-year master flex lease was executed with the wholly-owned subsidiary of UHS for over 50% of the rentable square feet of the MOB and commenced in December 2020 upon the issuance of the certificate of occupancy. We account for this LP on an unconsolidated basis pursuant to the equity method since it is not a variable interest entity and we do not have a controlling voting interest.    

In late July 2019, Des Moines Medical Properties, LLC, a wholly-owned subsidiary of ours, entered into an agreement to build and lease a newly constructed UHS-related behavioral health care hospital located in Clive, Iowa.  The lease on this facility, which is triple net and has an initial term of 20 years with five 10-year renewal options, was executed with Clive Behavioral Health, LLC, a joint venture between a wholly-owned subsidiary of UHS and Catholic Health Initiatives - Iowa, Corp (“JV”). Construction of this hospital, for which we engaged a wholly-owned subsidiary of UHS to act as project manager for an aggregate fee of approximately $750,000, was substantially completed in December 2020 and the property received a temporary certificate of occupancy on December 31, 2020, at which time the hospital lease commenced. Pursuant to the lease on this facility, the JV has the option to, among other things, renew the lease at the terms specified in the lease agreement by providing notice to us at least 270 days prior to the termination of the then current term. The JV also has the right to purchase the leased facility from us at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right). Additionally, the JV has rights of first offer to purchase the facility prior to any third-party sale.

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the lease revenue currently earned pursuant to these leases.  

 

We are the lessee on twelve ground leases with subsidiaries of UHS (for consolidated and unconsolidated investments). The remaining lease terms on the ground leases with subsidiaries of UHS range from approximately 28 years to approximately 78 years.  The annual aggregate lease payments on these properties are estimated to be approximately $508,000 during each of the years ended 2021 through 2025, and an aggregate of $29.0 million thereafter. See Note 7 for additional lease accounting disclosure.

 

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of September 30, 2021 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

 

Advisory Agreement:   UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an advisory agreement dated December 24, 1986, and as amended and restated as of January 1, 2019 (the “Advisory Agreement”). Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory.

Our advisory fee for the three and nine months ended September 30, 2021 and 2020, was computed at 0.70% of our average invested real estate assets, as derived from our condensed consolidated balance sheets.  Based upon a review of our advisory fee and other general and administrative expenses, as compared to an industry peer group, the advisory fee computation remained unchanged for 2021, as compared to the last three years. The average real estate assets for advisory fee calculation purposes exclude certain items from our condensed consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, lease receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. Advisory fees incurred and paid (or payable) to UHS amounted to approximately $1.1 million and $1.0 million for the three months ended September 30, 2021 and 2020, respectively, and were based upon average invested real estate assets of $641 million and $594 million, respectively. Advisory fees incurred and paid (or payable) to UHS were approximately $3.3 million and $3.1 million for the nine months ended September 30, 2021 and 2020, and were based upon average invested real estate assets of $623 million and $587 million, respectively.   

 

Share Ownership: As of September 30, 2021 and December 31, 2020, UHS owned 5.7% of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 37% and 34% of our consolidated revenues during the three-month periods ended September 30, 2021 and 2020, respectively, and 36% and 33% of our consolidated revenues during the nine-month periods ended September 30, 2021 and 2020, respectively, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Dividends and Equity Issuance Program
9 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Dividends and Equity Issuance Program

(3) Dividends and Equity Issuance Program

Dividends and dividend equivalents:

During the third quarter of 2021, we declared and paid dividends of approximately $9.6 million, or $.70 per share. We declared and paid dividends of approximately $9.5 million, or $.69 per share, during the third quarter of 2020.  During the nine-month period ended September 30, 2021 we declared and paid dividends of approximately $28.8 million, or $2.095 per share.  During the nine-month period ended September 30, 2020, we declared and paid dividends of approximately $28.4 million, or $2.065 per share. Dividend equivalents, which are applicable to shares of unvested restricted stock, were accrued during the first nine months of 2021 and will be paid upon vesting of the restricted stock.

Equity Issuance Program:

During the second quarter of 2020, we commenced an at-the-market (“ATM”) equity issuance program, pursuant to the terms of which we may sell, from time-to-time, common shares of our beneficial interest up to an aggregate sales price of $100 million to or through our agent banks. The common shares will be offered pursuant to the Registration Statement filed with the Securities and Exchange Commission, which became effective in June 2020.

No shares were issued pursuant to this ATM equity program during the first nine months of 2021.  Pursuant to this ATM program, since the program commenced in the second quarter of 2020, we have issued 2,704 shares at an average price of $101.30 per share, which generated approximately $270,000 of net proceeds (net of approximately $4,000, consisting of compensation to BofA Securities, Inc.). Additionally, as of September 30, 2021, we have paid or incurred approximately $508,000 in various fees and expenses related to the commencement of our ATM program.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Acquisitions and Divestitures

(4) Acquisitions and Divestitures    

During the second quarter of 2021 and during the fourth quarter of 2021, we completed three transactions as described below utilizing qualified third-party intermediaries, as part of a series of anticipated tax-deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.

Subsequent to September 30, 2021:

In July, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we entered into an agreement to sell the Auburn Medical Office Building II.  On November 1, 2021 we settled on the sale of the Auburn Medical Office Building II, a multi-tenant MOB located in Auburn, Washington to a non-related party for a sale price of approximately $25.1 million.  The gain on this divestiture will be included in our consolidated statement of income for the three and twelve-month periods ended December 31, 2021.  The assets and liabilities related to this property are included in “Assets of property held for sale” or “Liabilities of property held for sale” on our consolidated balance sheet as of September 30, 2021.

Nine Months Ended September 30, 2021:

Acquisition:

In May, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we acquired the Fire Mesa office building located in Las Vegas, Nevada for a purchase price of approximately $12.9 million. The building, which has approximately 44,000 rentable square feet, is 100% leased under the terms of a triple net lease with a wholly-owned subsidiary of UHS.  The lease on this building is scheduled to expire on August 31, 2027 and has two five-year renewal options.

Divestiture:

In June, 2021, as a part of the series of tax-deferred like-kind exchange transactions mentioned above, we sold the Children’s Clinic at Springdale, a medical office building located in Springdale, AR for a sale price of approximately $3.2 million, net of closing costs. This divestiture resulted in a gain of approximately $1.3 million which is included in our consolidated statement of income for the nine-month period ended September 30, 2021.  

 

 

Nine Months Ended September 30, 2020:    

Acquisitions:

There were no acquisitions during the first nine months of 2020.  

Divestitures:    

There were no dispositions during the first nine months of 2020.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Summarized Financial Information of Equity Affiliates
9 Months Ended
Sep. 30, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

In accordance with U.S. GAAP and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

Distributions received from equity method investees in the consolidated statements of cash flows are classified based upon the nature of the distribution. Returns on investments are presented net of equity in income from unconsolidated investments as cash flows from operating activities.  Returns of investments are classified as cash flows from investing activities.

At September 30, 2021, we have non-controlling equity investments or commitments in five jointly-owned LLCs/LPs which own MOBs. We account for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities which we are the primary beneficiary nor do we have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash funding is typically advanced as equity or member loans. These entities maintain property insurance on the properties.  

 

Subsequent to September 30, 2021, we purchased the third-party 5% ownership interest in Grayson Properties, LP which owns the Texoma Medical Plaza, an MOB located in Denison, Texas for a purchase price of approximately $3.1 million.  We formerly held a non-controlling majority ownership interest in this LP.  As a result of our purchase of the minority ownership interest, we now hold 100% of the ownership interest in this LP and we will begin accounting for this LP on a consolidated basis effective with the minority ownership interest purchase date. The property’s assets and liabilities will be recorded at the carrying amount of its previously held interest, plus the incremental cost which will be allocated based upon relative fair values.  A third-party appraisal was completed to determine the fair value of the property.  We do not expect a material impact on our net income as a result of the consolidation of this LP subsequent to the transaction.  

The following property table represents the five LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of September 30, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP.

(c.)

During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

(d.)

Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Below are the condensed combined statements of income (unaudited) for the five LLCs/LPs accounted for under the equity method at September 30, 2021 and the four LLCs/LPs accounted for under the equity method as September 30, 2020 (the 2020 periods do not include the newly constructed Texoma Medical Plaza II that was substantially completed in December, 2020).     

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

(amounts in thousands)

 

Revenues

 

$

2,736

 

 

$

2,624

 

 

$

8,373

 

 

$

7,637

 

Operating expenses

 

 

1,184

 

 

 

1,047

 

 

 

3,356

 

 

 

3,094

 

Depreciation and amortization

 

 

627

 

 

 

444

 

 

 

1,684

 

 

 

1,333

 

Interest, net

 

 

388

 

 

 

315

 

 

 

1,260

 

 

 

949

 

Net income

 

$

537

 

 

$

818

 

 

$

2,073

 

 

$

2,261

 

Our share of net income

 

$

303

 

 

$

517

 

 

$

1,341

 

 

$

1,371

 

   

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of September 30, 2021 and December 31, 2020:     

 

 

September 30,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

42,789

 

 

$

42,374

 

Other assets (a.)

 

 

9,484

 

 

 

8,818

 

Total assets

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

6,966

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

22,133

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

19,674

 

 

 

2,055

 

Total liabilities and equity

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in and advances to LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

23,123

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,896

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

21,227

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.  

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.

 

As of September 30, 2021, and December 31, 2020, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs/LPs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

9/30/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

February, 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

-

 

 

 

13,372

 

 

September, 2021

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

13,075

 

 

 

12,336

 

 

June, 2025

Brunswick Associates (2.80% fixed rate mortgage loan)

 

 

9,058

 

 

 

9,250

 

 

December, 2030

 

 

$

22,133

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

 

(b.)

Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

Pursuant to the operating and/or partnership agreements of the five LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

 

The minority partner in Grayson Properties, LP, as the Offering Member, made an offer to sell its entire 5% ownership interest to us at a stipulated price, and we agreed to purchase the ownership interest at the stipulated price of approximately $3.1 million. The transaction was completed during the fourth quarter of 2021, as discussed above.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Recent Accounting Pronouncements
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

(6) Recent Accounting Pronouncements

 

Accounting for Lease Concessions Granted in Connection with COVID-19

On April 8, 2020, the Financial Accounting Standards Board ("FASB") held a public meeting and shortly afterwards issued a question-and-answer ("Q&A") document which was intended to provide accounting relief for lease concessions related to the COVID-19 pandemic. The accounting relief permits an entity to choose to forgo the evaluation of the enforceable rights and obligations of a lease contract, which is a requirement of Accounting Standards Codification Topic 842, Leases, which we adopted on January 1, 2019, as long as the total rent payments after the lease concessions are substantially the same, or less than, the total payments previously required by the lease. An entity may account for COVID-19 related lease concessions either (i) as if they were part of the enforceable rights and obligations of the parties under the existing lease contract; or (ii) as a lease modification. To the extent that a rent concession is granted as a deferral of payments, but the total lease payments are substantially the same, lessors are allowed to account for the concession as if no change had been made to the original lease contract.

      

Based on the Q&A, an entity is not required to account for all lease concessions related to the effects of the COVID-19 pandemic under one elected option, however, the entity is required to apply the elected option consistently to leases with similar characteristics and in similar circumstances. The COVID-19 pandemic did not start to adversely impact the economic conditions in the United States until late March 2020 and did not have a material effect on our operations or financial results during the three and nine months ended September 30, 2021 or the year ended December 31, 2020.

Reference Rate Reform

In March 2020, the FASB issued an accounting standard classified under FASB ASC Topic 848, “Reference Rate Reform.” The amendments in this update contain practical expedients for reference rate reform related activities that impact debt, leases, derivatives

and other contracts. The guidance in ASC 848 is optional and may be elected over time as reference rate reform activities occur. We will evaluate the impact of the guidance and may apply elections as applicable as additional changes in the market occur.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Accounting
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Lease Accounting

(7) Lease Accounting

 

We adopted the new lease standard on January 1, 2019 and applied it to leases that were in place on the effective date as both a lessor and lessee. We adopted ASC 842 effective January 1, 2019 under the modified retrospective approach and elected the optional transition method to apply the provisions of ASC 842 as of the adoption date, rather than the earliest period presented. We elected to apply certain adoption related practical expedients for all leases that commenced prior to the election date. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.

As Lessor:

We lease our operating properties to customers under agreements that are classified as operating leases. We recognize the total minimum lease payments provided for under the leases on a straight-line basis over the lease term. Generally, under the terms of our leases, the majority of our rental expenses, including common area maintenance, real estate taxes and insurance, are recovered from our customers. We record amounts reimbursed by customers in the period that the applicable expenses are incurred, which is generally ratably throughout the term of the lease.  We have elected the package of practical expedients that allows lessors to not separate lease and non-lease components by class of underlying asset. This practical expedient allowed us to not separate expenses reimbursed by our customers (“tenant reimbursements”) from the associated rental revenue if certain criteria were met.  We assessed these criteria and concluded that the timing and pattern of transfer for rental revenue and the associated tenant reimbursements are the same, and as our leases qualify as operating leases, we accounted for and presented rental revenue and tenant reimbursements as a single component under Lease revenue in our consolidated statements of income for the three and nine months ended September 30, 2021 and 2020.  

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and nine month periods ended September 30, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

$

5,392

 

 

$

4,402

 

 

$

15,820

 

 

$

12,940

 

Bonus rents

 

1,828

 

 

 

1,680

 

 

 

5,171

 

 

 

4,477

 

Tenant reimbursements

 

354

 

 

 

299

 

 

 

980

 

 

 

826

 

Lease revenue - UHS facilities

$

7,574

 

 

$

6,381

 

 

$

21,971

 

 

$

18,243

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

 

10,421

 

 

 

10,390

 

 

 

31,425

 

 

 

31,155

 

Tenant reimbursements

 

2,694

 

 

 

2,451

 

 

 

7,899

 

 

 

7,371

 

Lease revenue - Non-related parties

$

13,115

 

 

$

12,841

 

 

$

39,324

 

 

$

38,526

 

 

Disclosures Related to Certain Facilities:  

Wellington Regional Medical Center:

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to Wellington Regional Medical Center.  The current lease on this facility is scheduled to expire on December 31, 2021.  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  

Southwest Healthcare System, Inland Valley Campus:

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031) related to the Southwest Healthcare System, Inland Valley Campus property.  As previously disclosed, a wholly-owned subsidiary of UHS has notified us that it is planning to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled expiration of the current lease term on December 31, 2021. As permitted pursuant to the terms of the lease, UHS has the right to purchase the leased property at its appraised fair market value at the end of the existing lease term. However, UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus. The substitution properties consist of one acute care hospital (including a behavioral health pavilion) and a newly constructed behavioral health hospital. The Independent Trustees of our Board, as well as the UHS Board of Directors, have approved these transactions subject to satisfactory completion of definitive agreements, which are in progress. The effective date of the transactions is expected to coincide with the scheduled lease maturity date of December 31, 2021. Pursuant to the terms of the lease on the Inland Valley Campus, we earned $3.4 million of lease revenue during the nine-month period ended September 30, 2021 ($2.0 million in base rental and $1.4 million in bonus rental) and $4.4 million of lease revenue during the year ended December 31, 2020 ($2.6 million in base rental and $1.8 million in bonus rental).

PeaceHealth Medical Clinic:

The existing lease on the PeaceHealth Medical Clinic, an MOB located in Bellingham, Washington was scheduled to expire on December 31, 2021.  In July, 2021, the lease was renewed for an additional seven year term, extending the scheduled expiration date to January 31, 2029.  The tenant also has two additional five-year renewal terms.  Additionally, the tenant has the right of first offer to purchase the property if the property is marketed by us; and the tenant has an option to purchase the property at the end of the lease term at the then fair market value.  Pursuant to the terms of the lease on the PeaceHealth Medical Clinic, we earned $2.1 million of lease revenue during the nine-month period ended September 30, 2021 and $2.8 million of lease revenue during the year ended December 31, 2020.

Kindred Hospital Chicago Central:

As previously disclosed, the existing lease on Kindred Hospital Chicago Central, a 95-bed specialty hospital located in Chicago, Illinois, is scheduled to expire on December 31, 2021. The tenant of the facility notified us that they do not intend to renew the lease upon its scheduled expiration. We are marketing this property to potential new tenants. However, should this property be vacant for an extended period of time, or should we experience a decrease in the lease rate on a future lease as compared to the current lease, or incur substantial renovation costs to make the property suitable for another operator/tenant, our future results of operations could be unfavorably impacted.  Pursuant to the terms of the lease, we earned approximately $1.2 million of lease revenue during the nine-month period ended September 30, 2021 and $1.6 million of lease revenue during the twelve-month period ended December 31, 2020.  

Vacancies - Evansville, Indiana and Corpus Christi, Texas:    

The leases on two hospital facilities, located in Evansville, Indiana, and Corpus Christi, Texas, expired on May 31, 2019 and June 1, 2019, respectively. The hospital located in Evansville, Indiana, has remained vacant since September 30, 2019 and the hospital located in Corpus Christi, Texas, has remained vacant since June 1, 2019.  

We continue to market each property for lease to new tenants. However, should these properties continue to remain owned and vacant for an extended period of time, or should we experience decreased lease rates on future leases, as compared to prior/expired lease rates, or incur substantial renovation costs to make the properties suitable for other operators/tenants, our future results of operations could be materially unfavorably impacted.

 As Lessee:

We are the lessee with various third parties, including subsidiaries of UHS, in connection with ground leases for land at fourteen of our consolidated properties. Our right-of-use land assets represent our right to use the land for the lease term and our lease liabilities represent our obligation to make lease payments arising from the leases. Right-of-use assets and lease liabilities were recognized upon adoption of Topic 842 based on the present value of lease payments over the lease term. We utilized our estimated incremental borrowing rate, which was derived from information available as of January 1, 2019, in determining the present value of lease payments. A right-of-use asset and lease liability are not recognized for leases with an initial term of 12 months or less, as these short-term leases are accounted for similarly to previous guidance for operating leases.  We do not currently have any ground leases with an initial term of 12 months or less. As of September 30, 2021, our condensed consolidated balance sheet includes right-of-use land assets of approximately $8.9 million and ground lease liabilities of approximately $8.9 million. There were no newly leased assets for which a right-of-use asset was recorded in exchange for a new lease liability during the nine months ended September 30, 2021.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Debt and Financial Instruments
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Debt and Financial Instruments

(8) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our revolving credit facility, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances pursuant to our ATM equity issuance program.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On July 2, 2021, we entered into an amended and restated revolving credit agreement (“Credit Agreement”) to amend and restate the previously existing $350 million credit agreement, as amended and dated June 5, 2020 (“Prior Credit Agreement”). Among other things, under the Credit Agreement, our aggregate revolving credit commitment was increased to $375 million from $350 million.  The Credit Agreement, which is scheduled to mature on July 2, 2025, provides for a revolving credit facility in an aggregate principal amount of $375 million, including a $40 million sublimit for letters of credit and a $30 million sublimit for swingline/short-term loans.  Under the terms of the Credit Agreement, we may request that the revolving line of credit be increased by up to an additional $50 million. Borrowings under the new facility are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the new facility are secured by first priority security interests in and liens on all equity interests in most of the Trust’s wholly-owned subsidiaries.

Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans. The initial applicable margin is 1.25% for LIBOR loans and 0.25% for Base Rate loans. The Credit Agreement defines “Base Rate” as the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%. The Trust will also pay a quarterly commitment fee ranging from 0.15% to 0.35% (depending on the Trust’s ratio of debt to asset value) of the average daily unused portion of the revolving credit commitments.  The Credit Agreement also provides for options to extend the maturity date and borrowing availability for two additional six-month periods.

The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At September 30, 2021, the applicable margin over the LIBOR rate was 1.25%, the margin over the Base Rate was 0.25% and the facility fee was 0.25%.  

At September 30, 2021, we had $276.8 million of outstanding borrowings and $3.6 million of letters of credit outstanding under our Credit Agreement. We had $94.6 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of September 30, 2021. There are no compensating balance requirements. At December 31, 2020, we had $236.2 million of outstanding borrowings outstanding against our Prior Credit Agreement and $108.2 million of available borrowing capacity.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts then outstanding under the Credit Agreement. We are in compliance with all of the covenants in the Credit Agreement at September 30, 2021 and were in compliance with all of the covenants in the Prior Credit Agreement at December 31, 2020. We also believe that we would remain in compliance if, based on the assumption that the majority of the potential new borrowings will be used to fund investments, the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):

 

 

 

Covenant

 

September 30,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

141,419

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.6

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.1

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

47.2

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

 

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan (b.)

 

$

5,268

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,337

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,395

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,458

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,866

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,494

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,530

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,333

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

57,681

 

 

 

 

 

 

 

     Less net financing fees

 

 

(387

)

 

 

 

 

 

 

     Plus net debt premium

 

 

103

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

57,397

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

 

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

The mortgages are secured by the real property of the buildings as well as property leases and rents. The mortgages outstanding as of September 30, 2021 had a combined fair value of approximately $60.3 million.  At December 31, 2020, we had various mortgages, all of which were non-recourse to us, included in our condensed consolidated balance sheet. The combined outstanding balance of these various mortgages at December 31, 2020 was $59.2 million and had a combined fair value of approximately $62.0 million. The fair value of our debt was computed based upon quotes received from financial institutions.  We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosure in connection with debt instruments.  Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

Financial Instruments:

In March 2020, we entered into an interest rate swap agreement on a total notional amount of $55 million with a fixed interest rate of 0.565% that we designated as a cash flow hedge.  The interest rate swap became effective on March 25, 2020 and is scheduled to mature on March 25, 2027. If the one-month LIBOR is above 0.565%, the counterparty pays us, and if the one-month LIBOR is less than 0.565%, we pay the counterparty, the difference between the fixed rate of 0.565% and one-month LIBOR.

In January 2020, we entered into an interest rate swap agreement on a total notional amount of $35 million with a fixed interest rate of 1.4975% that we designated as a cash flow hedge.  The interest rate swap became effective on January 15, 2020 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.4975%, the counterparty pays us, and if the one-month LIBOR is less than 1.4975%, we pay the counterparty, the difference between the fixed rate of 1.4975% and one-month LIBOR.  

During the third quarter of 2019, we entered into an interest rate swap agreement on a total notional amount of $50 million with a fixed interest rate of 1.144% that we designated as a cash flow hedge. The interest rate swap became effective on September 16, 2019 and is scheduled to mature on September 16, 2024. If the one-month LIBOR is above 1.144%, the counterparty pays us, and if the one-month LIBOR is less than 1.144%, we pay the counterparty, the difference between the fixed rate of 1.144% and one-month LIBOR.

We measure our interest rate swaps at fair value on a recurring basis. The fair value of our interest rate swaps is based on quotes from third parties. We consider those inputs to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with derivative instruments and hedging activities. At September 30, 2021, the fair value of our interest rate swaps was a net liability of $556,000 which is included in accrued expenses and other liabilities on the accompanying condensed consolidated balance sheet. During the third quarter of 2021, we paid or accrued approximately $324,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. During the first nine months of 2021, we paid or accrued approximately $945,000 to the counterparty by us, adjusted for the previous quarter accrual, pursuant to the terms of the swaps. From inception of the swap agreements through September 30, 2021 we paid or accrued approximately $1.6 million in net payments made to the counterparty by us pursuant to the terms of the swap (consisting of approximately $199,000 in payments or accruals made to us by the counterparty, offset by approximately $1.8 million of payments due to the counterparty from us).  Cash flow hedges are accounted for by recording the fair value of the derivative instrument on the balance sheet as either an asset or a liability, with a corresponding amount recorded in accumulated other comprehensive income (“AOCI”) within shareholders’ equity.  Amounts are classified from AOCI to the income statement in the period or periods the hedged transaction affects earnings.  We do not expect any gains or losses on our interest rate swaps to be reclassified to earnings in the next twelve months.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting

(9) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered its own segment.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2021
Related Party Transactions [Abstract]  
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities The table below details the existing lease terms and renewal options for our three hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2026

 

 

5

 

(a.)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b.)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(c.)

 

(a.)

UHS has one 5-year renewal option at the existing lease rate (through 2031).  

(b.)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  

(c.)

UHS has notified us of their intent to terminate the existing lease on Southwest Healthcare System, Inland Valley Campus, upon the scheduled termination of the current lease term on December 31, 2021. UHS has agreed to exchange, and lease back from us, substitution properties with an aggregate fair market value substantially equal to that of Southwest Healthcare System, Inland Valley Campus, in return for the real estate assets of the Inland Valley Campus.  See below for additional disclosure. 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Summarized Financial Information of Equity Affiliates (Tables)
9 Months Ended
Sep. 30, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Limited Liability Companies Accounted for Under Equity Method

The following property table represents the five LLCs/LPs in which we owned a non-controlling interest and were accounted for under the equity method as of September 30, 2021:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)(e.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)(f.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

Grayson Properties II (d.)(f.)

 

 

95

%

 

Texoma Medical Plaza II

 

(a.)

This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP.

(c.)

During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

(d.)

Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021.

(e.)

The LLC is the lessee with a third-party lessor under a ground lease for land.

(f.)

These LPs are the lessees with UHS-related parties for the land related to these properties.

Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method Below are the condensed combined statements of income (unaudited) for the five LLCs/LPs accounted for under the equity method at September 30, 2021 and the four LLCs/LPs accounted for under the equity method as September 30, 2020 (the 2020 periods do not include the newly constructed Texoma Medical Plaza II that was substantially completed in December, 2020).     

 

 

 

Three Months Ended

September 30,

 

 

Nine Months Ended

September 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

 

 

(amounts in thousands)

(amounts in thousands)

 

Revenues

 

$

2,736

 

 

$

2,624

 

 

$

8,373

 

 

$

7,637

 

Operating expenses

 

 

1,184

 

 

 

1,047

 

 

 

3,356

 

 

 

3,094

 

Depreciation and amortization

 

 

627

 

 

 

444

 

 

 

1,684

 

 

 

1,333

 

Interest, net

 

 

388

 

 

 

315

 

 

 

1,260

 

 

 

949

 

Net income

 

$

537

 

 

$

818

 

 

$

2,073

 

 

$

2,261

 

Our share of net income

 

$

303

 

 

$

517

 

 

$

1,341

 

 

$

1,371

 

   

Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method

Below are the condensed combined balance sheets (unaudited) for the five above-mentioned LLCs/LPs that were accounted for under the equity method as of September 30, 2021 and December 31, 2020:     

 

 

September 30,

2021

 

 

December 31,

2020

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

42,789

 

 

$

42,374

 

Other assets (a.)

 

 

9,484

 

 

 

8,818

 

Total assets

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Other liabilities (a.)

 

$

6,966

 

 

$

9,402

 

Mortgage notes payable, non-recourse to us

 

 

22,133

 

 

 

39,735

 

Advances payable to us (b.)

 

 

3,500

 

 

 

-

 

Equity

 

 

19,674

 

 

 

2,055

 

Total liabilities and equity

 

$

52,273

 

 

$

51,192

 

 

 

 

 

 

 

 

 

 

Investments in and advances to LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

23,123

 

 

$

4,278

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,896

)

 

 

(3,020

)

Our share of equity in LLCs, net

 

$

21,227

 

 

$

1,258

 

 

 

(a.)

Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.  

 

(b.)

Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.

 

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

9/30/2021

 

 

12/31/2020

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan) (b.)

 

$

-

 

 

$

4,777

 

 

February, 2021

Grayson Properties (5.034% fixed rate mortgage loan) (c.)

 

 

-

 

 

 

13,372

 

 

September, 2021

Grayson Properties II (3.70% fixed rate construction loan) (d.)

 

 

13,075

 

 

 

12,336

 

 

June, 2025

Brunswick Associates (2.80% fixed rate mortgage loan)

 

 

9,058

 

 

 

9,250

 

 

December, 2030

 

 

$

22,133

 

 

$

39,735

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

 

(b.)

Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.

 

(c.)

Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement.

 

(d.)

This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Accounting (Tables)
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions

The components of the “Lease revenue – UHS facilities” and “Lease revenue – Non-related parties” captions for the three and nine month periods ended September 30, 2021 and 2020 are disaggregated below (in thousands). Base rents are primarily stated rent amounts provided for under the leases that are recognized on a straight-line basis over the lease term. Bonus rents and tenant reimbursements represent amounts where tenants are contractually obligated to pay an amount that is variable in nature.

 

 

Three Months Ended

 

 

Nine Months Ended

 

 

September 30,

 

 

September 30,

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

UHS facilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

$

5,392

 

 

$

4,402

 

 

$

15,820

 

 

$

12,940

 

Bonus rents

 

1,828

 

 

 

1,680

 

 

 

5,171

 

 

 

4,477

 

Tenant reimbursements

 

354

 

 

 

299

 

 

 

980

 

 

 

826

 

Lease revenue - UHS facilities

$

7,574

 

 

$

6,381

 

 

$

21,971

 

 

$

18,243

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-related parties:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Base rents

 

10,421

 

 

 

10,390

 

 

 

31,425

 

 

 

31,155

 

Tenant reimbursements

 

2,694

 

 

 

2,451

 

 

 

7,899

 

 

 

7,371

 

Lease revenue - Non-related parties

$

13,115

 

 

$

12,841

 

 

$

39,324

 

 

$

38,526

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Debt and Financial Instruments (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement in place at September 30, 2021 as well as the Prior Credit Agreement that was in place at December 31, 2020 (dollar amounts in thousands):

 

 

 

Covenant

 

September 30,

2021

 

December 31,

2020

 

Tangible net worth

 

> =$125,000

 

$

141,419

 

$

147,263

 

Total leverage

 

< 60%

 

 

45.6

%

 

44.8

%

Secured leverage

 

< 30%

 

 

8.1

%

 

8.6

%

Unencumbered leverage

 

< 60%

 

 

47.2

%

 

41.4

%

Fixed charge coverage

 

> 1.50x

 

4.8x

 

4.7x

 

 

Outstanding Mortgages, Excluding Net Debt Premium

As indicated on the following table, we have various mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of September 30, 2021 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan (b.)

 

$

5,268

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

5,337

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,395

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,458

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

12,866

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

2,494

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

8,530

 

 

 

3.95

%

 

January, 2030

Rosenberg Children's Medical Plaza fixed rate mortgage loan

 

 

12,333

 

 

 

4.42

%

 

September, 2033

Total, excluding net debt premium and net financing fees

 

 

57,681

 

 

 

 

 

 

 

     Less net financing fees

 

 

(387

)

 

 

 

 

 

 

     Plus net debt premium

 

 

103

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

57,397

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. 

 

(b.)

This loan is scheduled to mature within the next twelve months, at which time we will decide whether to refinance pursuant to a new mortgage loan or by utilizing borrowings under our Credit Agreement.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.21.2
General - Additional Information (Detail) - Property
Nov. 08, 2021
Sep. 30, 2021
Subsequent Event | Grayson Properties    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Minority ownership interest held by a third-party 5.00%  
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Non-controlling equity interest, ownership percentage   33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Non-controlling equity interest, ownership percentage   95.00%
Limited Liability Companies    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Number of real estate investments   5
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
May 31, 2021
USD ($)
Time
Sep. 30, 2019
Jul. 31, 2019
USD ($)
Time
Sep. 30, 2021
USD ($)
Property
Time
Lease
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Property
Time
Lease
Hospital
RenewalOption
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Nov. 08, 2021
USD ($)
Related Party Transaction [Line Items]                  
Annual advisory fee as percentage of average invested real estate assets       0.70% 0.70% 0.70% 0.70%    
Grayson Properties | Subsequent Event                  
Related Party Transaction [Line Items]                  
Minority ownership interest held by a third-party                 5.00%
Ownership percentage upon completion of the minority ownership purchase                 100.00%
Minority ownership interest                 $ 3,100,000
Grayson Properties Two L P | Denison Texas                  
Related Party Transaction [Line Items]                  
Non-controlling equity interest, ownership percentage   95.00%              
Universal Health Services, Inc                  
Related Party Transaction [Line Items]                  
Number of term renewal options | Time 2     6   6      
Additional renewal terms           5 years      
Number of hospital facilities leased | Property       3   3      
Number of medical office buildings and free standing emergency departments | Property           19      
Option to renew lease, notice period prior to termination date of current term           90 days      
Period to purchase respective leased facilities at same price after lease terms           180 days      
Renewal period of respective leased facilities at same price after lease terms           180 days      
Number of renewal options at existing lease rate | Hospital           3      
Lease revenue [1]       $ 7,574,000 $ 6,381,000 $ 21,971,000 $ 18,243,000    
Master flex lease term   10 years              
Percentage of rentable square feet   50.00%              
Number of ground leases | Lease       12   12      
Aggregate lease payments for 2021       $ 508,000   $ 508,000      
Aggregate lease payments for 2022       508,000   508,000      
Aggregate lease payments for 2023       508,000   508,000      
Aggregate lease payments for 2024       508,000   508,000      
Aggregate lease payments for 2025       508,000   508,000      
Aggregate lease payments for thereafter       $ 29,000,000.0   $ 29,000,000.0      
Percentage ownership of outstanding shares       5.70%   5.70%   5.70%  
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus                  
Related Party Transaction [Line Items]                  
Number of renewal options at fair market value lease rates | RenewalOption           2      
Renewal options term at fair market value lease rates           5 years      
Lease expiration date           Dec. 31, 2021      
Lease revenue           $ 3,400,000   $ 4,400,000  
Universal Health Services, Inc | Base Rents                  
Related Party Transaction [Line Items]                  
Lease revenue       $ 5,392,000 4,402,000 15,820,000 12,940,000    
Universal Health Services, Inc | Base Rents | Southwest Healthcare System, Inland Valley Campus                  
Related Party Transaction [Line Items]                  
Lease revenue           2,000,000.0   2,600,000  
Universal Health Services, Inc | Bonus Rents                  
Related Party Transaction [Line Items]                  
Lease revenue       $ 1,828,000 $ 1,680,000 5,171,000 $ 4,477,000    
Universal Health Services, Inc | Bonus Rents | Southwest Healthcare System, Inland Valley Campus                  
Related Party Transaction [Line Items]                  
Lease revenue           $ 1,400,000   $ 1,800,000  
Universal Health Services, Inc | Customer Concentration Risk | Revenues                  
Related Party Transaction [Line Items]                  
Percentage of revenues generated from leases and tenants       22.00% 23.00% 22.00% 22.00%    
Universal Health Services, Inc | Customer Concentration Risk | Revenues | Tenants                  
Related Party Transaction [Line Items]                  
Percentage of revenues generated from leases and tenants       37.00% 34.00% 36.00% 33.00%    
Universal Health Services, Inc | Minimum                  
Related Party Transaction [Line Items]                  
Initial lease terms           13 years      
Remaining lease terms on ground leases           28 years      
Universal Health Services, Inc | Minimum | Southwest Healthcare System, Inland Valley Campus                  
Related Party Transaction [Line Items]                  
Renewal options at fair market value lease rates expiration year           2022      
Universal Health Services, Inc | Maximum                  
Related Party Transaction [Line Items]                  
Initial lease terms           15 years      
Remaining lease terms on ground leases           78 years      
Universal Health Services, Inc | Maximum | Southwest Healthcare System, Inland Valley Campus                  
Related Party Transaction [Line Items]                  
Renewal options at fair market value lease rates expiration year           2031      
Fire Mesa Office Building [Member]                  
Related Party Transaction [Line Items]                  
Lease expiration date Aug. 31, 2027                
Payment to acquire business $ 12,900,000                
Lease percentage 100.00%                
Universal Health Services Inc And Catholic Health Initiatives                  
Related Party Transaction [Line Items]                  
Number of term renewal options | Time     5            
Option to renew lease, notice period prior to termination date of current term     270 days            
Renewal period of respective leased facilities at same price after lease terms     270 days            
Triple net lease agreement period     20 years            
Renewal option term     10 years            
Project manager's aggregate fee     $ 750,000            
Change in control of trust notice, description     upon 30 days’ notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the JV decline to exercise its purchase right)            
Universal Health Services of Delaware Inc                  
Related Party Transaction [Line Items]                  
Advisory fee       $ 1,100,000 $ 1,000,000.0 $ 3,300,000 $ 3,100,000    
Cost, Product and Service [Extensible List]       Management Service Management Service Management Service Management Service    
Average invested real estate assets       $ 641,000,000 $ 594,000,000 $ 623,000,000 $ 587,000,000    
[1] Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) - Universal Health Services, Inc
9 Months Ended
Sep. 30, 2021
USD ($)
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 5,485,000
End of Lease Term 2026-12
Renewal Term (years) 5 years [1]
Wellington Regional Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 3,030,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
Southwest Healthcare System, Inland Valley Campus  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 2,648,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
[1] UHS has one 5-year renewal option at the existing lease rate (through 2031).  
[2] UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).  Since UHS’s lease renewal option for Wellington Regional Medical Center is fair market value (effective January 1, 2022), the lease rate valuation process is currently in progress and expected to be completed during the fourth quarter of 2021. Subject to completion of a lease agreement at acceptable rates and terms, UHS has indicated its intent to renew the lease on this facility.  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc
9 Months Ended
Sep. 30, 2021
Time
Hospital
RenewalOption
Operating Leased Assets [Line Items]  
Number of renewal option at existing lease rate | Hospital 3
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Number of renewal option at existing lease rate | Time 1
Renewal option term at existing lease rate 5 years
Renewal option at existing lease rate expiration year 2031
Wellington Regional Medical Center  
Operating Leased Assets [Line Items]  
Number of renewal options at fair market value lease rates | RenewalOption 2
Renewal options term at fair market value lease rates 5 years
Wellington Regional Medical Center | Minimum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2022
Wellington Regional Medical Center | Maximum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2031
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Dividends and Equity Issuance Program - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dividends and Equity Issuance [Line Items]          
Dividends declared and paid $ 9,600,000 $ 9,500,000   $ 28,830,000 $ 28,411,000
Declared and paid dividends, per share $ 0.70 $ 0.69   $ 2.095 $ 2.065
At-The-Market Equity Issuance Program (ATM)          
Dividends and Equity Issuance [Line Items]          
Aggregate sales of threshold amount     $ 100,000,000    
Share issued     2,704 0  
Average sale price per share     $ 101.30    
Net cash proceeds from stock issued     $ 270,000    
Payment of stock issuance cost     $ 4,000    
At-The-Market Equity Issuance Program (ATM) | Other Expenses          
Dividends and Equity Issuance [Line Items]          
Payments for stock issuance       $ 508,000  
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisitions and Divestitures - Additional Information (Detail)
$ in Thousands
1 Months Ended 9 Months Ended
Jun. 30, 2021
USD ($)
May 31, 2021
USD ($)
ft²
Time
Sep. 30, 2021
USD ($)
Time
Sep. 30, 2020
Acquisition
Disposition
Nov. 01, 2021
USD ($)
Business Acquisitions And Dispositions [Line Items]          
Gain on sale of real estate assets     $ 1,304    
Number of acquisitions | Acquisition       0  
Number of dispositions | Disposition       0  
Universal Health Services, Inc          
Business Acquisitions And Dispositions [Line Items]          
Number of term renewal options | Time   2 6    
Additional renewal terms     5 years    
Rentable square feet | ft²   44,000      
Fire Mesa Office Building [Member] | Universal Health Services, Inc          
Business Acquisitions And Dispositions [Line Items]          
Total purchase price   $ 12,900      
Percentage of building area leased   100.00%      
Additional renewal terms   5 years      
Auburn Medical Office Building II | Subsequent Event          
Business Acquisitions And Dispositions [Line Items]          
Sale price         $ 25,100
Medical Office Buildings          
Business Acquisitions And Dispositions [Line Items]          
Sale price net of closing costs $ 3,200        
Gain on sale of real estate assets     $ 1,300    
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Summarized Financial Information of Equity Affiliates - Additional Information (Detail)
$ in Millions
1 Months Ended 9 Months Ended
Nov. 08, 2021
USD ($)
Sep. 30, 2021
Property
Grayson Properties | Subsequent Event    
Schedule Of Equity Method Investments [Line Items]    
Minority ownership interest held by a third-party 5.00%  
Purchase price | $ $ 3.1  
Ownership percentage upon completion of the minority ownership purchase 100.00%  
Limited Liability Companies | Medical Office Buildings    
Schedule Of Equity Method Investments [Line Items]    
Number of real estate investments | Property   5
Minimum    
Schedule Of Equity Method Investments [Line Items]    
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member   60 days
Maximum    
Schedule Of Equity Method Investments [Line Items]    
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member   90 days
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum    
Schedule Of Equity Method Investments [Line Items]    
Non-controlling equity interest, ownership percentage   33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum    
Schedule Of Equity Method Investments [Line Items]    
Non-controlling equity interest, ownership percentage   95.00%
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Limited Liability Companies Accounted for Under Equity Method (Detail) - Equity Method Investments
9 Months Ended
Sep. 30, 2021
Suburban Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 33.00%
Property Owned by LLC/LP St. Matthews Medical Plaza II
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Ownership 74.00% [1],[2]
Property Owned by LLC/LP Mid Coast Hospital MOB [1],[2]
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3],[4]
Property Owned by LLC/LP Texoma Medical Plaza [3],[4]
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [5]
Property Owned by LLC/LP Forney Medical Plaza II [5]
Grayson Properties II LP  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3],[6]
Property Owned by LLC/LP Texoma Medical Plaza II [3],[6]
[1] The LLC is the lessee with a third-party lessor under a ground lease for land.
[2] This LLC has a third-party term loan of $9.1 million, which is non-recourse to us, outstanding as of September 30, 2021.
[3] These LPs are the lessees with UHS-related parties for the land related to these properties.
[4] This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS.  During the third quarter of 2021, this LP paid off its $13.2 million mortgage loan upon maturity utilizing an equity contribution from us which was funded utilizing borrowings from our revolving credit agreement. Subsequent to the third quarter of 2021, we purchased the 5% minority ownership interest in this LP from the third-party minority ownership partner for approximately $3.1 million and subsequently own 100% of this LP.
[5] During the first quarter of 2021, this LP paid off its $4.7 million mortgage loan, upon maturity, utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.
[6] Construction of this MOB, which is located in Denison, Texas on the campus of a hospital owned and operated by a wholly-owned subsidiary of UHS, was substantially completed in December 2020. We have committed to invest up to $4.8 million in equity and debt financing, $1.4 million of which has been funded as of September 30, 2021. This LP entered into a $13.1 million third-party construction loan commitment, which is non-recourse to us, which has an outstanding balance of $13.1 million as of September 30, 2021.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended
Nov. 08, 2021
Sep. 30, 2021
Mar. 31, 2021
Brunswick Associates      
Schedule Of Equity Method Investments [Line Items]      
Third-party term loan   $ 9.1  
Grayson Properties      
Schedule Of Equity Method Investments [Line Items]      
Repayment of loan   13.2  
Grayson Properties | Subsequent Event      
Schedule Of Equity Method Investments [Line Items]      
Minority ownership interest held by a third-party 5.00%    
Purchase price $ 3.1    
Ownership percentage upon completion of the minority ownership purchase 100.00%    
FTX MOB Phase II limited partnership      
Schedule Of Equity Method Investments [Line Items]      
Repayment of loan     $ 4.7
Member loan used to repay mortgage loan     $ 3.5
Grayson Properties II LP      
Schedule Of Equity Method Investments [Line Items]      
Construction loan   13.1  
Construction loan outstanding balance   13.1  
Grayson Properties II LP | Maximum | Denison Texas      
Schedule Of Equity Method Investments [Line Items]      
Commitment to investment   $ 4.8  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Schedule Of Equity Method Investments [Line Items]        
Revenues $ 21,205 $ 19,692 $ 62,780 $ 58,180
Net income     17,551 14,447
Our share of net income 303 517 1,341 1,371
Equity Method Investment, Nonconsolidated Investee or Group of Investees        
Schedule Of Equity Method Investments [Line Items]        
Revenues 2,736 2,624 8,373 7,637
Operating expenses 1,184 1,047 3,356 3,094
Depreciation and amortization 627 444 1,684 1,333
Interest, net 388 315 1,260 949
Net income 537 818 2,073 2,261
Our share of net income $ 303 $ 517 $ 1,341 $ 1,371
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
Sep. 30, 2021
Jun. 30, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Dec. 31, 2019
Schedule Of Equity Method Investments [Line Items]            
Total Assets $ 517,681   $ 494,009      
Equity 151,811 $ 155,364 159,005 $ 162,394 $ 166,240 $ 181,734
Total Liabilities and Equity 517,681   494,009      
Investments in LLCs before amounts included in accrued expenses and other liabilities 23,123   4,278      
Equity Method Investment, Nonconsolidated Investee or Group of Investees            
Schedule Of Equity Method Investments [Line Items]            
Net property, including construction in progress 42,789   42,374      
Other assets [1] 9,484   8,818      
Total Assets 52,273   51,192      
Other liabilities [1] 6,966   9,402      
Mortgage notes payable, non-recourse to us 22,133   39,735      
Advances payable to us [2] 3,500          
Equity 19,674   2,055      
Total Liabilities and Equity 52,273   51,192      
Investments in LLCs before amounts included in accrued expenses and other liabilities 23,123   4,278      
Amounts included in accrued expenses and other liabilities (1,896)   (3,020)      
Our share of equity in LLCs, net $ 21,227   $ 1,258      
[1] Other assets and other liabilities as of both September 30, 2021 and December 31, 2020 include approximately $4.3 million of right-of-use land assets and right-of-use land liabilities related to ground leases whereby the LLC/LP is the lessee, with third party lessors, including subsidiaries of UHS.
[2] Consists of a 7.25% member loan to FTX MOB Phase II, LP with a maturity date of March 1, 2023.
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]    
Right-of-use land assets $ 8,891 $ 8,914
Right-of-use land liabilities 8,891 8,914
Limited Liability Companies    
Schedule Of Equity Method Investments [Line Items]    
Right-of-use land assets 4,300 4,300
Right-of-use land liabilities $ 4,300 $ 4,300
FTX MOB Phase II limited partnership    
Schedule Of Equity Method Investments [Line Items]    
Debt Instrument Maturity Date 2023-03  
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) - Equity Method Investments - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 22,133 $ 39,735
FTX MOB Phase II    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[2]   4,777
Debt Instrument Maturity Date [2] 2021-02  
Grayson Properties    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[3]   13,372
Debt Instrument Maturity Date [3] 2021-09  
Brunswick Associates    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 9,058 9,250
Debt Instrument Maturity Date 2030-12  
Grayson Properties Two L P    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1],[4] $ 13,075 $ 12,336
Debt Instrument Maturity Date [4] 2025-06  
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity
[2] Upon maturity in February 2021 this LP paid off this mortgage loan utilizing pro rata equity contributions from the limited partners as well as a $3.5 million member loan from us to the LP which was funded utilizing borrowings from our revolving credit agreement.
[3]

Upon maturity in September, 2021 this LP paid off this mortgage utilizing an equity contribution from us, which was funded utilizing borrowings from our revolving credit agreement.

[4] This construction loan has a maximum commitment of $13.1 million and requires interest on the outstanding principal balance to be paid on a monthly basis through December 1, 2022.  Monthly principal and interest payments are scheduled to commence on January 1, 2023.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)
$ in Millions
Sep. 30, 2021
USD ($)
Grayson Properties Two L P  
Schedule Of Equity Method Investments [Line Items]  
Construction loan $ 13.1
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Member loan used to repay mortgage loan $ 3.5
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Non-Related Parties        
Leases Disclosure [Line Items]        
Lease revenue $ 13,115 $ 12,841 $ 39,324 $ 38,526
Non-Related Parties | Base Rents        
Leases Disclosure [Line Items]        
Lease revenue 10,421 10,390 31,425 31,155
Non-Related Parties | Tenant Reimbursements        
Leases Disclosure [Line Items]        
Lease revenue 2,694 2,451 7,899 7,371
Universal Health Services, Inc        
Leases Disclosure [Line Items]        
Lease revenue [1] 7,574 6,381 21,971 18,243
Universal Health Services, Inc | Base Rents        
Leases Disclosure [Line Items]        
Lease revenue 5,392 4,402 15,820 12,940
Universal Health Services, Inc | Bonus Rents        
Leases Disclosure [Line Items]        
Lease revenue 1,828 1,680 5,171 4,477
Universal Health Services, Inc | Tenant Reimbursements        
Leases Disclosure [Line Items]        
Lease revenue $ 354 $ 299 $ 980 $ 826
[1] Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively.
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Lease Accounting - Additional Information (Detail)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Lease
Bed
Land
RenewalOption
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Leases Disclosure [Line Items]          
Lessee in connection with ground leases for land | Land     14    
Right-of-use land assets $ 8,891   $ 8,891   $ 8,914
Ground lease liabilities $ 8,891   $ 8,891   8,914
PeaceHealth Medical Clinic Bellingham WA          
Leases Disclosure [Line Items]          
Lease expiration date     Dec. 31, 2021    
Lease revenue     $ 2,100   2,800
Lease, Renewal Term 7 years   7 years    
Extended Lease Expiration Date     Jan. 31, 2029    
Number of Additional Lease Term | Lease     2    
Remaining lease terms on ground leases     5 years    
Kindred Chicago Central Hospital Central Chicago, Illinois          
Leases Disclosure [Line Items]          
Lease expiration date     Dec. 31, 2021    
Lease revenue     $ 1,200   1,600
Number of beds in specialty hospital | Bed     95    
Evansville Rehabilitation Hospital Evansville, Indiana          
Leases Disclosure [Line Items]          
Lease expiration date     May 31, 2019    
Corpus Christi Corpus Christi Texas          
Leases Disclosure [Line Items]          
Lease expiration date     Jun. 01, 2019    
Universal Health Services, Inc          
Leases Disclosure [Line Items]          
Lease revenue [1] $ 7,574 $ 6,381 $ 21,971 $ 18,243  
Universal Health Services, Inc | Base Rents          
Leases Disclosure [Line Items]          
Lease revenue 5,392 4,402 15,820 12,940  
Universal Health Services, Inc | Bonus Rents          
Leases Disclosure [Line Items]          
Lease revenue $ 1,828 $ 1,680 $ 5,171 $ 4,477  
Universal Health Services, Inc | Minimum          
Leases Disclosure [Line Items]          
Remaining lease terms on ground leases     28 years    
Universal Health Services, Inc | Maximum          
Leases Disclosure [Line Items]          
Remaining lease terms on ground leases     78 years    
Universal Health Services, Inc | Wellington Regional Medical Center          
Leases Disclosure [Line Items]          
Number of renewal options at fair market value lease rates | RenewalOption     2    
Renewal options term at fair market value lease rates     5 years    
Lease expiration date     Dec. 31, 2021    
Universal Health Services, Inc | Wellington Regional Medical Center | Minimum          
Leases Disclosure [Line Items]          
Renewal options at fair market value lease rates expiration year     2022    
Universal Health Services, Inc | Wellington Regional Medical Center | Maximum          
Leases Disclosure [Line Items]          
Renewal options at fair market value lease rates expiration year     2031    
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus          
Leases Disclosure [Line Items]          
Number of renewal options at fair market value lease rates | RenewalOption     2    
Renewal options term at fair market value lease rates     5 years    
Lease expiration date     Dec. 31, 2021    
Lease revenue     $ 3,400   4,400
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus | Base Rents          
Leases Disclosure [Line Items]          
Lease revenue     2,000   2,600
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus | Bonus Rents          
Leases Disclosure [Line Items]          
Lease revenue     $ 1,400   $ 1,800
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus | Minimum          
Leases Disclosure [Line Items]          
Renewal options at fair market value lease rates expiration year     2022    
Universal Health Services, Inc | Southwest Healthcare System, Inland Valley Campus | Maximum          
Leases Disclosure [Line Items]          
Renewal options at fair market value lease rates expiration year     2031    
[1] Includes bonus rental on UHS acute-care hospital facilities of $1,828 and $1,680 for the three-month periods ended September 30, 2021 and 2020, respectively, and $5,171 and $4,477 for the nine-month periods ended September 30, 2021 and 2020, respectively.
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Debt and Financial Instruments - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 02, 2021
USD ($)
Mar. 27, 2018
USD ($)
Option
Mar. 31, 2020
USD ($)
Derivative
Jan. 31, 2020
USD ($)
Derivative
Sep. 30, 2021
USD ($)
Sep. 30, 2019
USD ($)
Derivative
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Debt Instrument [Line Items]                  
Net borrowings on line of credit             $ 40,600,000 $ 14,150,000  
Proceeds from lines of credit             40,600,000 $ 14,150,000  
Outstanding borrowings under revolving credit agreement         $ 276,800,000   276,800,000   $ 236,200,000
Letters of credit outstanding         3,600,000   3,600,000    
Available borrowing capacity         94,600,000   94,600,000   108,200,000
Compensating balance         0   0    
Interest Rate Swap                  
Debt Instrument [Line Items]                  
Derivative interest rate cap, net payment received or accrued from counterparties             945,000    
Interest Rate Swap | Cash Flow Hedge                  
Debt Instrument [Line Items]                  
Number of interest rate cap agreements | Derivative     1 1   1      
Derivative instruments, fixed rate     0.565% 1.4975%   1.144%      
Notional amount     $ 55,000,000 $ 35,000,000   $ 50,000,000      
Expiration date of interest rate     Mar. 25, 2027 Sep. 16, 2024   Sep. 16, 2024      
Level 2                  
Debt Instrument [Line Items]                  
Mortgage loan fair value         60,300,000   60,300,000   62,000,000.0
Mortgage debt                 $ 59,200,000
Derivative interest rate cap, net payment received or accrued from counterparties             1,600,000    
Derivative interest rate cap, payment received or accrued from counterparties             199,000    
Derivative interest rate cap, offset due to counterparties             1,800,000    
Level 2 | Interest Rate Swap                  
Debt Instrument [Line Items]                  
Liability derivatives, fair value         556,000   $ 556,000    
Derivative interest rate cap, net payment received or accrued from counterparties         $ 324,000        
London Interbank Offered Rate (LIBOR)                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   1.25%              
Base Rate                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   0.25%              
Credit Agreement                  
Debt Instrument [Line Items]                  
Outstanding borrowing $ 350,000,000 $ 375,000,000              
Net borrowings on line of credit 350,000,000 $ 50,000,000              
Unsecured revolving amended credit agreement terminated date   Jul. 02, 2025              
Proceeds from lines of credit 350,000,000 $ 50,000,000              
Increase in borrowing capacity $ 375,000,000                
Number of additional six month extension options | Option   2              
Credit Agreement | Swingline/Short-Term Loans                  
Debt Instrument [Line Items]                  
Outstanding borrowing   $ 30,000,000              
Credit Agreement | Letters of Credit                  
Debt Instrument [Line Items]                  
Outstanding borrowing   $ 40,000,000              
Revolving A Facility                  
Debt Instrument [Line Items]                  
Credit facility, Interest Rate Terms             Borrowings under the Credit Agreement will bear interest annually at a rate equal to, at our option, at either LIBOR (for one, three, or six months) or the Base Rate, plus in either case, a specified margin depending on our ratio of debt to total capital, as determined by the formula set forth in the Credit Agreement. The applicable margin ranges from 1.10% to 1.35% for LIBOR loans and 0.10% to 0.35% for Base Rate loans.    
Base rate description             the greatest of (a) the Administrative Agent’s prime rate, (b) the federal funds effective rate plus 1/2 of 1% and (c) one month LIBOR plus 1%.    
Revolving A Facility | Minimum                  
Debt Instrument [Line Items]                  
Facility fee payable on commitment   0.15%              
Revolving A Facility | Minimum | London Interbank Offered Rate (LIBOR)                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   1.10%              
Margin points added to the base rate   1.00%              
Revolving A Facility | Minimum | Base Rate                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   0.10%              
Revolving A Facility | Minimum | Federal Funds Effective Rate                  
Debt Instrument [Line Items]                  
Margin points added to the base rate   0.50%              
Revolving A Facility | Maximum                  
Debt Instrument [Line Items]                  
Facility fee payable on commitment   0.35%              
Revolving A Facility | Maximum | London Interbank Offered Rate (LIBOR)                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   1.35%              
Revolving A Facility | Maximum | Base Rate                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate   0.35%              
Revolving B Facility                  
Debt Instrument [Line Items]                  
Facility fee payable on commitment             0.25%    
Revolving B Facility | London Interbank Offered Rate (LIBOR)                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate             1.25%    
Revolving B Facility | Base Rate                  
Debt Instrument [Line Items]                  
Margin points added to the reference rate             0.25%    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Covenant, Tangible net worth $ 125,000  
Tangible net worth $ 141,419 $ 147,263
Total leverage 45.60% 44.80%
Secured leverage 8.10% 8.60%
Unencumbered leverage 47.20% 41.40%
Fixed charge coverage 4.80% 4.70%
Maximum    
Debt Instrument [Line Items]    
Covenant, Total leverage 60.00%  
Covenant, Secured leverage 30.00%  
Covenant, Unencumbered leverage 60.00%  
Minimum    
Debt Instrument [Line Items]    
Covenant, Fixed charge coverage 1.50%  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 57,681  
Less net financing fees [1] (387)  
Plus net debt premium [1] 103  
Total mortgages notes payable, non-recourse to us, net 57,397 [1] $ 58,895
Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,268  
Debt Instrument Interest Rate Stated Percentage 4.54%  
Debt Instrument Maturity Date 2022-06  
BRB Medical Office Building Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 5,337  
Debt Instrument Interest Rate Stated Percentage 4.27%  
Debt Instrument Maturity Date 2022-12  
Desert Valley Medical Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,395  
Debt Instrument Interest Rate Stated Percentage 3.62%  
Debt Instrument Maturity Date 2023-01  
2704 North Tenaya Way Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,458  
Debt Instrument Interest Rate Stated Percentage 4.95%  
Debt Instrument Maturity Date 2023-11  
Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 12,866  
Debt Instrument Interest Rate Stated Percentage 4.03%  
Debt Instrument Maturity Date 2024-04  
Tuscan Professional Building Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 2,494  
Debt Instrument Interest Rate Stated Percentage 5.56%  
Debt Instrument Maturity Date 2025-06  
Phoenix Children’s East Valley Care Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 8,530  
Debt Instrument Interest Rate Stated Percentage 3.95%  
Debt Instrument Maturity Date 2030-01  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 12,333  
Debt Instrument Interest Rate Stated Percentage 4.42%  
Debt Instrument Maturity Date 2033-09  
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting - Additional Information (Detail)
9 Months Ended
Sep. 30, 2021
Segment
Segment Reporting [Abstract]  
Number of reportable segments 1
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 251 331 1 true 71 0 false 17 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical) Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical Condensed Consolidated Statements of Income (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Changes in Equity Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity Condensed Consolidated Statements of Changes in Equity Statements 7 false false R8.htm 100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical) Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical Condensed Consolidated Statements of Changes in Equity (Parenthetical) Statements 8 false false R9.htm 100080 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 9 false false R10.htm 100090 - Disclosure - General Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneral General Notes 10 false false R11.htm 100100 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 11 false false R12.htm 100110 - Disclosure - Dividends and Equity Issuance Program Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram Dividends and Equity Issuance Program Notes 12 false false R13.htm 100120 - Disclosure - Acquisitions and Divestitures Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestitures Acquisitions and Divestitures Notes 13 false false R14.htm 100130 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 14 false false R15.htm 100140 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 15 false false R16.htm 100150 - Disclosure - Lease Accounting Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccounting Lease Accounting Notes 16 false false R17.htm 100160 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 17 false false R18.htm 100170 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 18 false false R19.htm 100180 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 19 false false R20.htm 100190 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 20 false false R21.htm 100200 - Disclosure - Lease Accounting (Tables) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingTables Lease Accounting (Tables) Tables http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccounting 21 false false R22.htm 100210 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstruments 22 false false R23.htm 100220 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 24 false false R25.htm 100240 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 25 false false R26.htm 100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 26 false false R27.htm 100260 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail Dividends and Equity Issuance Program - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail Acquisitions and Divestitures - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 29 false false R30.htm 100290 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 30 false false R31.htm 100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 31 false false R32.htm 100310 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail) Details 32 false false R33.htm 100320 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail) Details 33 false false R34.htm 100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail) Details 34 false false R35.htm 100340 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail) Details 35 false false R36.htm 100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) Notes http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail) Details 36 false false R37.htm 100360 - Disclosure - Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail Lease Accounting - Components of the "Lease Revenue - UHS facilities" and "Lease Revenue - Non-related Parties" Captions (Detail) Details 37 false false R38.htm 100370 - Disclosure - Lease Accounting - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail Lease Accounting - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 40 false false R41.htm 100400 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 41 false false R42.htm 100410 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 42 false false All Reports Book All Reports uht-10q_20210930.htm uht-20210930.xsd uht-20210930_cal.xml uht-20210930_def.xml uht-20210930_lab.xml uht-20210930_pre.xml uht-ex311_8.htm uht-ex312_7.htm uht-ex321_6.htm uht-ex322_9.htm http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "uht-10q_20210930.htm": { "axisCustom": 0, "axisStandard": 29, "contextCount": 251, "dts": { "calculationLink": { "local": [ "uht-20210930_cal.xml" ] }, "definitionLink": { "local": [ "uht-20210930_def.xml" ] }, "inline": { "local": [ "uht-10q_20210930.htm" ] }, "labelLink": { "local": [ "uht-20210930_lab.xml" ] }, "presentationLink": { "local": [ "uht-20210930_pre.xml" ] }, "schema": { "local": [ "uht-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 437, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 15, "http://www.uhrit.com/20210930": 17, "http://xbrl.sec.gov/dei/2021": 4, "total": 36 }, "keyCustom": 88, "keyStandard": 243, "memberCustom": 43, "memberStandard": 20, "nsprefix": "uht", "nsuri": "http://www.uhrit.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - General", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneral", "shortName": "General", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Dividends and Equity Issuance Program", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram", "shortName": "Dividends and Equity Issuance Program", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Acquisitions and Divestitures", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestitures", "shortName": "Acquisitions and Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Summarized Financial Information of Equity Affiliates", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates", "shortName": "Summarized Financial Information of Equity Affiliates", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Recent Accounting Pronouncements", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DisclosuresOfLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Lease Accounting", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccounting", "shortName": "Lease Accounting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DisclosuresOfLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Debt and Financial Instruments", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstruments", "shortName": "Debt and Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Segment Reporting", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Statements of Income", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "shortName": "Condensed Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables", "shortName": "Summarized Financial Information of Equity Affiliates (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "uht:DisclosuresOfLeasesTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Lease Accounting (Tables)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingTables", "shortName": "Lease Accounting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "uht:DisclosuresOfLeasesTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Debt and Financial Instruments (Tables)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables", "shortName": "Debt and Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:ScheduleOfFinancialCovenantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtGraysonPropertiesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211108", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - General - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "shortName": "General - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210930", "decimals": "INF", "lang": null, "name": "uht:NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "reportCount": 1, "unique": true, "unitRef": "U_uhtProperty", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "uht:AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "uht:AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "4", "first": true, "lang": null, "name": "uht:AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "shortName": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtGraysonPropertiesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211108", "decimals": "-5", "lang": null, "name": "us-gaap:MinorityInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210930", "decimals": "0", "first": true, "lang": null, "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210930", "decimals": "0", "first": true, "lang": null, "name": "uht:OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "shortName": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapMajorPropertyClassAxis_uhtMcAllenMedicalCenterMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesIncMember_20210101_20210930", "decimals": null, "first": true, "lang": "en-US", "name": "uht:OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsOfDividends", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Dividends and Equity Issuance Program - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "shortName": "Dividends and Equity Issuance Program - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:GainLossOnDispositionOfAssets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Acquisitions and Divestitures - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "shortName": "Acquisitions and Divestitures - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20200101_20200930", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfBusinessesAcquired", "reportCount": 1, "unique": true, "unitRef": "U_uhtAcquisition", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtGraysonPropertiesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20211108", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "shortName": "Summarized Financial Information of Equity Affiliates - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtMedicalOfficeBuildingsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210930", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfRealEstateProperties", "reportCount": 1, "unique": true, "unitRef": "U_uhtProperty", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesHospitalIncMember_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:BonusRentalIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Statements of Income (Parenthetical)", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical", "shortName": "Condensed Consolidated Statements of Income (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtUniversalHealthServicesHospitalIncMember_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:BonusRentalIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtSuburbanPropertiesMember_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtSuburbanPropertiesMember_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtBrunswickAssociatesMember_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "shortName": "Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "p", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtOwnershipAxis_uhtBrunswickAssociatesMember_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermLoansPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "shortName": "Condensed Combined Statement of Income for LLCs/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20210701_20210930", "decimals": "-3", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "shortName": "Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeAxis_us-gaapEquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_20210930", "decimals": "-3", "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "shortName": "Condensed Combined Balance Sheets for LLCs/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "span", "p", "td", "tr", "table", "div", "uht:EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_uhtLimitedLiabilityCompanyOrLimitedPartnerMember_20210930", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "shortName": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapFairValueByAssetClassAxis_us-gaapEquityMethodInvestmentsMember_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "link:footnote", "span", "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtGraysonPropertiesTwoLPMember_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConstructionLoan", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "shortName": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "link:footnote", "span", "p", "td", "tr", "table", "div", "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapRealEstatePropertiesAxis_uhtGraysonPropertiesTwoLPMember_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ConstructionLoan", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtCounterpartyNameAxis_uhtNonRelatedPartyMember_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "shortName": "Lease Accounting - Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "uht:DisclosuresOfLeasesTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_srtCounterpartyNameAxis_uhtNonRelatedPartyMember_us-gaapLeaseContractualTermAxis_uhtBaseRentsMember_20210701_20210930", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "INF", "first": true, "lang": null, "name": "uht:NumberOfGroundLeasesForLand", "reportCount": 1, "unique": true, "unitRef": "U_uhtLand", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Lease Accounting - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "shortName": "Lease Accounting - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "INF", "first": true, "lang": null, "name": "uht:NumberOfGroundLeasesForLand", "reportCount": 1, "unique": true, "unitRef": "U_uhtLand", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLinesOfCredit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Debt and Financial Instruments - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "shortName": "Debt and Financial Instruments - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "uht:DebtAndFinancialInstrumentsDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20201231", "decimals": "-5", "lang": null, "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Comprehensive Income", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:TangibleNetWorth", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail", "shortName": "Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "uht:ScheduleOfFinancialCovenantsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "uht:TangibleNetWorth", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NonRecourseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "shortName": "Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NonRecourseDebt", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_uhtSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Segment Reporting - Additional Information (Detail)", "role": "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail", "shortName": "Segment Reporting - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_uhtSegment", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RealEstateInvestmentPropertyAtCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Changes in Equity", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "shortName": "Condensed Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "INF", "first": true, "lang": null, "name": "uht:DividendsPerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical", "shortName": "Condensed Consolidated Statements of Changes in Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210701_20210930", "decimals": "INF", "first": true, "lang": null, "name": "uht:DividendsPerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100080 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "uht-10q_20210930.htm", "contextRef": "C_0000798783_20210101_20210930", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } } }, "segmentCount": 71, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r495" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r496" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r504" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation Fiscal Year Maturity Schedule Table [Text Block]", "terseLabel": "Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's/LPs Accounted Under Equity Method" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r36", "r90", "r91", "r208", "r229", "r517" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of investment including named security. Excludes entity that is consolidated.", "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r154", "r250", "r253", "r448" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r207", "r228", "r269", "r271", "r373", "r374", "r375", "r376", "r377", "r378", "r398", "r445", "r449", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r207", "r228", "r269", "r271", "r373", "r374", "r375", "r376", "r377", "r378", "r398", "r445", "r449", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_MortgageLoansOnRealEstateLoanTypeAxis": { "auth_ref": [ "r477", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by type of loan for investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "Mortgage Loans On Real Estate Loan Type [Axis]", "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type" } } }, "localname": "MortgageLoansOnRealEstateLoanTypeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateLoanTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of loan within investment in mortgage loan on real estate by entity with substantial portion of business acquiring and holding investment real estate or interest in real estate.", "label": "Mortgage Loans On Real Estate Loan Type [Domain]", "terseLabel": "SEC Schedule, 12-29, Real Estate Companies, Investment in Mortgage Loans on Real Estate, Loan Type" } } }, "localname": "MortgageLoansOnRealEstateLoanTypeDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r154", "r250", "r253", "r448" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.", "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r150", "r250", "r251", "r399", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r150", "r250", "r251", "r399", "r444", "r446" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r207", "r228", "r258", "r269", "r271", "r373", "r374", "r375", "r376", "r377", "r378", "r398", "r445", "r449", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r207", "r228", "r258", "r269", "r271", "r373", "r374", "r375", "r376", "r377", "r378", "r398", "r445", "r449", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r35", "r36", "r90", "r91", "r208", "r229" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by name of investment including named security. Excludes entity that is consolidated.", "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r151", "r152", "r250", "r252", "r447", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r506", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r151", "r152", "r250", "r252", "r447", "r478", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r506", "r508" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_AggregateSalesOfThresholdAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate sales of threshold amount.", "label": "Aggregate Sales Of Threshold Amount", "terseLabel": "Aggregate sales of threshold amount" } } }, "localname": "AggregateSalesOfThresholdAmount", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual advisory fees as percentage of average invested real estate assets.", "label": "Annual Advisory Fees As Percentage Of Average Invested Real Estate Assets", "terseLabel": "Annual advisory fee as percentage of average invested real estate assets" } } }, "localname": "AnnualAdvisoryFeesAsPercentageOfAverageInvestedRealEstateAssets", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_AtMarketATMProgramsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shelf registration.", "label": "At Market A T M Programs [Member]", "terseLabel": "At-The-Market Equity Issuance Program (ATM)" } } }, "localname": "AtMarketATMProgramsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_AuburnMedicalOfficeBuildingIIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Auburn Medical Office Building II.", "label": "Auburn Medical Office Building I I [Member]", "terseLabel": "Auburn Medical Office Building II" } } }, "localname": "AuburnMedicalOfficeBuildingIIMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_AverageInvestedRealEstateAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Average invested real estate assets.", "label": "Average Invested Real Estate Assets", "terseLabel": "Average invested real estate assets" } } }, "localname": "AverageInvestedRealEstateAssets", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_BRBMedicalOfficeBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BRB medical office building fixed rate mortgage loan.", "label": "B R B Medical Office Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "BRB Medical Office Building Fixed Rate Mortgage Loan" } } }, "localname": "BRBMedicalOfficeBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_BaseRentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Base rents.", "label": "Base Rents [Member]", "terseLabel": "Base Rents" } } }, "localname": "BaseRentsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_BonusRentalIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Bonus rental income.", "label": "Bonus Rental Income", "terseLabel": "Bonus rental" } } }, "localname": "BonusRentalIncome", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "monetaryItemType" }, "uht_BonusRentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonus rents.", "label": "Bonus Rents [Member]", "terseLabel": "Bonus Rents" } } }, "localname": "BonusRentsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_BrunswickAssociatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Brunswick Associates [Member]", "terseLabel": "Brunswick Associates" } } }, "localname": "BrunswickAssociatesMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_BusinessAcquisitionsAndDispositionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisitions and dispositions.", "label": "Business Acquisitions And Dispositions [Line Items]", "terseLabel": "Business Acquisitions And Dispositions [Line Items]" } } }, "localname": "BusinessAcquisitionsAndDispositionsLineItems", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_BusinessAcquisitionsAndDispositionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business acquisitions and dispositions.", "label": "Business Acquisitions And Dispositions [Table]", "terseLabel": "Business Acquisitions And Dispositions [Table]" } } }, "localname": "BusinessAcquisitionsAndDispositionsTable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_CashDistributionsInExcessOfIncomeFromLimitedLiabilityCompanies": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity investment distribution.", "label": "Cash Distributions In Excess Of Income From Limited Liability Companies", "terseLabel": "Cash distributions from LLCs" } } }, "localname": "CashDistributionsInExcessOfIncomeFromLimitedLiabilityCompanies", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_ChangeInControlOfTrustNoticePeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change in control of trust notice period, description.", "label": "Change In Control Of Trust Notice Period Description", "terseLabel": "Change in control of trust notice, description" } } }, "localname": "ChangeInControlOfTrustNoticePeriodDescription", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Components of lessor lease revenue with UHS facilities and non-related parties.", "label": "Components Of Lessor Lease Revenue With U H S Facilities And Non Related Parties Table [Text Block]", "terseLabel": "Components of the \"Lease Revenue - UHS facilities\" and \"Lease Revenue - Non-related Parties\" Captions" } } }, "localname": "ComponentsOfLessorLeaseRevenueWithUHSFacilitiesAndNonRelatedPartiesTableTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingTables" ], "xbrltype": "textBlockItemType" }, "uht_ConstructionLoanOutstandingBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Construction loan outstanding balance.", "label": "Construction Loan Outstanding Balance", "terseLabel": "Construction loan outstanding balance" } } }, "localname": "ConstructionLoanOutstandingBalance", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_CorpusChristiCorpusChristiTexasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corpus Christi Corpus Christi, Texas.", "label": "Corpus Christi Corpus Christi Texas [Member]", "terseLabel": "Corpus Christi Corpus Christi Texas" } } }, "localname": "CorpusChristiCorpusChristiTexasMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_CumulativeDividendsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cumulative dividends.", "label": "Cumulative Dividends [Member]", "terseLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividendsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "uht_DebtAndFinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt and financial instruments disclosure.", "label": "Debt And Financial Instruments Disclosure [Text Block]", "terseLabel": "Debt and Financial Instruments" } } }, "localname": "DebtAndFinancialInstrumentsDisclosureTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "uht_DebtInstrumentCovenantComplianceSecuredLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant compliance secured leverage ratio.", "label": "Debt Instrument Covenant Compliance Secured Leverage Ratio", "terseLabel": "Covenant, Secured leverage" } } }, "localname": "DebtInstrumentCovenantComplianceSecuredLeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant fixed charge coverage ratio.", "label": "Debt Instrument Covenant Fixed Charge Coverage Ratio", "terseLabel": "Covenant, Fixed charge coverage" } } }, "localname": "DebtInstrumentCovenantFixedChargeCoverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant leverage ratio.", "label": "Debt Instrument Covenant Leverage Ratio", "terseLabel": "Covenant, Total leverage" } } }, "localname": "DebtInstrumentCovenantLeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentCovenantTangibleNetWorth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant tangible net worth.", "label": "Debt Instrument Covenant Tangible Net Worth", "terseLabel": "Covenant, Tangible net worth" } } }, "localname": "DebtInstrumentCovenantTangibleNetWorth", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "monetaryItemType" }, "uht_DebtInstrumentCovenantUnencumberedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument covenant unencumbered leverage ratio.", "label": "Debt Instrument Covenant Unencumbered Leverage Ratio", "terseLabel": "Covenant, Unencumbered leverage" } } }, "localname": "DebtInstrumentCovenantUnencumberedLeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_DebtInstrumentMaturityMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument, maturity, month and year.", "label": "Debt Instrument Maturity Month And Year", "terseLabel": "Debt Instrument Maturity Date" } } }, "localname": "DebtInstrumentMaturityMonthAndYear", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "gYearMonthItemType" }, "uht_DenisonTexasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denison, Texas.", "label": "Denison Texas [Member]", "terseLabel": "Denison Texas" } } }, "localname": "DenisonTexasMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap, net payment received or accrued from counter parties.", "label": "Derivative Interest Rate Cap Net Payment Received Or Accrued From Counter Parties", "terseLabel": "Derivative interest rate cap, net payment received or accrued from counterparties" } } }, "localname": "DerivativeInterestRateCapNetPaymentReceivedOrAccruedFromCounterParties", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DerivativeInterestRateCapPaymentOffsetDueToCounterParties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap payment offset due to counter parties.", "label": "Derivative Interest Rate Cap Payment Offset Due To Counter Parties", "terseLabel": "Derivative interest rate cap, offset due to counterparties" } } }, "localname": "DerivativeInterestRateCapPaymentOffsetDueToCounterParties", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Derivative interest rate cap payment received or accrued from counter parties.", "label": "Derivative Interest Rate Cap Payment Received Or Accrued From Counter Parties", "terseLabel": "Derivative interest rate cap, payment received or accrued from counterparties" } } }, "localname": "DerivativeInterestRateCapPaymentReceivedOrAccruedFromCounterParties", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DesertValleyMedicalCenterFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Desert valley medical center fixed rate mortgage loan.", "label": "Desert Valley Medical Center Fixed Rate Mortgage Loan [Member]", "terseLabel": "Desert Valley Medical Center Fixed Rate Mortgage Loan" } } }, "localname": "DesertValleyMedicalCenterFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_DisclosuresOfLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosures of leases.", "label": "Disclosures Of Leases [Text Block]", "terseLabel": "Lease Accounting" } } }, "localname": "DisclosuresOfLeasesTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccounting" ], "xbrltype": "textBlockItemType" }, "uht_DisposalGroupIncludingDiscontinuedOperationConsiderationNetOfClosingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation consideration net of closing costs.", "label": "Disposal Group Including Discontinued Operation Consideration Net Of Closing Costs", "terseLabel": "Sale price net of closing costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNetOfClosingCosts", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_DividendsAndEquityIssuanceLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends and equity issuance.", "label": "Dividends And Equity Issuance [Line Items]", "terseLabel": "Dividends and Equity Issuance [Line Items]" } } }, "localname": "DividendsAndEquityIssuanceLineItems", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_DividendsAndEquityIssuanceTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends and equity issuance.", "label": "Dividends And Equity Issuance [Table]", "terseLabel": "Dividends And Equity Issuance [Table]" } } }, "localname": "DividendsAndEquityIssuanceTable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_DividendsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dividends, per share.", "label": "Dividends Per Share", "terseLabel": "Dividend, per share" } } }, "localname": "DividendsPerShare", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquityParenthetical" ], "xbrltype": "perShareItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10050.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information advance payment to loans to related party.", "label": "Equity Method Investment Summarized Financial Information Advance Payment To Loans To Related Party", "terseLabel": "Advances payable to us" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAdvancePaymentToLoansToRelatedParty", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10070.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information assets property plant and equipment net.", "label": "Equity Method Investment Summarized Financial Information Assets Property Plant And Equipment Net", "terseLabel": "Net property, including construction in progress" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssetsPropertyPlantAndEquipmentNet", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10030.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information depreciation and amortization.", "label": "Equity Method Investment Summarized Financial Information Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationDepreciationAndAmortization", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationInterestExpense": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10040.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information interest expense.", "label": "Equity Method Investment Summarized Financial Information Interest Expense", "terseLabel": "Interest, net" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationInterestExpense", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10040.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Summarized Financial Information Mortgage Notes Payable", "label": "Equity Method Investment Summarized Financial Information Mortgage Notes Payable", "terseLabel": "Mortgage Loan Balance", "verboseLabel": "Mortgage notes payable, non-recourse to us" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationMortgageNotesPayable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10020.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment, summarized financial information, operating expenses.", "label": "Equity Method Investment Summarized Financial Information Operating Expenses", "terseLabel": "Operating expenses" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOperatingExpenses", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherAssets": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10080.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity method investment summarized financial information other assets.", "label": "Equity Method Investment Summarized Financial Information Other Assets", "terseLabel": "Other assets" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOtherAssets", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Method Investment Summarized Financial Information Other Liabilities", "label": "Equity Method Investment Summarized Financial Information Other Liabilities", "terseLabel": "Other liabilities" } } }, "localname": "EquityMethodInvestmentSummarizedFinancialInformationOtherLiabilities", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10020.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity method investments accrued expenses and other liabilities.", "label": "Equity Method Investments Accrued Expenses And Other Liabilities", "negatedLabel": "Amounts included in accrued expenses and other liabilities" } } }, "localname": "EquityMethodInvestmentsAccruedExpensesAndOtherLiabilities", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "uht_EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments Summarized Combined Balance Sheet Information.", "label": "Equity Method Investments Summarized Combined Balance Sheet Information Table [Text Block]", "terseLabel": "Condensed Combined Balance Sheets (Unaudited) for LLCs/LPs Accounted Under Equity Method" } } }, "localname": "EquityMethodInvestmentsSummarizedCombinedBalanceSheetInformationTableTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "uht_EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Method Investments Summarized Income Statement Information.", "label": "Equity Method Investments Summarized Income Statement Information Table [Text Block]", "terseLabel": "Condensed Combined Statements of Income (Unaudited) for LLCs/LPs Accounted Under Equity Method" } } }, "localname": "EquityMethodInvestmentsSummarizedIncomeStatementInformationTableTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "uht_EvansvilleRehabilitationHospitalEvansvilleIndianaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evansville Rehabilitation Hospital Evansville, Indiana.", "label": "Evansville Rehabilitation Hospital Evansville Indiana [Member]", "terseLabel": "Evansville Rehabilitation Hospital Evansville, Indiana" } } }, "localname": "EvansvilleRehabilitationHospitalEvansvilleIndianaMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_ExtendedLeaseExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extended lease expiration date.", "label": "Extended Lease Expiration Date", "terseLabel": "Extended Lease Expiration Date" } } }, "localname": "ExtendedLeaseExpirationDate", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "uht_FTXMobPhaseTwoLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "F T X Mob Phase Two L P [Member]", "terseLabel": "FTX MOB Phase II limited partnership" } } }, "localname": "FTXMobPhaseTwoLPMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_FTXMobPhaseTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "F T X Mob Phase Two [Member]", "terseLabel": "FTX MOB Phase II" } } }, "localname": "FTXMobPhaseTwoMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "uht_FederalFundsEffectiveRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal funds effective rate.", "label": "Federal Funds Effective Rate [Member]", "terseLabel": "Federal Funds Effective Rate" } } }, "localname": "FederalFundsEffectiveRateMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_FinancingFeesNet": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11100.0, "parentTag": "us-gaap_SecuredDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing fees net.", "label": "Financing Fees Net", "negatedLabel": "Less net financing fees" } } }, "localname": "FinancingFeesNet", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "uht_FireMesaOfficeBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fire Mesa office building located in Las Vegas.", "label": "Fire Mesa Office Building [Member]", "terseLabel": "Fire Mesa Office Building [Member]" } } }, "localname": "FireMesaOfficeBuildingMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_FixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed charge coverage ratio.", "label": "Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage" } } }, "localname": "FixedChargeCoverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_GraysonPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Grayson Properties [Member]", "terseLabel": "Grayson Properties" } } }, "localname": "GraysonPropertiesMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_GraysonPropertiesTwoLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grayson properties two LP.", "label": "Grayson Properties Two L P [Member]", "terseLabel": "Grayson Properties Two L P", "verboseLabel": "Grayson Properties II LP" } } }, "localname": "GraysonPropertiesTwoLPMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_IncreaseDecreaseInLeasingCosts": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in leasing costs.", "label": "Increase Decrease In Leasing Costs", "negatedLabel": "Leasing costs paid" } } }, "localname": "IncreaseDecreaseInLeasingCosts", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in tenant reserves, deposits, deferred and prepaid rents.", "label": "Increase Decrease In Tenant Reserves Deposits Deferred And Prepaid Rents", "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents" } } }, "localname": "IncreaseDecreaseInTenantReservesDepositsDeferredAndPrepaidRents", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_InitialLeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial lease expiration period.", "label": "Initial Lease Expiration Period", "terseLabel": "Initial lease terms" } } }, "localname": "InitialLeaseExpirationPeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_InvestmentCommitments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commitments to invest.", "label": "Investment Commitments", "terseLabel": "Commitment to investment" } } }, "localname": "InvestmentCommitments", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_KindredChicagoCentralHospitalCentralChicagoIllinoisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kindred Chicago Central Hospital Central Chicago, Illinois.", "label": "Kindred Chicago Central Hospital Central Chicago Illinois [Member]", "terseLabel": "Kindred Chicago Central Hospital Central Chicago, Illinois" } } }, "localname": "KindredChicagoCentralHospitalCentralChicagoIllinoisMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_LeaseAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease and other receivables.", "label": "Lease And Other Receivables", "terseLabel": "Lease and other receivables from UHS" } } }, "localname": "LeaseAndOtherReceivables", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_LeaseExpirationMonthAndYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration, month and year.", "label": "Lease Expiration Month And Year", "verboseLabel": "End of Lease Term" } } }, "localname": "LeaseExpirationMonthAndYear", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "gYearMonthItemType" }, "uht_LeasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease percentage.", "label": "Lease Percentage", "terseLabel": "Lease percentage" } } }, "localname": "LeasePercentage", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_LeaseReceivableOther": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Lease receivable, other.", "label": "Lease Receivable Other", "terseLabel": "Lease receivable - other" } } }, "localname": "LeaseReceivableOther", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_LeaseRenewalNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease renewal, notice period.", "label": "Lease Renewal Notice Period", "terseLabel": "Option to renew lease, notice period prior to termination date of current term" } } }, "localname": "LeaseRenewalNoticePeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_LeasesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases Disclosure [Line Items]", "label": "Leases Disclosure [Line Items]", "terseLabel": "Leases Disclosure [Line Items]" } } }, "localname": "LeasesDisclosureLineItems", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "stringItemType" }, "uht_LeasesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leases Disclosure [Table]", "label": "Leases Disclosure [Table]", "terseLabel": "Leases Disclosure [Table]" } } }, "localname": "LeasesDisclosureTable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "stringItemType" }, "uht_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "verboseLabel": "Aggregate lease payments for thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_LeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leverage ratio.", "label": "Leverage Ratio", "terseLabel": "Total leverage" } } }, "localname": "LeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_LimitedLiabilityCompanyOrLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limited liability company or limited partner.", "label": "Limited Liability Company Or Limited Partner [Member]", "terseLabel": "Limited Liability Companies" } } }, "localname": "LimitedLiabilityCompanyOrLimitedPartnerMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_LineOfCreditFacilityExpirationYearAndMonth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of credit facility expiration year and month.", "label": "Line Of Credit Facility Expiration Year And Month", "terseLabel": "Unsecured revolving amended credit agreement terminated date" } } }, "localname": "LineOfCreditFacilityExpirationYearAndMonth", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "uht_LineOfCreditIncreaseInBorrowingCapacity": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Line of credit increase in borrowing capacity.", "label": "Line Of Credit Increase In Borrowing Capacity", "terseLabel": "Increase in borrowing capacity" } } }, "localname": "LineOfCreditIncreaseInBorrowingCapacity", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_MarginOnBaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Margin on base rate.", "label": "Margin On Base Rate", "terseLabel": "Margin points added to the base rate" } } }, "localname": "MarginOnBaseRate", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_MasterFlexLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Master flex lease term.", "label": "Master Flex Lease Term", "terseLabel": "Master flex lease term" } } }, "localname": "MasterFlexLeaseTerm", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_McAllenMedicalCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Mc Allen Medical Center [Member]", "terseLabel": "McAllen Medical Center" } } }, "localname": "McAllenMedicalCenterMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "domainItemType" }, "uht_MedicalOfficeBuildingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medical office buildings.", "label": "Medical Office Buildings [Member]", "terseLabel": "Medical Office Buildings" } } }, "localname": "MedicalOfficeBuildingsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_MemberLoanUsedToRepayMortgageLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Member loan used to repay mortgage loan.", "label": "Member Loan Used To Repay Mortgage Loan", "terseLabel": "Member loan used to repay mortgage loan" } } }, "localname": "MemberLoanUsedToRepayMortgageLoan", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_MortgageDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Mortgage debt.", "label": "Mortgage Debt", "terseLabel": "Mortgage debt" } } }, "localname": "MortgageDebt", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_NonRelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non related party.", "label": "Non Related Party [Member]", "terseLabel": "Non-Related Parties" } } }, "localname": "NonRelatedPartyMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "uht_NumberOfAdditionalLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional lease term.", "label": "Number Of Additional Lease Term", "terseLabel": "Number of Additional Lease Term" } } }, "localname": "NumberOfAdditionalLeaseTerm", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfBedInSpecialtyHospital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of bed in specialty hospital.", "label": "Number Of Bed In Specialty Hospital", "terseLabel": "Number of beds in specialty hospital" } } }, "localname": "NumberOfBedInSpecialtyHospital", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfBusinessesDisposed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of businesses disposed.", "label": "Number Of Businesses Disposed", "verboseLabel": "Number of dispositions" } } }, "localname": "NumberOfBusinessesDisposed", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of extension options.", "label": "Number Of Extension Options", "terseLabel": "Number of additional six month extension options" } } }, "localname": "NumberOfExtensionOptions", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfGroundLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ground leases.", "label": "Number Of Ground Leases", "terseLabel": "Number of ground leases" } } }, "localname": "NumberOfGroundLeases", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfGroundLeasesForLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of ground leases for land.", "label": "Number Of Ground Leases For Land", "terseLabel": "Lessee in connection with ground leases for land" } } }, "localname": "NumberOfGroundLeasesForLand", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of leased properties for medical office buildings and free standing emergency departments.", "label": "Number Of Leased Properties For Medical Office Buildings And Free Standing Emergency Departments", "terseLabel": "Number of medical office buildings and free standing emergency departments" } } }, "localname": "NumberOfLeasedPropertiesForMedicalOfficeBuildingsAndFreeStandingEmergencyDepartments", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of real estate properties including property under construction.", "label": "Number Of Real Estate Properties Including Property Under Construction", "terseLabel": "Number of real estate investments" } } }, "localname": "NumberOfRealEstatePropertiesIncludingPropertyUnderConstruction", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of renewal options.", "label": "Number Of Renewal Options", "terseLabel": "Number of term renewal options" } } }, "localname": "NumberOfRenewalOptions", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "uht_NumberOfTradingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of trading period.", "label": "Number Of Trading Period", "terseLabel": "Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member" } } }, "localname": "NumberOfTradingPeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease remaining lease term.", "label": "Operating Lease Remaining Lease Term", "terseLabel": "Remaining lease terms on ground leases" } } }, "localname": "OperatingLeaseRemainingLeaseTerm", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeasesAnnualFutureMinimumPaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating leases, annual future minimum payments receivable.", "label": "Operating Leases Annual Future Minimum Payments Receivable", "terseLabel": "Annual Minimum Rent" } } }, "localname": "OperatingLeasesAnnualFutureMinimumPaymentsReceivable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "monetaryItemType" }, "uht_OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, number of renewal options at existing lease rates.", "label": "Operating Leases Number Of Renewal Options At Existing Lease Rates", "terseLabel": "Number of renewal options at existing lease rate", "verboseLabel": "Number of renewal option at existing lease rate" } } }, "localname": "OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "uht_OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, number of renewal options at fair market value lease rates.", "label": "Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates", "terseLabel": "Number of renewal options at fair market value lease rates" } } }, "localname": "OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "positiveIntegerItemType" }, "uht_OperatingLeasesRenewalOptionsAtExistingLeaseRateExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options at existing lease rate, expiration year.", "label": "Operating Leases Renewal Options At Existing Lease Rate Expiration Year", "terseLabel": "Renewal option at existing lease rate expiration year" } } }, "localname": "OperatingLeasesRenewalOptionsAtExistingLeaseRateExpirationYear", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "gYearItemType" }, "uht_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options at fair market value lease rates, expiration year.", "label": "Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year", "terseLabel": "Renewal options at fair market value lease rates expiration year" } } }, "localname": "OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "gYearItemType" }, "uht_OperatingLeasesRenewalOptionsTermAtExistingLeaseRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options term at existing lease rate.", "label": "Operating Leases Renewal Options Term At Existing Lease Rate", "terseLabel": "Renewal option term at existing lease rate" } } }, "localname": "OperatingLeasesRenewalOptionsTermAtExistingLeaseRate", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "durationItemType" }, "uht_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating leases, renewal options term at fair market value lease rates.", "label": "Operating Leases Renewal Options Term At Fair Market Value Lease Rates", "terseLabel": "Renewal options term at fair market value lease rates" } } }, "localname": "OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "uht_PaymentsForDepositOnRealEstateAssets": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for deposit on real estate assets.", "label": "Payments For Deposit On Real Estate Assets", "negatedLabel": "Deposit on real estate assets" } } }, "localname": "PaymentsForDepositOnRealEstateAssets", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "uht_PaymentsForStockIssuanceOtherFeesAndExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments for stock issuance other fees and expenses.", "label": "Payments For Stock Issuance Other Fees And Expenses", "terseLabel": "Payments for stock issuance" } } }, "localname": "PaymentsForStockIssuanceOtherFeesAndExpenses", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "uht_PeaceHealthMedicalClinicBellinghamWAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Peace Health Medical Clinic Bellingham, WA.", "label": "Peace Health Medical Clinic Bellingham W A [Member]", "terseLabel": "PeaceHealth Medical Clinic Bellingham WA" } } }, "localname": "PeaceHealthMedicalClinicBellinghamWAMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_PercentageOfBuildingAreaLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of building area leased.", "label": "Percentage Of Building Area Leased", "terseLabel": "Percentage of building area leased" } } }, "localname": "PercentageOfBuildingAreaLeased", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_PercentageOfOwnershipInterestRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest related parties.", "label": "Percentage Of Ownership Interest Related Parties", "terseLabel": "Percentage ownership of outstanding shares" } } }, "localname": "PercentageOfOwnershipInterestRelatedParties", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_PercentageOfRentableSquareFeet": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of rentable square feet.", "label": "Percentage Of Rentable Square Feet", "terseLabel": "Percentage of rentable square feet" } } }, "localname": "PercentageOfRentableSquareFeet", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "uht_PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period to purchase respective leased facilities after lease terms.", "label": "Period To Purchase Respective Leased Facilities After Lease Terms", "terseLabel": "Period to purchase respective leased facilities at same price after lease terms" } } }, "localname": "PeriodToPurchaseRespectiveLeasedFacilitiesAfterLeaseTerms", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phoenix children's east valley care center fixed rate mortgage loan.", "label": "Phoenix Children East Valley Care Center Fixed Rate Mortgage Loan [Member]", "terseLabel": "Phoenix Children\u2019s East Valley Care Center Fixed Rate Mortgage Loan" } } }, "localname": "PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property owned by limited liability or limited partner company.", "label": "Property Owned By Limited Liability Or Limited Partner Company", "terseLabel": "Property Owned by LLC/LP" } } }, "localname": "PropertyOwnedByLimitedLiabilityOrLimitedPartnerCompany", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "uht_RenewalOptionTermsAdditionalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal option terms additional period.", "label": "Renewal Option Terms Additional Period", "terseLabel": "Additional renewal terms" } } }, "localname": "RenewalOptionTermsAdditionalPeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RenewalOptionTermsMaximumAdditionalPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal option terms maximum additional period.", "label": "Renewal Option Terms Maximum Additional Period", "terseLabel": "Renewal period of respective leased facilities at same price after lease terms" } } }, "localname": "RenewalOptionTermsMaximumAdditionalPeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RenewalOptionsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renewal options term.", "label": "Renewal Options Term", "terseLabel": "Renewal option term" } } }, "localname": "RenewalOptionsTerm", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_RepaymentOfLoan": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of loan.", "label": "Repayment Of Loan", "terseLabel": "Repayment of loan" } } }, "localname": "RepaymentOfLoan", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "uht_RevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue.", "label": "Revenue [Member]", "terseLabel": "Revenues" } } }, "localname": "RevenueMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingAFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving A facility.", "label": "Revolving A Facility [Member]", "terseLabel": "Revolving A Facility" } } }, "localname": "RevolvingAFacilityMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingBFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving B facility.", "label": "Revolving B Facility [Member]", "terseLabel": "Revolving B Facility" } } }, "localname": "RevolvingBFacilityMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RevolvingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revolving credit agreement.", "label": "Revolving Credit Agreement [Member]", "terseLabel": "Credit Agreement" } } }, "localname": "RevolvingCreditAgreementMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rosenberg children's medical plaza fixed rate mortgage loan.", "label": "Rosenberg Children Medical Plaza Fixed Rate Mortgage Loan [Member]", "terseLabel": "Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan" } } }, "localname": "RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_ScheduleOfFinancialCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Financial Covenants.", "label": "Schedule Of Financial Covenants Table [Text Block]", "terseLabel": "Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement" } } }, "localname": "ScheduleOfFinancialCovenantsTableTextBlock", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "uht_SecuredLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured leverage ratio.", "label": "Secured Leverage Ratio", "terseLabel": "Secured leverage" } } }, "localname": "SecuredLeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seven hundred shadow lane and goldring medical office building fixed rate mortgage loan.", "label": "Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "Seven Hundred Shadow Lane And Goldring Medical Office Building Fixed Rate Mortgage Loan" } } }, "localname": "SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_SharesIssuedAveragePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued average price per share.", "label": "Shares Issued Average Price Per Share", "terseLabel": "Average sale price per share" } } }, "localname": "SharesIssuedAveragePricePerShare", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "uht_SharesOfBeneficialInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of beneficial interest.", "label": "Shares Of Beneficial Interest [Abstract]", "terseLabel": "Shares of Beneficial Interest:" } } }, "localname": "SharesOfBeneficialInterestAbstract", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "uht_SouthwestHealthcareSystemInlandValleyCampusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Southwest Healthcare System Inland Valley Campus [Member]", "terseLabel": "Southwest Healthcare System, Inland Valley Campus" } } }, "localname": "SouthwestHealthcareSystemInlandValleyCampusMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_SuburbanPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property Owned by Limited Liability Company in which we have a majority, non-controlling equity interest", "label": "Suburban Properties [Member]", "terseLabel": "Suburban Properties" } } }, "localname": "SuburbanPropertiesMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "uht_SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summerlin hospital medical office building three fixed rate mortgage loan.", "label": "Summerlin Hospital Medical Office Building Three Fixed Rate Mortgage Loan [Member]", "terseLabel": "Summerlin Hospital Medical Office Building III Fixed Rate Mortgage Loan" } } }, "localname": "SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_TangibleNetWorth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tangible net worth.", "label": "Tangible Net Worth", "terseLabel": "Tangible net worth" } } }, "localname": "TangibleNetWorth", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "monetaryItemType" }, "uht_TenantReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant reimbursements.", "label": "Tenant Reimbursements [Member]", "terseLabel": "Tenant Reimbursements" } } }, "localname": "TenantReimbursementsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail" ], "xbrltype": "domainItemType" }, "uht_TenantReservesDepositsAndDeferredAndPrepaidRents": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount at the balance sheet date that has been received by the entity that represents collections of cash or other assets related to real estate operations revenue for which revenue has not yet been recognized and money paid in advance to protect the provider of a product or services, such as a lessor, against damage or non-payment by the tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property and other contractual breaches.", "label": "Tenant Reserves Deposits And Deferred And Prepaid Rents", "terseLabel": "Tenant reserves, deposits and deferred and prepaid rents" } } }, "localname": "TenantReservesDepositsAndDeferredAndPrepaidRents", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "uht_TenantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenants.", "label": "Tenants [Member]", "terseLabel": "Tenants" } } }, "localname": "TenantsMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_TripleNetLeaseAgreementPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Triple net lease agreement period.", "label": "Triple Net Lease Agreement Period", "terseLabel": "Triple net lease agreement period" } } }, "localname": "TripleNetLeaseAgreementPeriod", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "uht_TuscanyProfessionalBuildingFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument 100% consolidated", "label": "Tuscany Professional Building Fixed Rate Mortgage Loan [Member]", "terseLabel": "Tuscan Professional Building Fixed Rate Mortgage Loan" } } }, "localname": "TuscanyProfessionalBuildingFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two seven zero four north Tenaya way fixed rate mortgage loan.", "label": "Two Seven Zero Four North Tenaya Way Fixed Rate Mortgage Loan [Member]", "terseLabel": "2704 North Tenaya Way Fixed Rate Mortgage Loan" } } }, "localname": "TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "domainItemType" }, "uht_UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unconsolidated limited liabilities or limited partner.", "label": "Unconsolidated Limited Liabilities Or Limited Partner [Member]", "terseLabel": "4 Unconsolidated Limited Liability Companies / Limited Partner" } } }, "localname": "UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_UnencumberedLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unencumbered leverage ratio.", "label": "Unencumbered Leverage Ratio", "terseLabel": "Unencumbered leverage" } } }, "localname": "UnencumberedLeverageRatio", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "percentItemType" }, "uht_UniversalHealthServicesHospitalIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Universal health services hospital Inc.", "label": "Universal Health Services Hospital Inc [Member]", "terseLabel": "UHS Hospital Facilities" } } }, "localname": "UniversalHealthServicesHospitalIncMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesIncAndCatholicHealthInitiativesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Universal Health Services, Inc and Catholic Health Initiatives.", "label": "Universal Health Services Inc And Catholic Health Initiatives [Member]", "terseLabel": "Universal Health Services Inc And Catholic Health Initiatives" } } }, "localname": "UniversalHealthServicesIncAndCatholicHealthInitiativesMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related-party principal tenant.", "label": "Universal Health Services Inc [Member]", "terseLabel": "Universal Health Services, Inc", "verboseLabel": "UHS Facilities" } } }, "localname": "UniversalHealthServicesIncMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "uht_UniversalHealthServicesOfDelawareIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Wholly-owned subsidiary of Universal Health Services, Inc.; Advisor to UHT", "label": "Universal Health Services Of Delaware Inc [Member]", "terseLabel": "Universal Health Services of Delaware Inc" } } }, "localname": "UniversalHealthServicesOfDelawareIncMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "uht_WellingtonRegionalMedicalCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "UHS-related hospital facility.", "label": "Wellington Regional Medical Center [Member]", "terseLabel": "Wellington Regional Medical Center" } } }, "localname": "WellingtonRegionalMedicalCenterMember", "nsuri": "http://www.uhrit.com/20210930", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities And Other Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r40", "r41", "r42", "r432", "r454", "r457" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r39", "r42", "r49", "r50", "r51", "r93", "r94", "r95", "r298", "r450", "r451", "r518" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated other comprehensive income/(loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r16" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r272", "r273", "r274", "r318" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Capital in excess of par value" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition", "terseLabel": "Restricted stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfAboveAndBelowMarketLeases": { "auth_ref": [ "r79" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of non-cash amortization of intangible asset (liability) for above and below market leases.", "label": "Amortization Of Above And Below Market Leases", "terseLabel": "Amortization related to above/below market leases, net" } } }, "localname": "AmortizationOfAboveAndBelowMarketLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r62", "r79", "r220", "r339" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization Of Debt Discount Premium", "terseLabel": "Amortization of debt premium" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r58", "r79", "r220", "r341" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization Of Financing Costs", "terseLabel": "Amortization of deferred financing costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r89", "r135", "r140", "r146", "r168", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r293", "r299", "r327", "r363", "r365", "r415", "r430" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r191" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Assets Of Disposal Group Including Discontinued Operation", "terseLabel": "Assets of property held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r268", "r270", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r284", "r285", "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination Consideration Transferred1", "terseLabel": "Total purchase price" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r10", "r22", "r81" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r75", "r81", "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r75", "r331" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash Flow Hedge" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock Dividends Per Share Cash Paid", "terseLabel": "Declared and paid dividends, per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94", "r318" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common shares, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common shares, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common shares, issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common shares, outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r365" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2021 - 13,784,401; 2020 - 13,771,287" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensatingBalanceAmount": { "auth_ref": [ "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of a specific compensating balance arrangement that is maintained under an agreement for a bank loan or future credit availability.", "label": "Compensating Balance Amount", "terseLabel": "Compensating balance" } } }, "localname": "CompensatingBalanceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r56", "r423", "r442" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Total comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r45", "r47", "r55", "r291", "r303", "r422", "r441" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest", "totalLabel": "Subtotal - comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest [Abstract]", "terseLabel": "Comprehensive income:" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r125", "r126", "r154", "r325", "r326", "r479" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r125", "r126", "r154", "r325", "r326", "r458", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r125", "r126", "r154", "r325", "r326", "r458", "r479" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r125", "r126", "r154", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "verboseLabel": "Percentage of revenues generated from leases and tenants" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r125", "r126", "r154", "r325", "r326", "r479" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r83", "r84", "r85" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for construction in progress expenditures that have occurred.", "label": "Construction In Progress Expenditures Incurred But Not Yet Paid", "terseLabel": "Invoices accrued for construction and improvements" } } }, "localname": "ConstructionInProgressExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionLoan": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans.", "label": "Construction Loan", "terseLabel": "Construction loan" } } }, "localname": "ConstructionLoan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r60", "r399" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10080.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost Of Goods And Services Sold", "positiveTerseLabel": "Advisory fee", "terseLabel": "Advisory fees to UHS" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r59" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10060.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs And Expenses", "totalLabel": "Costs and Expenses, Total" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs And Expenses [Abstract]", "terseLabel": "Expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeDividends": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative cash dividends distributed to shareholders.", "label": "Cumulative Dividends", "negatedLabel": "Cumulative dividends" } } }, "localname": "CumulativeDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r124", "r154" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument Basis Spread On Variable Rate1", "terseLabel": "Margin points added to the reference rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reference rate used for variable rate of debt instrument.", "label": "Debt Instrument Description Of Variable Rate Basis", "terseLabel": "Base rate description" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r29", "r205" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt Instrument Interest Rate Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument Interest Rate Terms", "terseLabel": "Credit facility, Interest Rate Terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r30", "r88", "r92", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r243", "r244", "r245", "r246", "r339", "r340", "r342", "r343", "r428" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedPremium": { "auth_ref": [ "r211", "r339", "r343" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11110.0, "parentTag": "us-gaap_SecuredDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt premium.", "label": "Debt Instrument Unamortized Premium", "verboseLabel": "Plus net debt premium" } } }, "localname": "DebtInstrumentUnamortizedPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsAndOtherAssets": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred cost assets and assets classified as other.", "label": "Deferred Costs And Other Assets", "terseLabel": "Deferred charges and other assets, net" } } }, "localname": "DeferredCostsAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r79", "r187" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10070.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r79", "r133" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract Type [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r33", "r36", "r37", "r310", "r380" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Fair Value Of Derivative Liability", "terseLabel": "Liability derivatives, fair value" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative Fixed Interest Rate", "terseLabel": "Derivative instruments, fixed rate" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r36", "r309", "r311", "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument Risk [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r308", "r309", "r312" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Derivative Instruments Gain Loss By Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeMaturityDates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date the derivative contract matures, in YYYY-MM-DD format.", "label": "Derivative Maturity Dates", "terseLabel": "Expiration date of interest rate" } } }, "localname": "DerivativeMaturityDates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "auth_ref": [ "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "The number of derivative instruments of a particular group held by the entity.", "label": "Derivative Number Of Instruments Held", "terseLabel": "Number of interest rate cap agreements" } } }, "localname": "DerivativeNumberOfInstrumentsHeld", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group Including Discontinued Operation Consideration", "terseLabel": "Sale price" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Groups Including Discontinued Operations Name [Domain]", "terseLabel": "Disposal Group Name" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r247", "r427" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r102", "r103", "r104", "r105", "r106", "r113", "r115", "r117", "r118", "r119", "r120", "r121", "r319", "r320", "r424", "r443" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share Basic", "terseLabel": "Basic earnings per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r102", "r103", "r104", "r105", "r106", "r115", "r117", "r118", "r119", "r120", "r121", "r319", "r320", "r424", "r443" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Diluted", "terseLabel": "Diluted earnings per share" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r93", "r94", "r95", "r99", "r107", "r109", "r123", "r171", "r242", "r247", "r272", "r273", "r274", "r277", "r278", "r318", "r332", "r333", "r334", "r335", "r336", "r337", "r450", "r451", "r452", "r518" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "auth_ref": [ "r7", "r89", "r168", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "auth_ref": [ "r7", "r89", "r168", "r327" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": { "auth_ref": [ "r7", "r89", "r168", "r327" ], "lang": { "en-us": { "role": { "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.", "label": "Equity Method Investment Nonconsolidated Investee Or Group Of Investees [Member]", "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees" } } }, "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "positiveLabel": "Ownership", "terseLabel": "Non-controlling equity interest, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r23", "r136", "r165" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "totalLabel": "Our share of equity in LLCs, net" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments And Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Summarized Financial Information of Equity Affiliates" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsMember": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.", "label": "Equity Method Investments [Member]", "terseLabel": "Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Text Block]", "terseLabel": "Limited Liability Companies Accounted for Under Equity Method" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r321", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r213", "r222", "r223", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r322", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r213", "r222", "r223", "r259", "r260", "r265", "r267", "r322", "r371" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r213", "r222", "r223", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r267", "r370", "r371", "r372" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r221", "r240", "r316", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r185" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite Lived Intangible Assets Accumulated Amortization", "terseLabel": "Intangible assets, accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r79", "r186", "r189" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain Loss On Disposition Of Assets", "negatedLabel": "Gain on sale of real estate assets", "terseLabel": "Gain on sale of real estate assets" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r53", "r79", "r134", "r165", "r420", "r439" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income Loss From Equity Method Investments", "terseLabel": "Equity in income of unconsolidated LLCs", "verboseLabel": "Our share of net income" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Axis]", "terseLabel": "Disposal Group Name" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r190", "r192" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r78" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase Decrease In Accrued Interest Receivable Net", "negatedLabel": "Accrued interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r78" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInLeasingReceivables": { "auth_ref": [ "r78" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from lessees arising from lease agreements.", "label": "Increase Decrease In Leasing Receivables", "negatedLabel": "Lease receivable" } } }, "localname": "IncreaseDecreaseInLeasingReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r78" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase Decrease In Other Operating Capital Net", "negatedLabel": "Other, net" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r183", "r184" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets Net Excluding Goodwill", "terseLabel": "Intangible assets (net of accumulated amortization of $17.7 million and $19.5 million, respectively)" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r425" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income Expense Net", "terseLabel": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r73", "r76", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r419", "r438" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Interest Payable Current And Noncurrent", "terseLabel": "Accrued interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsInAndAdvancesToAffiliatesAtFairValue": { "auth_ref": [ "r470", "r471", "r472" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10010.0, "parentTag": "us-gaap_EquityMethodInvestments", "weight": 1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of the investment at close of period. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.", "label": "Investments In And Advances To Affiliates At Fair Value", "terseLabel": "Investments in and advances to limited liability companies (\"LLCs\")", "verboseLabel": "Investments in LLCs before amounts included in accrued expenses and other liabilities" } } }, "localname": "InvestmentsInAndAdvancesToAffiliatesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r11", "r24" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_RealEstateInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "verboseLabel": "Aggregate lease payments for 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "verboseLabel": "Aggregate lease payments for 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "verboseLabel": "Aggregate lease payments for 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "verboseLabel": "Aggregate lease payments for 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "verboseLabel": "Aggregate lease payments for 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Lease, Renewal Term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseRenewalTerm": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor Operating Lease Renewal Term", "terseLabel": "Renewal Term (years)" } } }, "localname": "LessorOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letters of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letters of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r28", "r89", "r141", "r168", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r294", "r299", "r300", "r327", "r363", "r364" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r89", "r168", "r327", "r365", "r418", "r435" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r3", "r4", "r5", "r6", "r7", "r191" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Liabilities Of Disposal Group Including Discontinued Operation", "terseLabel": "Liabilities of property held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r13", "r416", "r429" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line Of Credit", "terseLabel": "Line of credit borrowings", "verboseLabel": "Outstanding borrowings under revolving credit agreement" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line Of Credit Facility Commitment Fee Percentage", "terseLabel": "Facility fee payable on commitment" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line Of Credit Facility Maximum Borrowing Capacity", "terseLabel": "Outstanding borrowing" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line Of Credit Facility Remaining Borrowing Capacity", "terseLabel": "Available borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate L I B O R [Member]", "terseLabel": "London Interbank Offered Rate (LIBOR)" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long Term Debt Fair Value", "terseLabel": "Mortgage loan fair value" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Long Term Loans Payable", "terseLabel": "Third-party term loan" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MajorPropertyClassAxis": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class.", "label": "Major Property Class [Axis]", "terseLabel": "Major Property Class" } } }, "localname": "MajorPropertyClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MajorPropertyClassDomain": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date.", "label": "Major Property Class [Domain]", "terseLabel": "Major Property Class" } } }, "localname": "MajorPropertyClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ManagementServiceMember": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Contractually stipulated right to receive compensation for operating and managing business.", "label": "Management Service [Member]", "terseLabel": "Management Service" } } }, "localname": "ManagementServiceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r8", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers Acquisitions And Dispositions Disclosures [Text Block]", "terseLabel": "Acquisitions and Divestitures" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r32", "r89", "r168", "r193", "r197", "r198", "r199", "r202", "r203", "r327", "r417", "r434" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Minority Interest", "terseLabel": "Minority ownership interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Minority Interest Ownership Percentage By Noncontrolling Owners", "terseLabel": "Minority ownership interest held by a third-party" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Minority Interest Ownership Percentage By Parent", "terseLabel": "Ownership percentage upon completion of the minority ownership purchase" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r75" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by/(used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r75" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r75", "r77", "r80" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r7", "r43", "r46", "r51", "r54", "r80", "r89", "r98", "r102", "r103", "r104", "r105", "r108", "r109", "r116", "r135", "r139", "r142", "r145", "r148", "r168", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r320", "r327", "r421", "r440" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net income", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetRentableArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net rentable area for properties owned.", "label": "Net Rentable Area", "terseLabel": "Rentable square feet" } } }, "localname": "NetRentableArea", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "areaItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r2", "r96", "r97", "r100", "r101", "r110", "r111", "r112", "r157", "r158", "r172", "r173", "r254", "r255", "r256", "r257", "r275", "r279", "r280", "r281", "r317", "r328", "r329", "r330", "r354", "r400", "r401", "r402", "r453", "r454", "r455", "r456", "r457", "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonRecourseDebt": { "auth_ref": [], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": 11090.0, "parentTag": "us-gaap_SecuredDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt for which creditor does not have general recourse to the debtor but rather has recourse only to the property used for collateral in the transaction or other specific property.", "label": "Non Recourse Debt", "verboseLabel": "Outstanding Balance" } } }, "localname": "NonRecourseDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfBusinessesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of businesses acquired by the entity during the period.", "label": "Number Of Businesses Acquired", "terseLabel": "Number of acquisitions" } } }, "localname": "NumberOfBusinessesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfRealEstateProperties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of real estate properties owned as of the balance sheet date.", "label": "Number Of Real Estate Properties", "terseLabel": "Number of real estate investments", "verboseLabel": "Number of hospital facilities leased" } } }, "localname": "NumberOfRealEstateProperties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r128" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r135", "r139", "r142", "r145", "r148" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Income before equity in income of unconsolidated limited liability companies (\"LLCs\"), gain on sale and interest expense" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r122", "r350", "r353" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10100.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease Lease Income", "terseLabel": "Lease revenue" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r346" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "positiveLabel": "Ground lease liabilities", "terseLabel": "Ground lease liabilities, net", "verboseLabel": "Right-of-use land liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r345" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right-of-use land assets, net", "verboseLabel": "Right-of-use land assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r9", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "General" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneral" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "terseLabel": "Other Assets:" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r38", "r40" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10030.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax", "terseLabel": "Unrealized derivative gains/(loss) on cash flow hedges", "verboseLabel": "Unrealized net gain (loss) on cash flow hedges" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r44", "r47", "r291", "r292", "r297" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent", "totalLabel": "Total other comprehensive gains/(loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract]", "terseLabel": "Other comprehensive (loss)/gain:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCostAndExpenseOperating": { "auth_ref": [ "r61" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10090.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.", "label": "Other Cost And Expense Operating", "terseLabel": "Other operating expenses" } } }, "localname": "OtherCostAndExpenseOperating", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expenses" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "Payment Of Financing And Stock Issuance Costs", "terseLabel": "Payment of stock issuance cost" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividends": { "auth_ref": [ "r70" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.", "label": "Payments Of Dividends", "negatedLabel": "Dividends paid", "terseLabel": "Dividends declared and paid" } } }, "localname": "PaymentsOfDividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r72" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments Of Financing Costs", "negatedLabel": "Financing costs paid" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.", "label": "Payments To Acquire Additional Interest In Subsidiaries", "terseLabel": "Purchase price" } } }, "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r65", "r287" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments To Acquire Businesses Gross", "terseLabel": "Payment to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Investments in LLCs" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Net cash paid for acquisition of property" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": { "auth_ref": [ "r64", "r357" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.", "label": "Payments To Fund Longterm Loans To Related Parties", "negatedLabel": "Advance made to LLC" } } }, "localname": "PaymentsToFundLongtermLoansToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r226" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred shares of beneficial interest, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred shares of beneficial interest, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r226" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred shares of beneficial interest, issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred shares of beneficial interest, outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r365" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r68" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net cash proceeds from stock issued" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r68" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds From Issuance Or Sale Of Equity", "terseLabel": "Issuance of shares of beneficial interest, net" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r69", "r88" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds From Lines Of Credit", "positiveTerseLabel": "Proceeds from lines of credit", "terseLabel": "Net borrowings on line of credit" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfRealEstateHeldforinvestment": { "auth_ref": [ "r63" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from the sale of real estate that is held for investment, that is, it is part of an investing activity during the period.", "label": "Proceeds From Sale Of Real Estate Heldforinvestment", "terseLabel": "Cash proceeds received from sale of property, net" } } }, "localname": "ProceedsFromSaleOfRealEstateHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product And Service Other [Member]", "terseLabel": "Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r7", "r43", "r46", "r51", "r74", "r89", "r98", "r108", "r109", "r135", "r139", "r142", "r145", "r148", "r168", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r291", "r295", "r296", "r302", "r303", "r320", "r327", "r426" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyManagementFeeRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue derived from managing real estate properties.", "label": "Property Management Fee Revenue", "terseLabel": "Project manager's aggregate fee" } } }, "localname": "PropertyManagementFeeRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAccumulatedDepreciation": { "auth_ref": [ "r436" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10280.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of depreciation for real estate property held for investment purposes.", "label": "Real Estate Investment Property Accumulated Depreciation", "negatedLabel": "Accumulated depreciation" } } }, "localname": "RealEstateInvestmentPropertyAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyAtCost": { "auth_ref": [ "r437" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_RealEstateInvestmentPropertyNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property At Cost", "terseLabel": "Buildings and improvements and construction in progress" } } }, "localname": "RealEstateInvestmentPropertyAtCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentPropertyNet": { "auth_ref": [ "r437" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_RealEstateInvestments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investment property, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; and (7) other real estate investments.", "label": "Real Estate Investment Property Net", "totalLabel": "Real Estate Investment Property, Net, Total" } } }, "localname": "RealEstateInvestmentPropertyNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestments": { "auth_ref": [ "r437" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of real estate investments, net of accumulated depreciation, which may include the following: (1) land available-for-sale; (2) land available-for-development; (3) investments in building and building improvements; (4) tenant allowances; (5) developments in-process; (6) rental properties; (7) other real estate investments; (8) real estate joint ventures; and (9) unconsolidated real estate and other joint ventures not separately presented.", "label": "Real Estate Investments", "totalLabel": "Net Real Estate Investments" } } }, "localname": "RealEstateInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstateInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Real Estate Investments [Abstract]", "terseLabel": "Real Estate Investments:" } } }, "localname": "RealEstateInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePeriodIncreaseDecrease": { "auth_ref": [ "r489" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) before accumulated depreciation of real estate investments for entities with a substantial portion of business acquiring and holding investment real estate.", "label": "Real Estate Period Increase Decrease", "terseLabel": "Additions to real estate investments, net" } } }, "localname": "RealEstatePeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RealEstatePropertiesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by ownership of the property.", "label": "Real Estate Properties [Axis]", "terseLabel": "Real Estate Property Ownership" } } }, "localname": "RealEstatePropertiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RealEstatePropertiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents categories of ownership of real estate properties.", "label": "Real Estate Properties [Domain]", "terseLabel": "Real Estate Properties" } } }, "localname": "RealEstatePropertiesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r266", "r357", "r358" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r266", "r357", "r360", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLeaseAccountingComponentsOfLeaseRevenueUHSFacilitiesAndLeaseRevenueNonRelatedPartiesCaptionsDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r355", "r356", "r358", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Relationship with Universal Health Services, Inc. (\"UHS\") and Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfSecuredDebt": { "auth_ref": [ "r71" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.", "label": "Repayments Of Secured Debt", "negatedLabel": "Repayments of mortgage notes payable" } } }, "localname": "RepaymentsOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r17", "r247", "r276", "r365", "r433", "r453", "r457" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Cumulative net income" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r93", "r94", "r95", "r99", "r107", "r109", "r171", "r272", "r273", "r274", "r277", "r278", "r318", "r450", "r452" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Cumulative net income" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r131", "r132", "r138", "r143", "r144", "r150", "r151", "r154", "r249", "r250", "r399" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10120.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Other revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r52", "r89", "r131", "r132", "r138", "r143", "r144", "r150", "r151", "r154", "r168", "r193", "r194", "r195", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r327", "r426" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10010.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome": { "order": 10050.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues, Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r30", "r92", "r222", "r224", "r243", "r244", "r245", "r246", "r339", "r340", "r343", "r428" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule Of Debt Instruments [Text Block]", "terseLabel": "Outstanding Mortgages, Excluding Net Debt Premium" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule Of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r7", "r89", "r167", "r168", "r327" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageAndConstructionNotesPayableByUnconsolidatedLLCSLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule Of Operating Leased Assets [Table]", "terseLabel": "Schedule Of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "auth_ref": [ "r188", "r344", "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Schedule Of Property Subject To Or Available For Operating Lease [Text Block]", "terseLabel": "Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities" } } }, "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r359", "r360" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SecuredDebt": { "auth_ref": [ "r13", "r416", "r431" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Secured Debt", "terseLabel": "Mortgage notes payable, non-recourse to us, net", "totalLabel": "Total mortgages notes payable, non-recourse to us, net" } } }, "localname": "SecuredDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r127", "r129", "r130", "r135", "r137", "r142", "r146", "r147", "r148", "r149", "r150", "r153", "r154", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r78" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short Term Debt [Member]", "terseLabel": "Swingline/Short-Term Loans" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type [Axis]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short Term Debt Type [Domain]", "terseLabel": "Short-term Debt, Type" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r49", "r50", "r51", "r93", "r94", "r95", "r99", "r107", "r109", "r123", "r171", "r242", "r247", "r272", "r273", "r274", "r277", "r278", "r318", "r332", "r333", "r334", "r335", "r336", "r337", "r450", "r451", "r452", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r123", "r399" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncomeParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r242", "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issued (in shares)", "verboseLabel": "Share issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgramAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r242", "r247" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issued, net" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r14", "r15", "r242", "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period Shares", "negatedLabel": "Repurchased (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r14", "r15", "r242", "r247" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period Value", "negatedLabel": "Repurchased" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r89", "r156", "r168", "r327", "r365" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r50", "r89", "r93", "r94", "r95", "r99", "r107", "r168", "r171", "r247", "r272", "r273", "r274", "r277", "r278", "r289", "r290", "r301", "r318", "r327", "r332", "r333", "r337", "r451", "r452", "r518" ], "calculation": { "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail": { "order": 10060.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsForLlcsLpsAccountedUnderEquityMethodDetail", "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r87", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Dividends and Equity Issuance Program" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDividendsAndEquityIssuanceProgram" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r338", "r366" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r338", "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r338", "r366" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureAcquisitionsAndDivestituresAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureGeneralAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail", "http://www.uhrit.com/20210930/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r159", "r160", "r161", "r162", "r163", "r221", "r240", "r316", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r497", "r498", "r499", "r500", "r501", "r502", "r503" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Type Of Cost Good Or Service Extensible List", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r114", "r119" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number Of Diluted Shares Outstanding", "terseLabel": "Weighted average number of shares outstanding - Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r113", "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average number of shares outstanding - Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.uhrit.com/20210930/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 17 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(i)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r362": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 3))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r492": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r493": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r494": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r495": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r496": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r497": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r498": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r499": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r500": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r501": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r502": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r503": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r504": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r505": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r506": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r507": { "Footnote": "3", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r508": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r509": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r510": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r511": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r512": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r513": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r514": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r515": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r516": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r517": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r8": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" } }, "version": "2.1" } ZIP 61 0001564590-21-055256-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-21-055256-xbrl.zip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�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

4FZ/S ZAV *B>;@[_DVD! ?I12E!UD#-F_, ?4X32>Z&W3#NP)6XH"GR:X6-@3N>,#(0A[G$DC++F4XE M>V5OIC,TD!5PET,ZC-89"%,HL $IAH\,A4P"G@=@V SD4<[\9]L'G1Q03"D0 M"C._>LNV"$9PF4^NM6'!D@-T>.W)U#!E( R6X^'E\] _O@E_^MVEA,?[D%K# MH[H#H&*,[(L!CC=9*;2P^$5T8(!G@;AN8'@!7T0BIG#(XQ(2HCX;)88->,:1 M UB8>XF"_,,Q^/GT?-=V978^QEO0[$C24EBK+C-3I'3"1E#RHN2TK"5.L^K+ M1,Y*]J%CJ?7L\?4.S7>SQ[^AS*?3NF^("?@(O^PJ(KJK_.)M-K23B/CDI@A, MFL%@WR8&JYLV#@-I?3$3"XE!HV(J$;$MW7-U?Y-88F!8RX.10B#6Y.F(,#]! M75I"91(S &]'4TM.I:63LBE%04PD\Q]3;MET+8H>/WDXS4_PZ>&)Z,&;GFRR M'4C+2TZT^#"L2$E0@4^^_02\\@17)5&0EP]5T17F_K(SU;,X8VUT)2V/_7B# M4^.15X<^-[Y7R?Q\9SC/QBQXQ=[N[E-OD9U4=+"R:\AEZWJOTS!H@0]SDG60 M;4Z&?6Q42EWX&-D6';< GZ($ -Y'[2STKTR,0"]BF-+-3VC'PX+1J"UFX13K MTIE/C?W!06N#I2$]3A&(EAPMC8ID*?$[A5E KQ5N4T!?@21!KP,_)7%C:58G M^A@HX#N7!TZUQ:S'I4'2(S)&<;@TTW_J%SO T[0(M/[M2+BT!PN!#@0_=CL] MT^H/FE7>-($?1[UN=="H=ZM6KVZ.C/;0&M3-W?A1J:AH[XV,OLUC%&I&0<_; MD?EC'DQ!WG3AO<+A2"R2?(R%A !Q.P9"PY3Q3[8 Q2/0M' ,D8TU=U(P=XC, M#Q 0 )TQA1'07:='XI^*3E$\$*1)6;$(-6[)^#T4&@SAL$J_(F)^+6](CPIU54-:.:46& MW+GA Z P=8V2)S!&%*"%8]%&DP7%;XQ3F)*GQB;74DLM<1(E_.-$.#HG])(D MH5A6TS)1P=A!T3.3F(DH@B+/BT\-TB!XD8OO\;D]&49^(,);Z!:90/K>!.O) MXK0=\ PQRRRYE,S0)'4GJ43]@N8-4N-EBV=H.N A!R2/_O+NNTX(\XLIKRF$6)HCSUI:!W0C*" MAU.YAB)RZ/.T.X0,ESQ)T'N-K4P,_@-M'M-[=&&?J5CB1*1@+<84Y0& 13PU MERJ2LRB=-8#=(XRJ#KKR(JE56%Q)*!D3Z6KL7]R%E3K.K))Z$OY$0@.!$OM( MPB#Z2Z1VR-\D'\3<5I$E^E0V KR-2P$_ FZC\PLTRT#J<+R#TH59:/S@<:P% M3!1Q 4(3H0'+Q3W&%2D)$D@:X04@\HT):MQ%-I_C2QIR4J 1LHB5YP9@(BD, MT@5@Z<%;4R<1CS& J&1U2)*6DH.]..P+P(H%K B=9Z*)L-B\^;[ J:\^B%!. M6N:#3?L=*WPPU%PD3P7AH00,DD#RHA04B*:(CH?M=D1X;C(%?L!'(*20:O$= MA'QG1L=7V";L[,5N.K#[!SV%4ZX#/!*A$%^/P,&()3:62!$(.";Q2=[4P+H# M<;05YZ&)L$-F,7CIPG(+-TAT-C\#( ,E2#$:IFHX($2+I$B%3I2$E2G9GU88 MZ^G"-14O H\S,,7.25&$E #"F$V +(*)&$/%3H&T,6+>)-<:F 80FQQ7;!A& MQ LI5K@D$K_4S>EG1L/>)&2-7@ZR VWCF]C%'W8X_OVW^X^&:3OD4%ZYUE?/ M_28,ECMQMO2 \F ?OM%!<_#7U^X[)_*E1(64;Y)SLQ2"7S8:[QD F(T2",?! M/<3ORMLP-3.Q' 4FXGL!IK(GP K:DL)]#1(CUK/LP'@$_?U(+QQRD&7L-:D) M+PK@RN!-C5V+=<;<"L8IMF7$!/XPD4.)ZEFMC1/[(-'OUH8:^MISHR!>S5*& M]KF4 LFZGLQ'*?M%*.Y?4:HJ-QFO452+?"#&.#U" M%!U/V*2:^3+U_E1/-C7*))B^HJFDY9(R^%C:'/?X)E/:/E)IF)V =&/AH/8& MP#+T[5)*+&%-K3/4MCR"+>.TGGQJ:JDEV/$A+LPHE826-K=6F%M:)E[QN%4+P;()P?QQP"73N)9=EXE7)0PX[)5 M"0-."T&5PWDGR5([/0:R::[O5$Q!>%'6Z<'6"N"IN99:>A%5!]%"&GE*Y/EH M-+R4@8AQ5\T/)T>$5CIG@B>M=,X8>5KIJ("&H\6Y-2*TTKD(/&FE<\;(TTI' M!32(@P?-#R='A%8Z9X(GK73.&'FE5SI;G^KM]>I#I](:-'.3W=0C M^)*)G-T,H8.AH>B 2X-=4[]6N%KA%BC<[J4IW'JL<.M;*]QVI5W7"ERI]7IP5XVZM<*5T6L;*YP>Y>F; M&NR:^K7&U1JW0./V+TWCUF.-N[V+VVA6!FVM<96C[A(7ZRF#@]3X!)WFH!P_ MJ($&K8BW4,2#8REB9.!S.=UM@.O;WYLBUH+GL@6//MW5U%]B-&BUN[G:;=0O M3NWNX8RW4>GV]^?_:L%SV8)'G_%JZB\Q&K3:W4+M-BY.[>[AI+=3:?0:6NVJ M1MV*"AY]T*NIO\1HT&IW"[7;O#BUNX?CWG:EW>MIM:L:=2M4Q*LG+67F67,7 MOF ^MR?#R _X1-4BWW5:4)>BQ\BIY556%UNIG@RJMU0^DU=L7K-57GU[/ MM7IS,-!:_2SH6PVMKF?"GQX76JM? *JT5C^05C]6=Z_3^.JK#L?G6GVPQ[0S MK=4O5SP538_46ETU5:&U^MF@2FOU VGU8[40.XVOONKL?:[5^\VNUNIG0=\* M55BO.'.WO&CH< ;JOS0JGEB?^?R)NQ%G59:=FJIBKLJF Z(S2"VE;;!U2Y53 M#WW8"R:UW9"Q&_;9"4W)TNY>I=/;W\'\?K1-WBQ8JFI*)9E.FP.\XF"^A): MJOG86N-KC:\U_@X:?Y^=V)2L*N]66GUURMNTQE=7RZPXM-<:7QE5H36^UOA: MX^^@\??9\DW)@O9FHS)0J*)=JWQUURB.A*)#! XY#Z>^,V^P@/CN4Y?/3<][DD. MJQ1=YBH6*^T!G6M454C7$5EBC[2TM1?8C1HC;J% M1FV=D49MQ#.*M_=16PWP43M:HZI&N(K*%'TJJ*F_Q&C0&G4+C=H^(XU:CS7J M]CXJ:-1&1VM4Y0A7H6JM]"EJ/+M)PCCP'-MBXCI&&P-Z!V!>,&(>N M?,)_; MDV'D!WRRR\'K(?,05J%*3]I2"%69H6@[84NK\HPJ[ZBJRH4,^981(7L]RVU6 MNH/VWI3Z?A3("R(IK3VT6#HR;L1AKE;NJJH(K8I;7YY8JE]$&RUN:JJ@BMS<\&55J;'TB;]\Y3F^_A#+M7Z0\&6IN? M!5VKHJ$968;:4AL%/ZJ$Q8Q,< M%I/::,@8#8.3& U[*I9N51H-==+FENG]I;JD5%+GM/FY*T[82ZCJ5;^LM^U-K]<#;+BA%UK9*A M6>BQ&^Z'ANVRCX9I.S:-+16;%_^RS6#0W1X$1YC1^@=W'&#Y$.3J-_X(DL9P MV!=NV2"/ XH_=ZMO]US(./??[MG8R-@X;/'_I%AS+0&F?<9@]=FM4?PC;O\ MV7!NIRB8 \J^"C\:MO_%\+_S\-^&$PD-\PWH*5BA8*1R^F+\Y?EWO@S]"_QHW]W[2?N!X;S&S><<'S/ M_2?;Y $HQ>6N:4I]50-NOK,B?\8-_]6'SJ*$J^+WV*(?X<0\ 2AFA&P$8&(3 M@A.JL(@S1Z3"(*C8Z^7X:*^-CQ6X^/7'U,8;/?=_<=TK5?\WPWT4^AX^?+%= M>Q)-L@ _%[Q]@+^:BQABX1C,A,?Q"A;HG!;DQH^S!GFKL0CR-\R?JYB7Q6XM MK7(>QIR9D8\&EN08N#$;IN.8IS)::$N#G. M?H'E-BY3@KVSX(D3V-C8,F8HKK@+]@ WZ5[6:E08WK:(PPQ2[FW7Y STR=__ MU@//OY@N!;2!SQ9T,H0J,N;3!V.GT&LPU+IZ2,O M\L,Q^P^\&)?HC0@H-78?#?^"F_%6>1^^%GXVY((,> \E'Z/0-TR33\D@EG(> M7P_/FP05%FMC, T &/AZ.\1/(=X+CR=8IG:Z2/89A A#?+FQG3)<3 +Z,E-U M0]/U-(9,HR<-L[$?;W!J//+JT.?&]ZHQ0M/-<)Z-&=@@;X_E=&1\(L $B@[; ME7292)Y6;_"G9;KAG]U.S[3Z@V:5-\U!M3WJ=:N#1KU;M7IU'XF0@/QT^8S?&9!H%I32]>RJ8 MW@FJYI@2B!)H$E@22"J3&=X_)S-<71QN:Y(/SLDD5QK\+YCG:'!L+*W1OB(P M9(V28&JXL?R^7E8!E8UHOOIPA4_C3[87!6"[62).Q:T*6%C/8\]Q9E7OV86U M!M$PL"T;#4,POV(!ZWJ@&FSX&185CH'A[1"-P2FLV27;SB/[RW;1;L2]<@ F MDM+TALL+P?;Y&&/\ ]<+\Y)L3%UUL) MU3.B,] OTZEOV/A+7LW )41N0#SRI0N4APNJL=^\9PZPFJ^%_ GIUL("0"A5 MR(L0-^&I!QOYWH0A&2)+A'88Q:X0+LX&M?9L@RL#K&@\PL,>D?+SZZ-[ 3XV MX'S&.#@^C@ 5+!P6O 53@-OE\S#RA1](,(5;&3P#5P!4R,,$ 45/J#'T_9?M M"8@^ /CA \#N D\K@H?2JL9>,,78.7L-7JH3X;$.R(XA'QL@5'SX?DP[8%/X M[,!3WQ \#09*!':.SPW]B/S#_#WQLVML/>'VZL,#[<[B4TYV*'OPP7KEG'8. M/B:[]@P?A1M@"3QE)JD/L4^_X&6_V#ZXG)X/,(7U<"(S[PF)8LR1<%+\A^"* M_=, 9$0 WB+<.5MP5BT^ H."G.O$7X6G/X]M$P@%8)ARF04:YMXX,F.,MLRK M0WDLJW#F36NK0 MOI.U9J !.?=\&DJB MK0NB9:^W0-A>9N)LT9#_$G'OF++*7(3\: M^M)$*,K.W,AFV)A_^MI:."T#[:49MP9_;"WT-^2@M)F0N.(7E(5YQPV3"\C. M\T(\^G2+EEV:%(5EH.O5PKQ,\\"#C/RD=Y.(F2[IB 7'9>_NSY5H"P"]#V M)7,W?QH+:ZT _81@!\=V<>'!%L5MPQ49#>W,L>VO]$1N%1"9NC06)Y])$ANL M)+$'"G?2U#@0_AX=X*S0N+!X@D5:WW;J:9#!6V#=MZ.KA![IAF-3TS)7^-/7 MCWDJZJ_:,ZMBV0U^\D/!JO/HQ 5<%J0K_.4[L MH-!R!@-S0"&GAW-\9,_UP 4[R4'>_9HX7,@3\WP=&C&HN#O M?^L,WHNTONR[8%LR"W+IP_-'@JFC8?DC_+^;/ZW+;'F]>/M+BF:7P'GG.'&( M?5'MHE.3;P>S[]CV=N&=SC[#V_L"Z_J^8M[2W3D"4[LDR_?_P!I\V.5O\7GU MS1B _^A16K1O.!=F_R[-ZRG.PGD).I@/M%JU7G,KPTWM(L4*%WUR[Z= Q$#_ ML_AEN["37+AR.L1$/(H??*LKA MISPQS!0J,J=K[ ].R1="TPMY:,]SZ\B0\+ \ %#-Z,&TN""5-12,O/!\>">8= M+!KS5S:TK]+6$R7G_ "F#3D\< NEO\]XV]&EU&*TJZFJ:;67H42'A?+Z,<5\ M5'XM*(?/W'DJA'/>\&+;U,"K;7_]&V6BB;F$5?;K$]SQ!##CF,UHP94&4=:- MYV-Z\\W81_NDPA[X#R-XE_%:DTPEF9N4%AW9$JV#QFY/%]0D^@K(QWSVY@;( M*&DA4$D;(P60KBP'=45:)M9JTZ0@$K=?TV2^ZF]\; QQ8_3@F)?GO\L];6^8 M?#'B8%,C%VPB0"T'0Z[-^K[!(' D493Y0-C:(*&.9Z;;&BIR="6]Y+ABAG-V33OY-D"SDR4?R"N=K1J8YO6RM2 M8=URRI@-*HOF[!2>[K^-Y5+JUAW,6MQJQK#-FK6!M&N#30Q;-$%]D MK)G+29OTI%7SZF8ZM@L@MD,1FA!'-^^.HZ3C-Q^>-=&=%&X*;D^DXN.%'OFM MMI\,W<%RC;A8(JFLLD69PN^_W5,U!_"BRX6!30\2J=JQ_BUV3$'5_IR[>3M:5FE@50BVL!-SBA*>K;%; M^)&.%*K>J!J!)! @$,4M/I\"CZ+;Z\67(?-'<1417AK7QJ1#_W@@$,4BT[&% MO8'(R#[0&P)%&O$9 XD4<551^I7/ MG"2-Z3VZ0*B6"&$8ECS; / \>%.P0OKM)F7[6/%90[Q045V4N"')TKPGOKAQ M"H!$(;P97X0[Y,!K$ZF!059/1";1T/-][QGWA6(W+EO!4UP+V H+8VB_MBM0 MCNLTG@S;(>%J$$EG6DHT!D3>%A>5@;%[],(.:D5>0*XOVV"A+]L52F2LDI"2 MYBI+/82* DS,B),QN)1"1:)6YQ5>5-4C#\9PR8TF(U,K8'1M(+29T+*@$WT0 M)7BE? J^PS!-:OTG'A_8L&K#=T3P289OV6,$G( :E#15[#C'Q)6V=0"A,B@V M;\]&+7=X_WJT&RUJ@.SW^]V>+/7&%H;]G%5 M)<3YNO^&(8Q)CB=09BDP+Z&/':.WQVA@"MNZL!/R+X8+B1INC(J,X+VA)" 8D7>$B\Y!KI(]LO4,Y)^J\(,(5LMN62!) M^8 @!.&-83.3RR?GJ,Q'0/I)_FUHF_:4C&_#A!\"6_9ODO'9I,U _"#1R.^1 MNXA*02#IAUC@%%(3"9]3.P,[2/ "_* $3#81@Y(CB*6;ROF'+@H1_+S+H!S M*J\L(>T4'U!W0B(I]-.POP7F&R92@9Q4TR;2%=;E(B0IO" \:+B" _L_D;<= MTY;/)0G $V#=E#@/ 1$VS!V\3S> &< MP&]X#L<'2]DZC8R^%4GDK!D[CAA2)J8DYO0H>7PBK'+$IB_:G5BK2.0U@JQ9 M?W\C?KB*?Z"O&^_?()CIF>DGQB&*.*$JR:#:P@G+'9_=81M-;@4??6_R&?10 M<#L2BWOY\$A<)_N')S4TW^+=BY^3+68G]3:3/S*^7#?3BJ"SHDQ]$;04[4BC M0WCT=#33B8LZ)?3O,*S/EN&@QJY(08JX?#@6# T<(:-8B_>)B,*\X4X._]%=G0[-DRVH^MVH0Z6$SKHPX[J]/ZNIUEE!-O M,=LU#]RU+QAZ.!B@&OUZJ]E+_ECG[#B1Q[D^D!4T49YL2YY/&,N-4VDNSSD6 M[!47#0@'3>-(Y !NP9BY'&XEJ#&&[<(9R7J@?_DPF\K!-W'Y:ACBT91XPOK ;*]064$T=.R)'PN,YSH='-^*R\GN9=INE;)C MUW.':&Y@84P\D=7HA#Q&!ECL(1D @ZB M7(QR/_!7^D6H#>&1!T*!6(!L[E(6B>',@PCIBR9>$!9[EL7]3?&<>5>OX9S(N!/>2-9%.UET?ZKDJJ_,D M[6O90KN1UU)0+)(7*PI=B5[48 G(,&QRDXR\LGD+C0)[ M,5?QD 76+SPP?9M,K-M1>O<$Q6,8CV@2P58Q/9R,_M?&&S*3KBS,-(1U&M14 M^^I1QIK)#P O8\)EVGTZW\B\;YMQGTT M,+WN9R+3U^8;ZJ,NBL$$$8NG;DJ_F?F17TA2W+HQA:FEI XA&?*\4"Q6R?,3 M7@.UBID:X"?$\\:H#WUR/C#BG,SE))-W4YSTQ-$+XPE$ M$B9GUF40T% .\P=39^8J#K^#%(H 11H\R1Q MF?LMHCKXB-75"6*,4(8V6D7U"=3-*D#-(E9TBJ#:SOV7 E 1Z?K?W2--:AW7 M;S*E0^Q#5B:0 JBD3)@X]R2)#Z)4QABAJ'J@L@B,IHC@":8<$6L0'V4[5(6% M">AA890DJ9(0&IF4/1X7Q]F]FTJY0_CTZU'W]6%4\TM5/R\9[>L2R,\5*6>R M:)G3QRY8.83/?Q"LY!R%#W5^O&-IKG3YNKNFW _CN(/PY M3O5/"YD+J^U<(C.?.1L;V[3_Z*\\'=VIUJ39Z[[0^[#6R>("=WJTX/D$MF3\E^&-;7 [6RO?Y1K7C MR( ;G'6_#(]!^P6 S L/YP:I*=]<82Y/3@)74,5JH!I+:MHHW.(+&V5SH.;< M(1"(X# $5)IU+3)?MZ*G%TU6M\!B-5,O3_)N91:J\"08 QF1:UNSBXC(]Q19 M6T2\U!JQU7VA,=(28LB@_1'H.1"'B,6IBUM*E,%:P8)M^>FE7D;U_@N@6<50 MF[8T4+ZTK- G1O B[ID).X)5^#-FC$8VE3H_"4?%Q10V_&""I2H;1\QSMB@5 M1G:+P*19F3J!.QZ&W'*I3)C2&"KY_'N1 &N[F%$OQP9B2-*0M=FBCI'*C#%> M8-G!U$O?;MGHRE,B>?(P"^.@]I!&/"Z+$E,@(-DY'J_[MIG=(L/$/3\I55D2 MSQ#^6?:H6Q1M"@M_9/_ PH(QUL?0L^=NG+A@X4EQBDC!$T6TI/"NR"V^+W*Y M:U* (:XEC1^"X)J(^!H+,1B(+(#ZXQE/WS,#).=T(;/_Q<1'(W)DF0AE]_M< M%B^(U%%,80*8/CYRT0#=-+F3+HPA61^(?L1YG5Y\\B\;4%#KB FXMB2V19VW MXR1C<1/\+RW$=$ M&SGI-%51S)[)+Q>/Y%8M*0A.!:0ON#9WH'AM[C\62K,SI;(;U*>N*G ==#MM MH]7N53O=1K_:[H\&5J,W: T&HVYON#PIJY6RA K]S*__':4I''> MQ"SV@'IY'^6ZRTI2E:>W!TJ-4B-B[KJ%+B@T0N ML/6C34%S<="7=%%-A)E4A:)]0*'4Q!&^CF'R9>(S.W!XB504\H[J4^9/*QB, M9L&>#3_1$K0F+PI 1@=O@A"0#A\A-\-/86R1@C+\ MYRL@9]">3H!6J?N8?)YBX%U^EL\1=V"XRS&F 7\7__$>!+\5CF%3L'_Q!I_^ MQ:9G^&Z\%<$W?]*RX)E\:Q472]"-OZ F(N_JM5XG]>4#HD!\)5;0;=0Z_9_? MR[W%2*/N*$Q<**9 8WLT5T+C966R'/?R8[+:+#'@%VK0PS_>AM9I,*(<0G(] M )8U0^JODV=\GJB)O[J>PU%BJU7KM5>C:S[7NB2HB@T&S4<*(J>0CV E>,;P MSU?-5PKPU* VT!R505IBX GL@96W=L^E\]^\F-YP4E'R\_OGL1WR*II\N(5G MWYB^W[!IT+F ^RP$Q$NBO702(G;:I(!HE$Q U+6 .*& >"N]UT4?%G:V O0W M'S_6/]X<0#Q(GW;OX%^_%>FAPU"Y X)MR?]@.+AT%.SFCAX.[%EW% &[F5ZD M;J;[4 W*8.KENHE!"_'9;;YG\&_C_4^-9J<"WV=:K*J$8\U:)P'[&FQU#"- M&3S]I!R*^NG P?9(NFQQN''"4.9\,#8]OO+P#S0\-DVO:V4;/KG1Q/)"^7N2 M*03RN-%N5-J-?%]OY6CN2*:_,O2CI?-YX$E%Z9R.VFCQO"?Q/-A>/.>S-=<7 MS[U*L]O2XEDU^ME7<.9@L=O+#\YD*@35.["^[/.H7D M=,"_E_6IN\8I]"GWA9VCZ#A%/D[1B>,4K9WC%)I?+HQ?2J:T%46#CE-L;FPW M,W7?PA[87[BB7\OWRE6.;,K&O5M'*S0&+EU^ZFC%Q@*TM9L ?2%HT=]CN%>S MKSHQ"YU9L2WP?T]WS]()%F>IP72"Q3$#%UV=8'%R-*G*+R73W(JB00[ MVVF[.VT4[#'9HE?0IU8YXBD;#^MDBU-C0%DIJL,7&XO1SA[$Z$N)%XU:6XM1 MU2A%)UZ<$/@?BQJ0JQ?7NW L*!J&UT&,@B!&+^[. 419_Z'S+Q3BF*W:PAT, M!=0WLDR\LZG%UTU;?*2(;D@/W7A[\YL+$FU_J,>K)3/XSH)W\^)3,V^:>7N[ M,^]+WEJMIYEW!:$(8HAI8179'*.@_RT-)8!O+?MIL\UG]KK]:),54V:.M82E M,TUR8Q/G#!WZX>2:JCS.YPE$>EFT:X7R?ATJF'[+6>07)Q,T@Z\&G;3OU[D/1IA)ZNJV[&$:;[0$U[8D+;.YK" MYMAP]ZL/\8A&]A4$W(D/]6/7]X4)&'K0@II]U!NM6D8F*3LW-X ,Z3VIA0MYY>Z08M^4 PSM2+U6L&5 M6\$U]"BA!:Q]PNWP("R1J/\&#F8IA+4:X%9&8I>&IQ7-RFKT:ETM?3.8^F*$ M$0X&+Y'T_65!^BJ6<"2"3Y=[]M>KU]G]V+"\9_;9<#D#_X7]"XC!QQ#OE]OK M@(TH(\F7:+I4. @9*?Y-8MC,\< #?#W(Z#Z&(%& M,Q.TU',$-DTO*)PCT*OW%X],OWKN-WF6AV>F*\Y' S_\(B7J9Q"HP2W<:#B_ M!B'H%/SB83;E5S_LX,]H'-[S)^[^!H3B&NE;*YX&GNIZ_ MMO>\OT9W42]G$YCB>"XJQWM4N-8=]S&& $KRK%3VIZ\?%[(1._NK'=.*^=0E MN%HG7Y:LS\1VE\KZ\@GV7#)JKYGI5Y"5WG$\^ L\3\%470+]S17$P85KB5UJ4'A:^_73.)?B;PSV("2(6# MLV%2]8Z7M.#7Q?*E18.(@FI?:K,@9ZXNY#!!3I"OQPYCMEKYXBWUJ%8+#R70 MH#6G)O[2HJ&N6^YM'(3LG3P(N2^5F@\S-K7B5(Y %>STIW7FR5)(RR>9"Z*( MG9-$$;<6NQO$"7_A)MUXT%BA3B#=-G^7!]P/V;\-Q^&S)&IX0UG*>P\6ZE.B MRSHE*IG9HBH:=+!PBV!AHWZ<8*$0L$*^2O$JI.O!HH7M2FO0T;D5JE&HJM)C M92W=Y0D*5=&@N4$)-.CPX>;APUQMP='#AWM3LHOQPU:MN[])(5IXG#I^J!W0 MRY+6.GX8QP^[)XD?;B]W-TDT--S(\&?S^&%+YQHJ0Y'-7KW-O@*2Q^R!N\;, M8'\8,YUEJ AV5#WW*9F]HBH:=.!PF\!AXSB!PX=GCY+\_S_N>Q_AX21DA8P% M$7NPZ&&WTN[LKV1:BY +%R%:?VKB+RT:=+!P\V!A+D?_Z,'"_2K6?,;A'@_? MM 0Y=<10:\[+$MDZ8AA'#'LGB1CN*'PW"!M^]9Y$WB$[3,A0IQQN29+WT61" M\T[8;UXPM4/#65JM_.G3)Q%++$WO2IULJ08ZU(-ZR2PV5=&@8Z;;Q$R;1VH_ M&:N66+,45C<\C'W.#Q9 ;30K_6Y7)XVH1K2J"A2M337QEQ8-.H*Z<02UF2M< M.'[+R,.IV7PXM=[2NE0UFM4)F%I^ZW!J)IS:/TT;R#U*X@UBJU=3WW;F"9EM MG9"I#(4^1* ]77;G>R,>!* M#4=W?U0-2:J>CI7,C%$5#3K&N$V,L76DO$P2 ML+.T@#UX \AFI3W87[M\+3\N7'YHY:F)O[1HT"'%S4.*N9*&XR=E[D^K+H80 M.[7._H[CM/@X=0A1J\W+DMACU .HVWQ)3=Y=6CU9U1J:6VSJMS7T>=-,QT!#4>)R_)+C-1GG ]Q2V%%RPSOGD!=P'+CTFL]?\)DMKW.\?X MKZ%!*90^IBBH1K-P+NLJ@UC<(:':.$]!,9'@LPJ7\ M)O%]R*+R5FM_A7![T@KKZP0M>\Y'8U^T7%$"-YIOU,4-Q3WWAIZ+YJ6-XZ.Y M"HVCQT?WJKWSM>KM_0T+TJ)&R7#IR;7S)6%!"8%/ 5-M*6T06&V<)+"ZF^C> M(*1ZSZ=ATCFTI3N'JD.2#UYH.!7&?YA.1/7L+@]!'P]#-O7YQ(XFS' M^G)D MNX9K4LD[YX%ZIS3Z;.PT9\*QG$>@ZB"IJGC*!DFWQU49]//Z$=+6#DTX=PI> M=GJ5;K^AR6%O%$/ SH^-"^IBQOM MPRF#"EU(IW;BT(I(E>5%0XU M$2ST6!14,'RE7MEP"5&G:@A^C9*E5<@K94CK)_70N&;UV5Y0>=&*;_-P5ZZ' MUSTW(Y];!ZY.:PW4R81:YG,LE?.E$A=*=(PXJ19.0W3H.58:GC:8-+:Y/;;. M#1%J,8G&S.H0U_;(.826U-C2?*0^9K3#IPPJBL);:^+B2%:^0$ ,_U6H.D9T MZVV(D13XUK*?-J/,S%Y_WH3PTLN!5\*;XY<*Z",\!6YH<1*;_WP%GH/)'0?E M&B _^2R)@3['Y"7P#]!WC&G W\5_O&>QYJO+-+R5T3UQ<:O6:A4EK2ZE'EK_ MB_!;"\62?HPH]-9'M\/#$'8OX31_V>;8*6#D/'S:M4Y?!?@4B;K><;Z+:*%U[G9"!MXR1;>FW4WOSC+>YKF4N->+]4@L\@= E: M"E$(MTJ@I9^0%?HBPC+RO!"#UR*.\O6! B/8#?W'Q'GG&"B^N%O]_?[5ARO' MR0Z5")C/_Q/9/LZ:<,.Q,V-3WW9->VHX& G'#*. A6-8\N.8361K/^JQQNUP MC). (P=NBG.0F.!Q)TI.#4 K'M@LB MFC,77L/"9^X\26D>5)@1,N N<\Q"V A[QNM!!6 ,'"3T\YB3#(>G^5QT3N!L M&OE!!!#";PUXYG-68:"$'\Y8%-J._5_LLP#RTO>>X:^ P;[A:5[DLQN?6W;( MKAY]SE'@U]80YXM=5I<0S%]1$-JC69I"&LUI$0UM[T3L_:1YS%/GS. ?LD"< M:B H$74^1^7H>U/N@WKU1O3E,+(=BP!K!( ZP!O\-[G(X4: #P-5C/YF4&/9 MMWA1&(3P*^(([H-G)EUM6:N.C6V;#38V+$"RZ4V&M@NK&1FVCUP;<;S>F,++ M?MA :!Q4_$^;G^5T%\]R/GONXP/W)WB8\Q'>]6]\U8I3'7E?Q M$P (J#B +^ O.HK$UOAH7Q'+!F/.0X'_!)5I],?7";J"U^06AG(BW@R+]\&> M@6ZV0'L_W:\@[L;\POG=(3!=;S2Q4?4R3'<&M7RO_AC3Q%>'Y8Z>BMSQ LRZ MS5I^G'K"'42!62@A]5*]%](20!+>282+M$Q.P'\BRKH!#N#V$P+9]R9Q%Q^0 MB;8+TCZ,\#U!AOO^X,0+-FH<0=3 .T/._OZW?K-9![4.^V)-^M1XSZ2&3*UM M'$.(A&,4.H1B>1UH[;$'K@FH:]"ECQ'P&_(/R'EFV8'I> &J7K@8EN!R@7!4 MQ&*K=E*5^+0,6?*Z > MX)H0B!0SE^35^"Q;SM! *1+YJ&1@V:81C-G(\9YK,C"V&(M#/=I=6XVNCLT? M)AK_,2&*>?5+\&YQ.ZLMA?5W>!I#X9/+OB!5SO4(C0LER@3ZSIB*5; AJO:/ MZMBV8.7OI%09_-E\]0&'19*]-2<&HJO@V9@R(S;*D%@,8!O,@@//&X@8_@!/ M/L*?1EN(M'8C7ZODVT_$15_E"Z[H^2]+M?F=7@YNF(:3A&#/RI1YX1TJC""IAFR$V -..C$8I[4 I>PJD=:2VAQ;#$ M28.+E\[2:!>,C(_!&,_2^ 7UQ'EC4 S?D*@L'+YA&;-X_D8&LKU%Q[#&/@D' M"01IE6YEGS]=WWY#Z!M##Y"S,2<5C*72G#3GI J!VT3)S?VI@>[GU)@%Y*L0 MV2_%AX.-&8$/W988$+<@;WV5NHGD;] MY'4FI>.E4W[0Q/0Q8]07Z7R!'2Q+MBIZ&D@1D7$US[>B-"MA,"/)VSQ.5E50G%\54VLZRTHDZPD29$A)3S;MB%V%!4FOE8*,JF60>R93 M!YN6.[8QM!U;9.=N;M5W5X7MXI2\V]'\R\_Q^XXA! Z;8%M?U8;E0Z?3K<"6 M\O:^R)&U@TPVK&&:?@1_\A]33(@5J/TFQGQE<;G'&LWQO0K#^]$ =4WF2YYZU^))7P$?KX1 M*NQ.\/,9THTP6+J#)9:'>P'13C])'<1S!$Z5$Q^@F MU!I.)5,/053!_4D0I^B3E,@0S=!NW-J M/#.$%LHC4"J(G]2O\XC0O%ZRH.#B$#30/ 4-[)GUEY%$-OV\4>LNCPN!=D!% MG52M3@R++Z>-E_'-7I,A!.8EL/8>$OZ[[;7P=(9(6LVWC<&@F&\!80FRO(03 MYX@#) V+G#-O- H T?#;SBCI;(*26WKO+Q%_\!1%Q"*W])=S"Q!T GPK*F84 MU#GX_!+A1+ M@<^SM7MS2?IXKR)"RV#,>QW[#FP@0!_:_3>,ZR@#V?9XC!ZN0".Z<"J M[9$=5[?@8V-XRS<&(<;Q$ 3219H"?#Q2$^(O409"$+=$FQE)XP;%50%$AN]B MK>!BD8SEX;$$VZ/\/D @O,=P%?QJ]C2NM,+ MRWE;=1JZ+#+=ZN=R N[YHY#L4VR6X#[^DOBZ#["6:\NGM8IZ-H#VMJ!]/7C#)%Q8 IC+HIY;8*ZI#Q+:!],C"L S" +AUCYQ M85S8HMP0*WKQXY@;3C@V2:YB8".:X'DE]Y]L#)(89NSDQF:F9?O(V]ZS"S)I M;$\9V;KBM[\\X&OV!%# D$I%.M7&(QBKC\CG=")J,'RO@YR.&*#&&8% 2HW] MP45(!34L+ 3KP%%$C<+?8'5[Q9J7V^:,E- V@@\(9\0ZZ0FY M3JF"4R 0W?J!0@ I$3P?[@;B8>CN2P5$+[OD0,!D6Z4T4%X^I2+G@7S(-G\ MN3$%;"CME4\#NM;EM'$L8_BNL3#)/4B4KEGSO[*3*<9(9SW8ZV3@S M4^^G*8J$+'8H4DV0=M2__CT7 0ERI9O$21A:C=MRQ0(G(-SOQ'9HJD+,%/O M0HT(<%Z7UL9A&=);1 A7N&X^@,P(\!PG5TEW\]2\')V_PU(6 KP@^)/:, MP)MDO4*Q#?;Z%O8R->7"]6_[.!B%5TA'(JOYDT[96*S8@^*NY$=#L9\+"X. M!O7Y\_"K87'J:S=I[S3"5!V^<:U$V)<5BX8O/Z]SR+M:NA <"@ M*83';!K >'*1VZN M'0,>;I"DI@1U>XF:B0(R"F3V]86Q[Y>M9?Z6M^!Y2DQ0JNX6U&**66@F\+4H M#%F[U-$&Q#5RV.O,R!ZC<2WH"M)D(HQ:'PX+(79,%R @G )4_&@*.@SZ]T@<=X)HE*0Q+!E@[NR@;*("B&C49ZG MY&29<]@O,USC#NDYQYL1U?J8%]>8,_%KGG]'87FA4VPYP'$FBC),L@#K5H*/ M853FQ5,' 5<3 /O_\BJ0H[Q*8W+4\;PNE1JDIE%P(C*GLF"4%/-APKI@,Y'! M_W&U#'R3\V?8W:>6I0+2J$I#_+LI'L54XP*!.V3@FD82F, -[RI'>KK%:99A MX@BOC/E'@+IQT-O=^5]3MH.M#0*181KWW)B*3OL6N:P^4WG>G'9#D:\SG)%+F#;Z=1M#7&8P??D34R3\XPQ@6!Y]?XG-*0[KX<*8U)$QU M6@3!:Y7V33"@],$AA=:&%27V4!A-I>UP[IWZ0WM"3O"M%0@*E5+O;4(AK/[R<%\I_]4*6ASGU>(V]V-Y,)T-;\XHQ0E.(;_$DELP6I 3 N<,%E_ ;F"QJH$(PFM*S<7KR(7HUOHAM86!:Z[$ M(R*,1H0$IU&)S$113U[HVT=YQ]S2 ?O*"&"3P B)/@56IG#ZXNR+.L&TWA/% M-88J4=CP.3U+1[$YVSZCW#=@@1*;YT1%,L#"Y52*:TRC#/ ?E?G]($;8'#Z$ M:[6H=/9X#DZHX:_U3AL2,% BD#=UZSI!O=#1DZ;GT(+]-XMENF[5=?>-/VU> MT:T;YZ_.*R%$6:;RG>\*,GF\GUJBXI6.PDJR" GYYNO[#E)L[KJSD$/)K$7* M8FK<+"WHX\*#:NK&?&TJ=@I5@ZM+D*6PB!"64+8DF,U;$(>4D(^+Z 17."6Q ML0@$*"? H'-')7VSTE42$$)0!KAJCJ*C'99["UZE\_Y#, . R<7=8/9HMB9G M=_ZP/P^O0F#EZ'()2[,3/,;KG ?X7>8Y#;P"#8A5$YV'3#(;+]>\FH+MNRJJ MMZ")@L3X\/,*CD#*MJI:H:PJUD?Q[JI[N^"\BZ\Q\VHEC.KF(K9 N4! :FI1 MQ-3!PD ,RTIOKE#'>K6IG)FT\I+A$)00 M %C&]63PU3 >)UDBRX+[!A3BLN*N= V;JPBQ-=D@S/1L7/B"L@X[V%$@19(! M\@3SF34-4!BF.V&Y,\(Z2!+)\. ?K/QAL6Y'-8[)Q[FNA)0Y5] EF$N!M->I M*WOEJ"KC_%J]GJY%7>EGGE)=RJ9\["M0$I.L62C%?XGJF9$*>0JOU"/. K?N M1; TYG37!WTG] (Z\ @&+JAM68-:M$%+=Q*X"56U = --H?<'P= K/YB?&C6 M'N14DO4UCW!T4E1I9?IWV!ANW7"H"SK! M? 'E^E(=U/Z*A3A9329I0G-6Z89QD7#+]1'C29I/A0$;'\0F,%R &&$GF(Q" MD$.1J$K<5J-PP+RQTW0/ Z.1NORP5+S+6A$V]>7+AUDXU'#'[A.Z\YL9;SJ8 M-OB.?6P%J YO9XK7)*$1YDP8M!8@&GE7VWU4):QB .LQV2K>JB/DC:S*OF7C2Y\2 M/0?U:7"[>#U#S@VF2G(&/K9>0;9'8D//?(>UI"9!CDT9,M1\I(VF,E6$FDX5 MC[[4ORI@:!"P>\]4"",?T,4B?%9*@]#5ZG,'MN_M"!0P0+D$)L*Q#35\=PBT MR[?>"!HB9NLSZG:IQ4E<1:J%(*H;Z!14[68R^G2(GLYH;EQ/(RXPD:\+9QMR- T>$7J YG$":B*?+I_ M_>-"LVY0Y4RO 2KZ-BMI%[:A,/@V7>GYS2YBL?I"LDJP82Q(6R8([Z3"(=O MDJ&(^D:"$QO4&BGK4,K)K"QL,*Y)':#:36RP%H/-)?6\!BUR\BBJ #C1U):% M^4P[F7HBA#%![?[*M;1B$]_H=RGV]&NJ(6/T%H3[N[1"\^1'\96EI:_Z\V1?SJ(O$]Y.WS*;M//$_N4W[/3REAZMGN/ M' 5['AB_ M\XR?%=O%L9!MY,6P90Y_1(M.-8(3/U2=+3_/S>GF#79^<9C*W+;7']DET=BL M"MO6MC[/77#&7U&IV16A7IH;GVG$.>N*X$:**EC L,<8.K[H#VQ#C;E1EO-) MI3W9*B<%04A-4TK9?"0EYD9PW) #HQ.+PA[MX*8S<90%GF&-T 1;C&984U=K M4J+:R\]6S0Z[AUXU^]EZAV++7CE; DB;IIZMX%@;JJ#];"IZ8A5-/4,*C>HH MA<&F3Q084KVQ^)M@C(W'L#G6(,7^L&$PR>'-H)]FJI\K MOE; M4OJS9!,+M1H"&O>3(RI<-@D-BBO\QWZ;>:8@IOFXVBU]C]/,!9* >$B MOTI42&.JFKM0OH )T7'P3&K4P=E,488"=S_X MC?4;+PD'^&>85;B%?=I_G_5Q"UFD@C-D!%\6\4.,E49L4BQQUL!E!GNIXZ"6 MJDFY&P@2S%%1!1\ SP$"$K5U2<"=4.@\FKE'!#NES5&_;D[%5TUJ)4:, R3E"+.^1BCIB:(#[2F M4T9B$<8 X$*?R4FIVMM>A$-1LD[_#\XB.+721S1&:P[SP33#^ 8P [8' ME^$".V5@VC9'S35-:OM&-^<%Q8T:,>>8#FOBYWR-K0O<&U$-^567.-90,AHA@-&OE=&S?7 M>?&=$F'T5OZAFUA;^1I63D"Y()>DP>9@'Y\NZ*Z8G&BB>LXTTCDT:G>-+:MF M^$ 9%3YB,>AN\"L<,D6K+L74*@8P&TA%I?NX<\6-2LFXQJY5&;Y=%8APKC,P M8:[R0H^\N9E7B>6]MQ)2T'[&,U[R+A24?LO10JX*LK'A)8CIR^2*)H3"2^#[ M*27QF-;I]-IYB+185[7?724SJP2&F9!K!\AV0&T49;/,!9WM5G/QH=5N'(Q( M'J7Y\")12^.9UX&\/>:#EVZ#:--L,>\J7T?Z>6([#"?(4:3T,I$M>;(HIO," M=*6KI !]]#0![>TK*:4STZ\?+O#3NA\,_O5+.(U& M(OH>?%$I?B#+OBAMSE+'SE!@?\A&*$-)*:7EU=)?OGSYQ]D'>VWC73ZE.0!P M[*]"1A6\#O7>4Q;79.F9Z5U?OYS6.QN%4NOO<7")N;U@8G#F%OHZ;\Z:55\L M2.G 45B2G+-C[7!M]_C.IX E6%>&B6B@/N.X2,X^T]518 !5!5T!O6:;(@%O MTG!7\#:PXE)%.';'0$LK^58J-54-FBI]I4%35JE*OF4_.!5]@3:"9?/L3+YF M!W:5:?>UUJNN1X+GL[4L9E+#=>&:R#AAGPM:$ZUMM4!+*5:9K6R%6N^#_V#B MFAKRUH@TU"@LIQ,U/(5PQK5E5M8%[4D9HYSUMP2 Z1(:("TT5+KAG'XWLP;:2J),2.&["U@U'AL@ MTN78)G.8 DR3<$KN 3U/%31Y(BKTA/ %[N@$/:DF_&'EILC$,*$(B_)KL"=E8'DZ[GJ[EHR?>+W8/;GN]6*O%WN] MV%F]^)12Y,N0'3\T;Z<31TGVQ *3^U'2T' N="AK3TH'\^H[)D%A/ $1 M,C?+>^_H!?'TO?T7>OU&BT;S,MW=@_JG[] ,53/WE9M]M(P2QY6Y_Y&JRN<9 MC50IU]S&H=K&WI+;P.GU#]M%MUE!/X^4>;1^I/^]F<.6M'6,F$>FHJJ,=,= MIDN5(V3GVO!X9VLL8,O^+)J&>P*Z:I@RC$+2ON^!Q213XSH-7=CC;&@0M8%\ MVPH<0UIT)C5J@0@R$VUS?^S*P[!E[,($?L=1WFP:8Q3@6O4E*HN*:Z+GOJ/7 MYKV=9S6'^X9SD(0P)L6[/"SBN30VQ"K]!1][3W-GJ><1>[.1ZZBH'EZ(>DIU MHS&(!#*0G-3$/6E!7BBZH(F2"6GO=&]4#Z9Z: 1GZ5UBQP\^0AWQC55F'5&% M_6J@=Q,7H)@6@!5LWSJJ55,I7\HQ3E9$AX=>>[[(R]N#OLC+'5-@ 2LT M:NJ#&&JP]Z"O[S[HVTJ[?OG\0:OTNP_;A985#UL$A/: Y0P5-:.$>MBQ>K44 M>_C.K'KK5X^PM_WN_J. _$;Q?%,[W(??F0!:FN*HH*_6+1GK/"Z M\U3+=$QJ)[?,2.4;_7_R!O^9[#:S6I-AZ\[%#U%$B=1U_7G=(JKAY:L=LMKA MM^A4..N-W7)Q3MF)9*QC(Z\$G/ L6=5W/2[UQD+5C?B MG5;=PB)FU<-ZEA!^I7>?1A%&I2G\OMQXD4;6AMTB>*9:D%SF^&OM6E-^V=O\ M\ D-E,B$]9T[>V-]-'QM!8!7H+P"Y14HEQ4HE7^H(S^JX)VSDW3IO!WZ4G$W MC.X-A,A:^B)P)8CN'!B;A#38V^LH1$BHTAPMW*D^J6XRQ#H!RV'JTL<1(,Q< M5'42=0N&NKX!=2F[(S_NGR="3?%/"YH1>=&RMJ3A18L7+5ZT."M:3K$C.[JF MR96M$I\Q,1=#_/2CK,N!R<0B<3()U3@/L#S2\)H-^&:_O7'X.]:^U1U>9IM% MQR*%Y;&DF(P*ZGIC6KVHIM^EX"YRVL*9:X)>&\EVX028--U& :!LJ0!:L,#MMB^1P%\S3^"J1&#A2/(8YW-*.1,0I& M8\VL?%^)G:MC%=1*BIC&$U)G338<3\A'>)TO3/"AFIX MFIIVS9#AQ*NY.JM77L2O+8OR(MZ+>"_BG17Q7XQ]5:=O"'(.HJ@ET12)YLS# M!/OXB%EU(,RLT5>Z9ZPH18=2_1+3Q[*LJ. 7>V\.BY!:6-+0)ZMU#[X]%D-! MX@\'$>Q\!P%E"L>;ZH*=AWFAD@M[NWN]NB2[Q$[ :?!597*>Y3BS.93P"AD5 MR8!.Q K'_L]7.$ZC/ZI$)K5&\![CH27/(EUJ;)D7C>M*VEXT>M'H1:.SHO%S M^EY^N>KWN^[BQ?Q_R,O"K)B$&-F]/KR(?V'2@O4[/?^>>ZZ7_';I[+N0CJ M+ZIF+E6S [2SC9UE41HF8YJD)PH:27 9X@@\:G2%P3354XH?OB'WL$M/Z]&& MC7+ F3D;*4U("'4:!AA(V-P.8VXC>'*4IS%O"X<&6A,3[;_"_R=7G*49\1S# M^NQA.G-Z/3 /\T?0M+,7+4UO)@X"JHS&234 8P@%*WE(50LV:HT[#O'RP'$O M$NP3BX=^<%\]RX7Z"*WU&-M+=]-;HIW2'5\M$QY:>5MDMD.%KS00 TSVJ@@O MV16MM!=&VU6BG+.UVYJZDN$C;!KC'^_K3<>;^(7K+0$(2QFTZ.76>4C_RC!] M5\(BJENXGA.%Y8'869L:'YIM0/VK-PEH_'B90T:(2GL< 7<>,$1?)@Y"E7U&+?-CTJ9&AH4T]V1!^) M2KPB#WN![@R:-8J]EY/,:W=K*YV\=N>U.Z_=.:O=?0R3%*UJQ91O5J_:XJ0S M\\X:BD\]"6YNC&[[^#*0/B*3/$3/C F,=&4]==)G+S(GV=YIUFZC=<*B(D?* MH5+]7;W065NB\4+'"QTO=)P5.LV2#SN2VN36X\?F:7JR:*VSSG$F8Y24'=S>%F$LVAHLLAK3*-5?FM5P6^OT%9A MK^?--/WA,S[P^HLS0V+(U4TSB&YR=RMKE".L5E.D6 S4G-(,FQU2?W35F-D7 M[:\S17J)YB6:EVC.2K33>=FD>\ 8,63-M+8K!>OZ?-WYQ=3FUXT )B*?I&BR MJ"*16,NF!,>>B[@;_$M/R@+[)TJ*J!KSY#;5D>8&5SE)(>SU7R3D<@,(\(AJ M'!O0G)^[8..Z'TUL-:-1Q9(L!_58;ZYY 2F6I.3@7%(@;6IG_'W?&=_K EX7 M\+J UP56I@OLWHW8Y36$I;6*IP%_#8J7(L6WPLJ) T7=+\5"*Q;^R!'VQ M%R4)Z67>=KW,0Z06+/,@9BFGTZ5.J9V[M6%M=_69Z],STW-(6^A+'?$IMC_? MY<_V2=O]]&7P4K4LHB%@\ZYVGK. RIK=7$+YP&?FM^KN1^H]>B0"E9*I'L.W MN<'-#NJF?S[!>J/YHME4&:C)-29>)1 M)DXUF:2Z?>PXY(&4RAXGZE72A=:UN\AV[(Z!NHF$-N_KUD-A[;_06D:,?0+S M">D@\+(9)P!J):"M9$DUIJ5U/UW52-?+D;6E R]'O!SQF:: M,2G_-PT6@=\D3BG&:2(A)VNWQE)GDIA'55%@GST??ESC*^E9NF?IGJ4[R]+_ M7I?:6#F7-E.>Z?I=B&0\J K)$ZFHH;=D3] -V9DT0SP<>SZ^OO?0\W'/QST? M=Y:/DVHN)>KA0]KAW(B&)(L!BM@1!CN(61&1Y>&PR&G M\.^4CE78;]2RR#Z;D5HOS6>=8%"55&)&_C!*L>S,=$IMRS\=UE4#<16909'F M#8T-M_;Z>U?%EZ(,SN &%7EJM2OO<3>=1$:5FMC!N3YP:V"S*=Q0V%N"8!!I M?OVJ*8)?CK''H.2XG9H"HLM5K8[F WYY+(98-JK:S>'C'?VZ22C+CMIWO0ES M6MRK>2FFI*J:T[O=M%=\&6(Q1F1-1I@$Q9>!_S!SWZSQF4!\5'Y)P%:]]XH@ MO"R$@GA+#PE><\8/664J0XI+044ZW)E@!(WSFG1"TWR43JK&1H"/J SKRD6= M$!5RST.I3TAOQ&,#&S//Q*HZ,B@+D<7ZT"(:94#WE^0,Q5U-1B$PITA4)7T$ M&X #JW.:,2[F4+POJ8UW@ S=+_1ZH=-Z MX6*% B5&3OT>L@QGE/,TDZ"0[-4B)#*\I%#I($SG" M7<.>4%M,) "QN7*$30H NR#\5+\2ENW_)"7K0J" YTX&^! WU*7S!E^--O02 MOT#W?/<-?\]\@3[MO7FE,XVNWN6T@W* MBED%M#MEDAC%'[^@:JVUS3Z $84!F/>,TS ^& 1Q/!'W6W-$[)ZK]8RNXP M=%\[[A8SB2Y.@(]=CN9[3"/,38=19## MW'@5QKWZ7G]W;[?+0.=__X,M)39D^7.9%H7ES#]9X]4)C*?/94 M=1!,U600^EFGIP.2\::R].8LJCKESK)ER:+JJ+R]2C6"]?WOUEYW\+JWU[V] M[NVL[GUJ'$K(@Y>0Z'<+R,8F:,SP?:BBV=GUZ=JHUZBY\5\@$:]A MX+_8+\VK%.,5!\9 M4GO*\#L-5@&U S$1&L4%-X>"5J+S[1)>P<"%%Y@\>FP)4T@].0M;[ G3:V"" MQ9SDPLL26()@"GH>Z+0A=FDG98LVU7R$ $LN_-C:%8E(62LQW') #08!Q("N MEK);F_O#&AV3-$2U!Y0NV(W>O#($08G(6E9G'Y_X M$>+&T8.GCVXN*$%VC,J^!EEN!X;K6#!KOJ=?OYR:YG* (=B1\B&KGGO<)\B, MO+&N$*N)H:5,)K+9W3ZO79_FF?I,O(%O136>!*>SF(@#'B:J+CBBA=HEH'N? M+FE1I4+^ CK6*Z2.0:HC+LBQS'1/H.(\2M2:-M#YCE'5R(#NX'A2<@! Y[(B MY!I]BU3D1?<98IL67X+C8S@ 4T:GFFY0BL M[!WTA'=,L".NBL:^R1>.(.C@BKBD8@&4(I!+8*RCL&![5:O(2LF6C GTI1>- MHY.F?PGFQR25FHM"W?CCWNT;I:% YBKFXC>8*F M:Z6F1)G94W;L!BQ(V0W.:[\2>;% -F-76>!FDB$^P]?8["NVA MX0K_ZEYT@_'UNGHOTDZ"+#QK0X4H2ABQ(& M_70520?<<#A!@*B08F,GZNJQ>O Q&0*AG&$OAD3O 0YV2M^6P56.)^[O]*B7 M+VST.\YUOJZUE 9%H>-0!&'[]KCM,#OX@*I4OU^S377'FD6?%]4$F2+O2SLO M04.F(6< I/NUL#W#D&%>9$D87'49T$N52>J+CYP-&$0"DD0S%NYP# ITA#Y5 M;&JA7;/^[W2TO#GS+B\WPD2G:]5ZR)8"T:7ZR%1QK M0SUE/YN*G&]]\6V9A[ I/ 9,5J3)K:C M/6[U4+MPD*/[:";R6-*K2#5@%;=NM%!/MVNV7%C8-=EJ%ZGZ%>LJ*97?!4HY MMG*H,Q-U7ZU:%>*JW]IFYL"IZO*/)PSGOF2Y"&[>'NL\D4BN9N.,"U]HIN*V M]P5K:R&Y34XS1]/0W&3M5GY_'7#^??<#83C5D2:J 2 MB@!*)A2-TIK#VCB]+:"!T"10?( M:4"#EQSK>_.]Y/"2PTL.9R7'MULZ%]_$JFV#15<0R=;"E2"_QMEMUKI-*2(X M4-5:Y:0CO=:7><.<0(BM_%"T<7%5W4R/S#$VFA))0H_W %^I<)A?1=94?2X5 MO>(.S7%0MTD*;BEU^Q2=IJD X4:^>-4*"OZJ@:G^K@+[:7!&/F8,I>P=[>Z0 M81Q5I6 P:E.1(VI?*6J*60=G6 HU[02U]W_^11=Y58ZNL744SZ:C!2\HJ67G M/$MQP7^'L)4IK#*>H'$6!KV]A5OP,G=M>8:7N5[F>IGKK,P]:]:$)QFY[B@] MX2K)4^., Q8?_JBKP>U9;[7X5 T*56H-5INP_X_M*'JNXHR<2G)-"?ZE(:5S M*9,ZK&H\MYC#H8+]9A]6 H_5-MAJNVL5O&()2A'0=&'T1L8)S>@M*5U"IZ5A MD'?G>\)%4BRV=0K:0T87+'T'U:\HLWXY[!X>O6@$.7>8,_I Y]T NW18>WN% MX[U Y(7C=@A'M^GG9S1H:>8)JAX1=N]U#E1I234.P4321:^G7S]<<%E>9@E! MSF&2/&9[&O!8>9ZB;;(F3=8Z!R+!.A2!N.+T>$IKQ0]4AC?N "#%&:))G8YH MA*F5/&C7 T8FF5G5"B2--O)6T:<^Y-GG?Y^_W^F=!)B:+'#X@#42K^Y.HT^D MC$%I!HI[.VYM]5 G1)6WX[RH6E/Z>6)1=3$B9GZ-Q6A6W;\]K)M\=)PB#087 MRH^84J8'U?S$[7 R29-(KZ("0:+1J$PW E%I'*? MPIY,V8P]^U1_E1>R?+D2A$8T,WZN=>!J2T*)ES!K2R%>PG@)XR6,LQ+F,P[> MN@:6+4?)I!X-@M$PY,6__GHF7__ZA0HY5&\<-@3@>-D.5EI@X1;*!A0!Y=2L M,%N2-*D*+-PLFPT(2:CP$%2L&=+;L'L$JDK!A9NQJSU:-S9_.A5"H_Z4.]R? MUK>BPM:*V)TSFY(9UFD,[)+5X'*+53?5<@44Y&=>I/?6LH?FL?#!"WB+V1D"$[-_(K)!:=0N M5B>;7E*+5OM&1 8??,'OUJV:\J(NJU4M@71]XU('6^H$7]22]BEH=;CMP(!4 M%U/LC86&>(DWQ]XM%W:UO0E+S ]W\14GNT$<3KDPG!!FH>EN)YI]A]IK)0HJKB9$]SD)H!T,CBW#,54 M<=/L:@Z^C02Q+SPZ3PI\%#9UH$^#-(LES#&5GN5I$I/.6RN@5&;,C(AJXWMO M[EE3=U&-0>( 6X^#CV;U\ZQ1H_Z!.>CI< @*^=)#'8?4XNZV8/K 5?5402#/G'Q9BC4>/EXRT%ETD_IY<<<\>:7<5(GL"6_1(W3:I&D^45V6:5Q1-CT(* M;8B8HNC8URC%%'+ =D5&3\+]P3)NU*7ZO>ZD>4Y-G&N3KAN@\RM$\9J: MK-0WU5PII]YIU Z(8OJ>I FY4#JZA-2M'S 4"%K7)JF@6_1K!6->'V/=GT!C!S M_?60^I$W;U9C!+-UKX-F[\AFRB5'Q:RVQ>:52>T[P+D^Z!+!TZK^QR8@-YAB M5F4W.$W3FW:-DT,P8JA#@Q5MBT>%2 K[47B0:ZW%*$R'!#QU'P$X]9P1UE&3 MHNXSQ:. I*;;$!MAZE??]5H>+WTMU5T;Y&E\YWMZWTMY8V<&ZL>(S=2#Y!90TA(*RX/IT''B_4:=$\4D+(SSJ]7GQFYU7 Z] M4-SAO0;8I ">G$RP12$'G9%;LG>PSGIJ-LS"UEUC@:-L-8E(O.O:02\TU&>% M3S [J2LG*3DOZW^Q%IY8@+6Z?4C3:'%W:;W:4VBE7_AQRMDJ8_$8ST MY;=Q:=J7YLB_6-P1T!6>;#394[)^K^++&K U J^Q5^RUOF9B)K&@QL>L8!^" MX9I?HPIZ Q8VH8G7H?M-O!Z? !8)A20#J9N43R<,?OK;=>#*EC 8*CB-@)QD MHMGN.57A&V[[%@0'-2M(([21RI M]02,O:54KYM2YZ!!E:2Q2CY0'2 :(_M4NUGD'5JKG7G#[ 5MO%$=PYR)^E+M MJ,Y/^$7JB*P_(+M0O=(:7H("BV7K2O1O;-.?#=911SX>!D'U"/*X[L* MOJ<0OT^AYEN7TP3\9RB)+D1]\VL62Z,3ZC01?9](=^91KU1R+L-4-2&G7[F0 MD7Q"U/B,&6H8(P!%S,UKJ&N JOU05SD?@.(N9(1N/=,2UN8)G+SPP/-0!4\?E9B"[RDY#E:5R'JNAWC5%)9*J'<288[_$>5H*)H+"'1D#49YG*L MKX8SSV_%#\U< +US([F8--4$C7G82 V4;O#)K%:?7RJ)7Q]CEE'4$#';FC?+ M- I)T&.G[DSWM:^DZ-0M&F0"5!!27L]8@(D1H_''2$!ZH0E:J M,)D682#'7 M5IL;"2;2E@:\54L[&857A$UN*T0,G)PM&*0Q@WN5/*XOA[5+IYI+Z'>S [(6NO- MBXD41EW1]0*D/Z6YE,ILKC+3>#"V_*1F6D!<&:8^FD[0W\76(.UPIYJH^J=N M\%$YP;3QR)BJ;R5"$YXE]P O2-/HPG0JZZY4-)9"684(B2@LBJF>E-#8C.DL M/[.1>@/T-:4PJBM79_VI.C*EO/'8$&&N',MQND]J-[188S.=YMEH^[*A"Y7A M#^Y<8H\64*,9Y@'=-(A1]\$6\[A[\DI>"MMGIXG%#=HF^Y&_=9; M &(9W_JV128@@FF:;:I9*BX5Z^:C:^*C=S&7-@RD23WL\@W'F)_V)U.8@A;/ M7F1NAAW#V<6:4 =/,^&<_XP37XC=*9RN5F9OIN9P;D27\3. M+:IY&_.5-ZBYZ ZG)@NTT9>59$%;IU&2SJUM0@H3*"..0UXS'!C_HB^NVOHK M$]"@0!%I*SIUSZ2-JMQ&F@9.):[*6\G.M0G-_IG)QYXC%!Q)8A)$-4''C ?; M<*$CR5KF8-! 4PA)GA;AK-4K "'24\[3 &:V .P0_HMCWSOTA0:F]"-$MJ$N MF148AM GJ@F9,L*17Z9FT+R&(A^!%*.AGE1SAW?8+"*8I)0[.6V:2,/D!X"- M\ [8$M<\@AW9JI[ZH+P!NG]QX_7VE:OYEJKAU=-]X"R*JZL*L!9FU@*#&WC: MW,[F :-VUF&./Z.T&$+C1^N(FC(2FTP^4]7.OIX5J%8?=1=;T\9R/W&][ZI8V[^7]_RZW)G%A93&,\J6<9#0)7 M;U,F-;;:!/Z,0Y108I!])E0&Y[1NX,D&$2:N,_4?'QSB=3H^W-4WY1R]6EAT M^E61VEG.XZM[)\>'RL" 1[*8>];,364$.C)YH\U)L_G\=GBT Y8(CP40YNT: M\B8D:1UM1)+6IVTIKNJ]##F9]IOP'FBGK>58D9>K^2G8N86C_A7K5 MZJY,.)B7.&L9G.R^T'4#:MH[$1X0*.G^FE[S "=Z"]5_KQN<-FBBSGVU1YQ9 M'2H4^7<6I_W,GIUD\=)/LTD=-1D,3<#FWVC,N&@ 0 ;4?A%8 XE.:B?8..*] MTIZ=I^?_\' Z"S?UM&/Q(\+YZP@[-/^J4MD"H$*E "=0*'!(-2HJB5(!K&^0 M4UH&^R],DP3R^*,VR5KW\8&Y:7D!%Q23\!5^R&U]PG]'MX5RF9'_2C]C'/:- MO6#9@4#M$3M]V5W'&EIGXSL=[OTQ1-.P&S3D%K[#.I(18RI.8C6R;$VKQ@D, M]$6;:A:M4!M;53<@) M+%@<19YB=V\V9U4+/&0E8-06 FTZO$+:>\ >.N6G;-ZPVH&M++K-BA@L78'R MM2Y;^VS&,VXFUWU?\Z)R5 BQ,X;G1B:>EZ$K]P*+1JBCS=XN-T?IV-2 /.7Y M07>^@U]G=W:WC M8#2BOEF4I0L27*_>/^GV5U^9[OADZU[WR('R?3_9VI?P.T5%3US$_[Q_?$)L M%C7A4DT&&U"40O'Z8M9GAV&.R\L"YT6+QD-!K1S7S7)#S/P!J5)):S[F;(69 M4;!4%+$E,(B/9>(:N_&"5"Z+BM3?,]2 @G<"_>\YJE4\A$N7F$^IJ]MF=(#Q M,L3+$"]#O QQ4(;T]H^;JCKP[T&>55+%G60@P%*O\T+(Y# C#^_0#P2,6<_1 MU_LN>H[N.;KGZ*YS]/[Q(7%T^#IS=,XWH8IY](K:^A.?NURCX7*_^@5=?Y@2/VSG,]>8QECLO ]OMOMZ\WE'W<+$[K[??W6_S MY\V_<:%/;Z_;,RMXO]Z:\AXOP;T$]Q+<=0G>JR,S-:N=D>+(O2FD;1QO%EN7 M M,<9^(T/3OIE9X*4UW3)F+*Z,R'0YQG83*.=2XRO.8"VY-=QO"53G#ZE2%-N;:^P%P1>$'A!X+X@J+7VUMA.BVWGXSM>A'@1XD6(%R%K045/+4(.3_9] M?,<1CDZIA2Y?1B=8^GVAY'GZMO!TY^GHR4,\1T<^Q+-&*=O? =UU"8O@J/NT8M.,^/Z#BG>,V&?A1G;NIC1;&/?#A[1-DZ:V[A+:*IE%U8' MB!OB3%;M?MV12N_10.]6^]7^GC0M6!KOG=\E@X7IB,KNYVKS=0'V;9;P;7:O M[56E9SO!>7X=ZN*7:[4QX$'\S'L1$80[K:A[J"YW/0(U:;J#(W+C-L5NT^J. MSKE,WTRX6%R,SP-A^)<9SWEC+,8"Y[F:F72=JV8@;7C0."^1/R =6C49]'4@ MS&/S@:Y:FV<);/P.1 MJ58%IO>%&="N1E#"!G7F#M M=RV,HJ+B#G*:TZC2,1F.#=LT[5O@R<;784,5-2&A?A_\ >\PE+JS8;VL@F[; MM&BK")':,:#W#]M@S)#-_"$:US.@Z[+4/0'\/>_W#TBA4;=R#W]IO;$'1[WZ MP8,]>K!Q3^_PXN;R& @SKM.6X]DLX$:B;O#WO)@ >SX;%=AHK .WXD>H&H=] MN )V=064AOP_ Z:;A3^=U\[HN3N[W9ZIV'NZ46<55F^26#65Y]*,JO_X\;,9 M3H\-Y-!X!_SH5G5_$B>@/II4#,G=9$+= LH:^&'- @F^%15V-='OP%ISJ=]" MT]) !4Z .KBX&[9 &,+_3HAII%2^3-6FFF4CB6$3RK^?GGZQ"DK5WE1KM9%( M)UCKJ6K"N5B3!J%)\Z2I8S97SCH4;4[7AN)^DOD^A'!:K$=&IBQ1?T[DB!OO M($G\I@O[3Q5_5;QW.4#]=HJ@TI#21\>A;*HLW]+KX(RX05-H"QM@V4K09LC& M.7WQE@/1ONG-7%JMFCD1D8AH;B4K-!>YP5%BN9HSHHXI]I1:PUQU_RB5:EQ0_NK51++CX2GX^Z\"CE0!V4$_;8U8S6-S)Q:5]4R@^I892U'L,=FZE[%H- M)1<@:Z:3(5X)"W4#P9TC0OE+\'(MX)&LQ2Y5?WCRGZ*YJ2FT.6[1UCIOQR3G MRM7-Y^CAH"W-B&8;:&UF MFY-W')7@T0 @ M"\;M"CL30LOJJ,D*8K L7>?5Q8@%+4AO-*PB?RE?N%#8.Y M2--'^M\;]M"+J. M'V1[")WIF0+%\@JO^M7LK7D'\8-57L,;0^)\J">'?Z^[MTKPVR"E[D^+ M1+ MM6!_5$3 3I#W_>W9X;.?AQ3]T;L:IHRG_EYW__!F1-4AT*6,X_5'VS=BP9_8 M*?L!6>[2GH'U/[P1+GQY0<*LF)&T9>ML%F9MNND\QL&TCS/=H5G+\L_MIFWOU:6T3;:1Z[BQ%M*[B#""-V^"T*W MM]L]L(0N0KA5XGJI; <==_N]E(9U'K2C-.Z&3>/^ F*UM*=]LF#'B&M_9X=4(G\PSOJ1RB9Q\_[GX\ M>P)B4S[2GZ'9K291Y#>3A71?\G@RV+,DVES0/TS:/QW8EY M/X-#.8.GY\ZA MZ&0Y#>!6+%D"O\"]/(:\=P9M!YV]_7WG4/>37#/.8,%5)N=EBYRYQSJO&QQ PT_+1C@P>YEBYD>=@X-[1V>\<-EP+N<-%R]< M',"3%RYKB;;>?F=__\@YW'GALII"@.V->[W'_C2ZLQ@U'QQCB\<_^0/5/B^@ M 29UE\'9>J)- HC=R4>U?*-VBJN*FGL-R#&P;SV+=@(-K.5LMQ)SV#GNW=O[ MZ@EDLPG$BP=_^[<7#5X\H'C8.SEQ#C.>0-Q @P_.^=N_M6CPX@%+ 1X27_,4 MLMD4XLT'?_NW%PU>/CQ[VSOI &Z<0XVG$%\:YFB(K,JV,D@6#H?4W%O<.T;F MLX0V+DMHRWFT$VCP6LRSM_OW5V$\>6PV>7CAX&__]J+!"X=G;_LG7CBL&@>. MDH>/C_G;O[UH\,+AV=M>IW=RZ!QF/(&X@09O._C;O[5H\.+AV=OCPWOGUGGR M<"PVMAES9)Q!R]]#')2>T21U'/=:B# -A"S#4JA)ZBZU]MU>/#F:?'%+A]BM M+#-W%%7-6O,'86NCE84=WW/91;2XUV?>"R/'.)P71FN#*B^,O#!:8[2X(8Q< M&WB]C;CPPFC]4>6%T7+H>]GK[.W>NSV]ETA/B9M7JQ9&WC)RF,-Y8;0VJ/+" MR%M&:XP65TK@;@KSQ7DU2$70[VZ/7/H(H)7!QR(?!Y\GHJ!RN)65@-V@,FPA M:AS-&UFF>_1-R-M*G6)M.TP_"B8W6M_H]3N'O95UH5ZD="SDEUM%=JMEH5Z< MN8,++\Z\.//B;!EQUNL<'_>].',1-VZ(LY;HHA=GKO!!+\Z\.//BK$;MWE'G MY&1ED[.].'.7A7KKS!U<>''FQ9D79\N(L_W._M'*"MJ].%OW0L8ME&S_H:5$ M'(17H@@O19!5XX$HL*91CN#P,LBK4I9AAG ,=H+W25JISI^.I4UM(?(Y^AX9:/LO&[B+NUYF>8.+KQ,VP)<>IGV MB#+M:&7S,[Q,W02-[[RTTFTM%9^!O!3$',$E,.C/CW+!62M1WJ6UT4V)3W+ MJR'W0NUN]\27SCB)&9]K[''AA9D79EZ8W4&8'?M,8R/""S,O MS+PP6V9*<->7S;B)&3>$F;?,5H\++\R\,//";"EA=K"RF??K(LP8^AKX-^'I M9X0Z7Y M)PAE$.5CO$%Q4.8+G]SM,L3YWV_P5"9*LYO@&I:9% E $& #;X5%\E^"E\DK M6M \EF3Z:_F89ET^[QWT[$/TV@X!:\>)C"J)QPX'^97XZU\.3M[ \K!^&#P_ M.-ZWU]AO6\/>0BPFA8@2BL,&809KCO.B3/[D#\2/B MK++F1\-ADL(Z0G;HS#4$%"0;;](+PR=(SS&^ 1\Z2Y,K$;P3H_ JR8LP#?XA MPK0>/%7_3T4UW^O6YO]D#]^Q! KWLTLTYO[VF( M(,FNA"S'<#VDZP31"0"W91*F\/9\.)0 ^L&4U@>,5Q'M &ZA@:1"%P!S;P:8 MNR=MP+S$L;UFZ\O<.7@Z)3 I8.B!OV$P%G$2P4%AGTDD@D&5I*@-= ()*(,+ M)@* !?R3R#(O\$DXD_@1I16^6E8 #-R-#(:88Y(#Y< C494RF.$-0$B-*SS' M*V[5#.[/&&Q9O1Q[NMLN%,\9Y&E\9WYU7^;T/Z!D98V#Q'@1"-Z_@ HHBA30 MCUP,\%SHK!^X'U^%K%(0_0;C8"3 T/1)I?(WM5(-",#3G4\W[-3XAEP@>[YH.&?E8(L4,< ]E- MDLZS(!)IBE8*;,3\KNP?^KW! MDWX)JS)_HRP@L#[2< *72__P)E!6TBYMJ8ZKRSG>[W5/7CR^";:V7JLG M W2_>[C_!(!>:.O.&KMG (%!D6P+N'LO5NMJV';P][K[?8\"3P%;"_Z][K[G M]_ZV;PGX3U"+] CP]W]+P;_7[7EN[V_[EH#_N-L_]!CP!+"UX.]W3SR[][=] M2\#OV?VJ,;"]!+"H.<1/ZN+!X9%E1[@O3#J,!(;='B/K<"YVN@AGQY,EDMW6 MDTSL@(I'S3*H@9U@,/]OS_K/7.!F?0H.W(0Z#;2M0=LWC*P'GR@7YX:LA$T[ M]@<,YF_1>1MI"UMT;DS06'D_KI^A0KD!;A?D,P? O'Q>0_F\>YO2Z\7S=AQ[ M:\4S4^G6R>C5SS;P,OKGRNCYL.4&W_ UD+TGY&OULM?"VF]8I>)%[X:?=]M% M[^K-XV5--2^B?ZZ;>S[4O,&4X$7T.F+-B^AM..^VB^C56\=>1+LZ3N)G%U@Z MTWWHJ[C*TRNLUXT*$2=E$%X60F#W!>W=VVY_2O+:*NIQE,NU%8!N-#4XB@YW!_9;-XO+!YY##:NO4I=08!G_*BO PO MA6G0ZUP-NH^>N8$'SYK<0,.2'4XWFD0.^WON(<;3APMH\.$O-_#@R<$)-"S7 M('6C">1P_\ YM'CJ< (-/H+E!AX\.3B!AB4;[FTTA?0ZQ\?W#D)Y MEL O%! M*#?PX,G!"31X>8'RXN3 RXM58\&78ZT8 6;$91&6(I#7X43J48^O7_)8WU<= MFO'[,NR^[O5]YONJ<> H??@@DQMX\.3@!!I\ MD.EM_^3$.;1XZG "#3[(Y 8>/#DX@0;O-'SV]@$N0T\>FTT>/L3D!AX\.3B! M!B\MGKW=W[MW!T!/'HX%F'RATCT1<#K.BS+Y,RR3/ OR83!,LC"+ !3!4 CI M7 #6!Y34GKWM'=V[X-C3QV;3AP\HN8$'3PY.H,$'E-[V5]?V MW5.'V]3A TINX,&3@Q-H\"["9V\/=^^=J^;)8[/)PP>4W,"#)P/AX)!^[5L_IXDAMXV#9*0?$72/6%_%DZ2 M$D#\IXC-]*0@SX)Q^'M>!),B_UU$I:],6CF>'$U$V#96Y2H:?!#IV=L=]]#B MJ<,%-/@XDAMX\.3@!!I\'.GMR][]VZ)Z\EBU?]#7)&TXA]HV2G 4#=X_Z(V* MU6/ 4>+PL20W\.#)P0DT>%D!5D7_8-\YQ&P;?3Q",.FA@3T[Z'DXUF78YF*/1N1I8&W%8Q M.%=1Q2&H1T'71I/:O>>X/PX+O(6D;/[GR>HGXX8#55X\.88<+Y[6'U4GMRGC M7CB1";NRD1Y>.CF92V\'QKQ@6A=NYP73VJ"*':=>,MV&OOZ]VXY[R;2Y9&7' MXKQX<@PY7CRM/ZJ\>'KB/!$OG=:A0>%#P[,WA 3CO!JD(NAWMR*X+S<2/ MB K55(MV$S:W4,9Z[A\9FU/!I M4;G1=-KO] ]6-FQED1*RD(%N%=FMEH7>$%KT\FW5R/'R;;/E6R/LZ*7;_:=. M=DX.5Y9;ZZ6;NPSTAOBDEVZK1HZ7;ILMW9K.82_>[C_YK'-PN+*QREZ\NO&V:N1X\>;%FQ=O2XFW_O'*AK6MBWAC\&OHWX2HGQ$??5V& !WX-$ZN M%EW4WRM9)L/I[5>UTF_ZYO.MQ%N0AI.I/A%__ F4#=V=U?U%[@Q5JT-X+V]MD+? MA4QF:=PMA0%UG<.JS)?'1BK*$@"@0%6_;+F;<8OP=QI$]5&.;SGT0X#Y[.W_ MP*^9/MGRI!2+*"]HI""_\-T<3Z93K.)$+\/NJ_]YC<=Z>P/B-_C2-U"Z #&M M2(2O*KC9*S3E4/LS3=S.?N.KF!1" F>7F,11]Q">A* I#:9!)5^_+'/XSRO\ MK1R)(((-PT,@;&(Y"D+X[GB0 M9"(&<.+1PC0(Q[@<3KM\WMO?#0"**?RA.WM)2*[=1ZKAE3B&<-RHV BBB2/ P$GB8,+,2G%>""* M8&^W$_1W^[U.$$J$.VI',2-)J-])\OU1 2+A>< / Y?BBL13(H$ :@@"_\ M$KQ,7@'NGO>.]V@?>G?P RV6S&X?9YE615"(JSR]PBW#\W%2!N$E['H,\+;6 MAR]6:8D/#8M\',"UM9?'9<(K4827L&I5RC+,4 ZCN"[R:_A)!B^?]P].NL?Z MYLQ!*2 HR87PF07/\WY_M]LSRZDS+@;8J[_^Y>#D#<"(@=0_(1@Q+=4':=*$ MO XG&EKFZ_1]I:^T7>Q(X!KVO>[UFZS/_MW)B]X_4><;%?J $T#MS@#@]'TG M',+Y?@G3ZW JGP6O[Z:SW_^0MB;R4)ZR0MC.\_R5^0$6R* 5A1[[QQW'MH0, MPK$MM?(JS<]1(@!G# -02LQ3CAT@6G(0@E.;#EX"[QB!L+@&21CEF2R+*BKA M!$-0+].$]*MK.(IKP);5 $5QF80I;-RQS:&H!C6=[D'P7D0D[CLLJQW;JFN, M"=2OV+$M:?7(L6U=.;:?5X%K]KCLU9X8TW;"(]R M2A-YA=^\&3P(>87[]&8?"0?_H01Z%Y_V#_3FWS7(J_G(Z]=)* M;%-KO$E-TR>X8@B<-/<_/98"H0?_!BXC MIL%9.)Y4DLG^PQ4 ]@K8L<"G8@!HR'\XRPMX*#@;%0G<@T[P3?P(U7>^B# 2 M_)9Z&[#!)++XR?_"C4"F_P]]LK,1/'B9TX:+,.VVQ:0]R_CY+./7Y(\J@=N* M.D([YWV.T_LE*XUV\/5BVT +K!-_CS\[WN MOOE:0Q?$C89E622#BG-9T$18D[R7XVYK?_N'90 <.IH!T+]?VLO^D2,@N@/9 MKE_>RQ,?Z:]_.>[W#]\\<>Z+VS=_I;DOA-_9KX2@@E[ES'2C49BA@V"(K';/ MXM!L&#=="HH!YV-@UFDE7X^3#/1'9.-AC)ABQ1J^5\!10.%&)T;]%?@\6UH. MO8PQ0P=T=E*J46VQS=Q.T^@M:C,H'.17XO5 I/DU&.S%=W@A60RR,V)ZEY>D\0,FPI2@"K!+ M T%F!\A$*4KYBCQA,5AQE23S'7=,"O5RV3]>N#E'XEZX>>'FA9LCPBT+JJQ5 MONT?:X]PH)U(D4BN\#'/?M?Y$GKVZ]FO9[^.L-]VVV+_X%CSWE)D(<=>17&% M>CEH^KE,P'! _=FHW?@+*.>4D(\%;M+SZ'6^J9Y'>Q[M>;0C/'JABGRP>V"K MR,;I0751=>3/<^$UO8N>"WLN[+FP&URX)>=JEB=+8LJ'^U2 V+$RP.K$2,H% MHZJ_9(Q_@2]HK5DGN4W"*3GFN\%R?/O>-X! O52D_PY1\ >'O"O)R79)!M;& M;)AA0\/\-YZ90OS[O?80_S I9-E(9>5X_'Q$OW?8'M%?M,)N]\'07GC!5@/N M]_?*C+@&$&%R3LP9S<][>UU3 -ZQ,L)H#X@V *^*/.6<2QM&?U2)3'2D"C_Z MF!0B^"1DB/G 202Z596DM S<@D_AU,K!KB-/6,YV6PH[FY#J4 M.+W>FUM7/ZU/PN;_^T22,P _4"^M\X)5VFJOUSVPTXMU(IZ*/-;Q-K[]')2L MX6IR=0U@[?@A'@^TR)T!QB;%*+Q*@".GP8A3X2CCSB3RI7D4JDS>LS2YPO2Z M_#KLP!IA251V0^HOOG F_Y>P4F2,49*5<8BK(J7,*]D\.GS.SF3 M\+QG067,=R[- ?PJ[4:/>@,8I>[L;T3AE+<3J3:Z+%8GW)9PJ/W-G2):.;:E-^7%L MBX9U.;8OQ4D=V]6N8_M!.>/8EOJ.[:?GV'Y()4<',%@ZCFUM<3N3U>SGIO8A M*[I,7<'[.U@84162 MBB$J:=OOCAVH5]LOCNVLV>* O"R.[;!3Q^</@V)9< U$X9EL(G:D%^W"=,XP6]B5R;)^E8_M9W#UP17??*6BRNZ4S&P5MN_/*Y#IK.$^*_+((QYV9 M(8U !:(8$_"O1TDTPC>-PREL)$T["ET #8#C#M]CW :V@FJ@J MB_#R$OL_EUQ:(#$.R'A_WMLU13[X;%[@F+Z\NAQQG_Y+I)%!F'V7W>"W7+^2 M^L?CL0 2S;,D,@ (Z).K R]5Q]4-+A($$OXSH?SI)58FK(S"*[.;?N=H=U]O M$QE.9F8-V&?N=?=VD=?QDPKL=3;W3.%&_VAWCHI,#OA+_(AR[*V.>[#C=_GP M%,@^@J-C'BVVN(ZZ^.#,XM3[Z=4-?$4Q6T0-P*;B)B3--0YV31<3G8N/?(W" M3*K:?J0Z*)% M4MZ<"-VC=9%]_+)A.>RG6+:![=?Q1BFYM*#)O:D>,OGF"'%)%[LFN>4[<%)+ M4+L1-,)X81_GVS$6S"&+*IHG E\)Y-4-X+!A*O/Y$R\\&NHX]+NAOEKWN+&! MJ/[""AN)TIX6]A*M]V?5! *<;^\O2LH?/LI)*%.@MR'L 'F0!.E57@O!4+5: ML^)6EK\9"NTBC#2R-ZZT]S\"!Z"DH>E$A9RJ9EQ(&Q@Y9"[4()"&2OO(!/)^ M"?G>H3\3Y39W-R-5;V\#/R/\CJQS@983HM(&2C^7)+= PU;G%?R64D^6..2N M/F2_Y:4/.N3^;8=L-U>6/M_NSY'W#@@K/??)<&L]MJBE(P'>]]D'6XNDI(BX MC% 5[5KC7&8D S;7$*Q :U6-&VZHF1?TSDJ*^HOW*,"J*;6!UH_:E" =D$R) M)?> Y@A+,-"TX8580@Y,-I2-0DX29O%52!Q]',;XGM<$-*ZB7*:,M6-W$9#8 M^@/14E:%4)67JG*R,V,*7<0)PXNT0Q1)+\@>M -$VKJ MKS71>IO('JK".G,W^!HBGCJ-MTE;%),>IN:H%*)998OF'?Q9_%"5K#8P;: ; M\:T>X.DL?$,:Z"YT[7+ BD(UT8T@C+EIF!YHTT1#!*K2HBJ^H M-N;7H(@D:D,$76%;KNJV(33*E(IO26G:.&7@' 2Y0-]!DA$_ N@!B'HI=F?#S\:@I?+L*SCSUP_GWXA3VQ[(^CUD:BMXJ.%Z MJ/D;DN6N1\;_8E.3U2QEE$NZKRQYU,UL>!OYC;C$L"(^I^D7+?3$8JVDSM=L MKN4UO!.NGG_7)$G;FIWI\=_0Y1O(4"SW=RW=F^0 AP:5 M">^)]>X93J8O>I.3P!>QZ4H#5"PE%(^M[XN"CGU9)OJJ/YPA'3G%C\ X0?,P M8G20GB2(O^L;3<9C3-)<:0NS?4( 91855V62)G]RMR# $#G$;#<=Z1O&FX,7 M0-H9=_P)*2^ 9-.)08D)BZU8/G8:3T8X?+YW5#>NN2'8\)*]AZ,0C*R3?:M8 M'WU]5V&2ZIZ2_ H$1AA12PWE.5PP!#6D>XK=Y5@>JO?2+_.VV:M9%C9_)HP< MU-HKJCQ:$RA'21'OX.S6J7(:6*Y7$\^A?A;FW*B!HILY9LU"*2L-SP^)\_EV M&J]__=+H$=2NB37V,..<)!;Z.B_J7D$UV[978ITES;/+'21P.ML&$MU I DP MM)OY9H=_-B8-0ODJ3)7.?<,]M4CB!BI@:@8E3AH'LR)Z=E));?:"@L?LT^+> MM<:J-4&;GYO3=&PK+;,=5TH7X'MIG+4 Q* $P7:EC29;9/)V2(N?WPCZV5+4 MQBO):L-W,=,O)A-X5G1CP=]%1K#CA^&^PPYY3A'H6BG<)Z3:D/4-!N:%EJC' M!X?XW/'AKC8=SQ6G"[X"2G&9LSRFR]P[.3ZDICCX%/ZM1%4X$\HMR+#?\+X; MO0WNNW&D ;;=?3;:6 <:C0T'A9T=H'TJ$6Q_@.D%Z&^N"I(!W/%.&$5/#614 MNH#%0- RBC#PR$]P/+8@1D5>@,9? 0+=X'.%QFSO8KX#L(@J MC5F1#0-T\148MK5[7R=C8+YE'?%OT1X[5HW/>"W;VP4?FC:9E MG]VIM.$CL(RPF9R7^7-:21RSB3$-9_4WS/@ X.:L[0$&95*[)Z2QS+4CVG;9 MT+%5TJ*?*,$Z:LK[VVO#Q15 %GB*:VGHE@$P6Y4;1],>/W ML?> UA*F[(".#4HSO8CE>Y?HJTNDP0-L* ="0)'OZ;*O/0I+$,OD:,!=(9*Q>UW=K MQF[&T&<")@/?,PR/ WNBP -<&S*T9[T2Y"LWV+*\(_-PNH13E:,[IM>YSJ,_ M9Z9I@6F3VW ?H(;55AM_D]]%9=PI@7>J_V#2[W!97-->4043Q!5&O6!#Q@7R M?.^@3H1KR:N4C?VQ,^.?52:" ]7(56_G2Y' !5BTJ6YP2A*#U5E4+O&&LU%( M?5AGOM=1:7@ZGC('C]I)3&%C/157#3>W/%@42K%/.<-MV][-U )T+Z.1B*N4 MEP6%E1R^#9P>=+2!SP9XN%B@*1%;'PK;&"/322U7OKWW1N9N\'R_1I2L!FDR MQK7SHLU9ALB'I19\02+[0+?N:SD"ML(^(N3;S33??QGLF#S-=E2IO$VD_GK_[_#5X20'LC-0,>$4')9A,?BBGV:M M^=,PHH01:'@ IVQ3-V=>)@HI(TP+1D 1PUA%O)4Q3%JNUH-(=**G,*=0%PMD M3C2W@C&LL2+4JA26%T2WY4@G<]V]@Q?$!Q@*1/AT3W?U([OF$7-VQ1_H10G8&*@5SK\06&:OVU^X?/^F5>>P M':/V =M7 L9\2,FQ%0M6%.)(J(I#+229@JX M>SG@+PP%:G%::P$KB).\^$(1UGNO^^2-?$%G>1F]PIO#5T6=E!][P:5OC&(&XG\BT'XN?9-$+Q+5'@M0F6M MH@E#DPB\(((3Y92$'PY!?1^S>L#9]I?\2P2L!J=]-(*F9#NI/"VTDY5I@2<> M@$4,6@H\3FI^9]X'-9=!V"$U ^UJT@%YM%Q'B>W8FA@S4YY3+]:(R2Y0GT@> MFY.CLEPD4?.( 1JBA7'7+E K6$0T%5<]?8ASJW^@J3&11A72&/@I[$?+_JZ2Y$O4K) %D&->H2S>SO\R]4!XP MKA,)JU2Y2LG#134;=;DBVKP T\M+4>A(66H[A\FF)QTU:^&"[7K\?YC=)!E/ MITJ(R9"K$6U'Q>EJ_"VP!]#265#&P"6,=UM^$;=I87%\ KQYC>0,#$52[ ]8 M)1..O8%DV%%JB5G,+)6OJ6I,YCF'Z$RR, MCZ\&1.'BYANKV5 K]VX6'BY@RF;6H=T+8HY-!R]CG-1=&"%%&,LK"2)"OOJE M:?6H,;3WG1'.-/H+3?1]P+QPIO%Z\O@B"T_M8 >'FQ-'T!]\)>SL=H\.K ^_ M(:OBCW@'A[WNP?&+-^JX+L+)S.W;&'"O!8.XC;5O'8?0QH]B$+TM8Q"[GD&LD$&\5G;L MK#4+)[L!]&Z;X'#WA7NX M\"2P$K!OO2AV @UDM&^WLKI_@(,-'^P< M8K:-/E[X,/KJ@'^A2NT>:DC[L."&.N[\A[4E@PTA@R^2PHVCPAO3; MX^Z]D[\]=:S:CO88V'3^Y.WHX_L[^CQYN&-&^VCT?8'_+[LWC0]*KZ6$\$%I M'Y3> ,B[20);)HP=18.WI=_N'W7[SN%EV\C#0;FP91APED%Y8WJ_U]UW#C'; M1A\^*+U"X']LZS/KGH-IP['@J+]U*ZWI_IL KMON#_>PL8U$<*].0$^& FH5 MMD7DL-\]=I .MDP_6@NZF&=-&TX81YXP:B0PH#6?W([;<+W?^BEVL8Z3B$94JD$",WW/U0"6*Q'@U_-*FK&J.'Z#)R#P M; >>^6+-7Z4!YGHD"+^ 9P;@T27U2\^H,CVTQR3+D]._;R1D<>5 D%A$3FZV5$-!-NJ^VHG7L0AMAUDC0,'/+ MH^HEW)9+N%[WY!;E-A4.C>GUVKL=I#F8@2\'][?HGC!38%Z(;1X^W .[[WSL>N?C M7K_ANO2MCUOQ=M#I']Z[6=,&AK<]E_/"9>5@]\)E/?"TVW =>@FS('_JX-Z% M%U[ K+HTS,N6#>-937?;0IZU10SJGU4F.HRN_FZ__W OU)/Y2C?>"_7NZ[O@ MD\ DQ#3X/!PFD0C>54F*T+#\3TV_C'L>;<_9?"WE]J*!W2[;K?,>=/;VCMQ# MC:<0)]#@Y8.__=N+!G::;+=\V._VO7A8-1(<;)?C)<,*4Y"VB/^\%Q&5TCVJ MV\,GW]P?'5(49?#O,$W%U#A SBC%Z]']'MZCNV$>W2T3VZZBP?L]0*_M[)T< MN(<:3R%.H.'F?/O-HP97\>#)P0DT>$?(L[=[W<-[]PWV!+)J1X@W)3:,)6V= M(^2?85:%Q;3V@^SY](_58:-_M+L?_)87Y2CX)K)P&@;_":<^\<,5]+CJOMTR M<>TJ&KP#Y-G;P\[^@9]]OFHLN$HA7C[XV[^]:/#^#DS\N+]_W!/(JOT=7C)L M&$O:.G_';_D5)WX$C^/K\#D?]\7$134>4\O>X!^YG"1EF"ZL?#D_/VOW-\>.@>;CR).($&+R#\[=]>-'AO#WI[ M=O?3(DGKW)9]G]NR.EQ\JV049L&7(A\**9,\"U/? MV\0Y++GJJ-XRF>TJ&KS7X]G;?F?_Y-X-_3R%;#B%>/G@;__VHL$[/9Z]/0 9 MZ1YFMHQ ?(J+9TE;ZO1HMG,]\#DNJT/%EU$NLN1'<#9*TK@0V5__KGNH\13B M!!I\3Q <0]G3Q/)9TK8Z@%1/EZ"_VU1<5Y/RTO#U MW#3FG$XW"0N Z :3R==C::$G6ZW?V]NZ=0?Y(;&]YGN=I:XU$TD83CA/(\83C+FZ: MDYL?C)^-)J;][OZ]>_1Z4G+2R;-Z\;-):'""HQT]P+^PT>SK0DQ*T_-FS_>\ M62$JON5EF'8"\2-**ZI[RD09Q&)0!I-"C)-J'(193!\.DRS,(BJ-$D*ZYU3U MONP5!7%N'5R_50J JWAJ.GCNCZN-%DP'1YW#XYY[R-NR2*FK-.0S:]S @R<' M)]#@,VO*KP9=2Y>PE]2. MH\'7%3U[^W+O^,@]S&P9@;QR#P/>[^$&'K:,$EQ%@_=[N(L;3R).H,';$KZS MS#KY/1[JBO(51&S MM]TE+%]!Y#YR/.&XBQM?0;1F"//$Y"YNO%7D#BY\(9'C:2\WN7_BO!JD(@#; M:&N(AHJ*3*,8"7\HX=]). T!$AWX-=LI1)17A11!F0>5[*!/R,'*R2W$G:NN M[25J5VY"WE;ZB9Z[A\8ERY >!94;+?H.CCI[)RO+UEFDP"]DF%M%=TY4GZ]6 MGMD@'>1I; ,T >T@B>Z/KG7#A%M4XC%SB\?H_MAY"H'CT>4)R7W,>./)'5RT M>HN61,9/4ID9 QH!-^'J9SB+7I?HEX!/X^1J$31^KV29#*>WPZ-Q_!=WN8SV M#F$7L!F]#]X"@IC11?M5"/[;L]UG0232%)D=7 CSN[H@]+N^_43P\0SZ 0QZ\! &O>X7_HFY\[=1(HDK!_!?&8U$ M7*4BQK@=L4H!3*D<)1GP8Q%D\)J@O!;IE6+=LA.$90#4%8V"$@X27./SP.]A M+PFPX^N1((8-JQ6""^1%,*D*60&$\-,0UKQN2@=DYX-I4)5)FOR)Y?3 +XO\ M&GZ2 9P;5LNK(C@K1)R4P>EE(01R]^YR['P)"8YWI-=OO23W5_X?/00[$E8 M%N>Y2A$!MF($':*J$"CYBGPB"I"=^9 ^'%1)&A,@0PFH CS!?\U#J0@E+@9R M%DU'V0V:;\FK4I;P5\0)? _6-(T^@[U=[/79[P6C, :D1OEXD&2PFV&8%$BE ME<#GPPF\[$<"%TN _'Y^N-O="P!Z*5S9KEU'<%H&[T5$*_,'>SU:'EX"%PQ? M@1#)*UGO#BXB' ?>P9?Q6@!(V@+12E&(X0>Z1U&.Z)3P ?Q$L2K87(Q:!-U5 M.1*B9$"8,]EPT,\Q@.$U-;_>9Z,P0]@EJ+ 5WT5)LVG@SC'2K'$U5&B2C(&YDLXH9H"&?^[ O8=G M2@ OYBJHIW&M!$<@"UGBK:@*I![@/5$H1\$PS:^[RP/U*?P%3^8HSS3E* M[W#(^YZH(==F12")BC0A.?AY. S>*4J]0(H.3HL";QB9&I;D> AD#A= 9CD- MZ;&Q?;J 01,'17DQ"9'G U>,@/F'R T!2 VV!X_50"+VF 8@.G!PL0 !R@S M4+FA=T4LD$T1SB- !DR*;7D?9]<@1Q(2.$]C#)FX1D)%"^+KH^:Z&(<@%:W,P#]^OM..(3S_1*FUT!9SX+7 M=XM[/5HD85G2/7:9=(,D_MNS\V\?/OUW[[__]Z_3W[Z=?SO]=O[O#_C+K_KG M]^<79[]^OOC7'0C]'*ZPLB&ZP?^AV9G M09J)[*'#U+\O[\[_$PI#93458!")#$[#= MQB1KKT#I#Y=D($2&-@-:704RQ:BV3'"U/V9OU!_J1N'OL87QN"I0EI.%DA1@ M>BW8$QHGM@[S\Z^!G07QL(MQAVOP MT8BF\TR61:6T][LPP4/'YC6IO!\E0\E>@N\RR6!B,(QG&8X%!$11VY.>J 46"2?!3[(V8>/ MNL$YN[0 ECM$1<&OY^\^?\4%PD$.Z_,1.DK!J7!';/),0%B3*XC>MW"5%/MZ M @ RL](U&DW3N07Y%7$RU#QJ(,IK9!M,Z\9348,57SSSQCOX&M;D&JN9T$]S MD?>6OX?TA?W;[[,ZR6-<:+/4PV^TAF_;E;ZC MA%JCZ_V^%N;E*"E(ZA?E_]_>U38GCBOK7W#^@RIW]U2FBCB8E[S-;JH8)KG# M;B:9(IG=LY]2 HO@,\;FRB:9_/O;DFQB$DB 0-Q!_64&@BU+_70_W2VU);4R MH1RY>[AZXB[/K>]NK3:_NK,%=/RQTKJ':]%RU?_5*+EI:14ZKF4Z3<47G#W! MKM=_0T0JN XR533]5#'T:D9^AEVIK50K3]*LAL1^NFPT.0T_JS5 #.Y1\^XA MV)!^C; GHT%J50HH7V03A7^;B0I?K0 F_2A6BCL]'TA52AQK]>P1DF@EUK2Z_@(6I99_'XS\CT]\:?B\7PP M#U=#5T*AIT",14*O_%MSF_\0G)I5'3 UO69FYI74B%ACVFQF:YX8T]GG(??U0DO6FT<+6]5*38]@/#F58P&U+JPX MP%/&I2:KTD1I*,6M7G;+GJ?;5B??Y1>;=;>$',39>J@6Y42OG\G-7N[Y8:W^ MMCW/>]A393< -FB54LK<=0]NYJ&J:LI4^LOC/IYXR[7$)^:D&==A"XB(RU!5.VQ86V8WNJ'H* MK1#9[3$(.S .(($N@1>;NZSGNBP5SFF)QU0$VLBU9A''7G*"94'GEM0=="O9RC=2>M6 MU2RB(I_8UKE+23>-:"#%)CC!Y*FL=Y7%:N90S?*(HR^EL("5V[1C!> MT)1NHJ;)QZ75GH:I8%5_^G[,:XJL3<^.='7D*PJNW^JEK@/'7<460),KKJ]Y MJPM'I5)QK]F5G;T7]CI]V_?K9[UE=SA7.?$J@8">J+7'W[UL(MAPY*#ON M"UN9/10[K]UL<.#V-2/VSSH6^D9Z8#"!7-U3XV]Z%O,6-Q)!F;63V'AS. MQL R=^G%]F<5,LATV3\:Q1!UQ2^\DT*."HVCPN"GW+)SL,366'8[,I4*D9LJ MUHS>?*\1M_9*,R'"PT!XAP[1W>)T5R&ZLXSNRO.8B4T(X*(QB-O*!T1D"Q/9 MTD?@K&LSN4(/'\ !"P["FRN^LPD!7(1WX%1>&X#;R'+BM%@OG!:)[A"&=T1WV.F.PL"EJNNDT)L"$.M9QGHU2FHQLYD[625$ M=#;W.6^%,QFEM6NL)EK?8?&FP.@MSH*87^ KK%$]BV#4ZBTF7>U]5-0)HC/E M;\J"-E;\Q9[;^JIC# LZ*HU@RD_ES%6*A>4$0H)NPL+(@(I'0<_RD-3)NQ!, M4V;.R+F\3^3(N:! 09?$D=3)N1!,4U*7N:H1R;O@@XZ\"PH4*'4A[T(P38=I M?[Y%?_(N^* C[X("!5WM25(G[T(P39D8(^?R/I$CYX("!4I=R+D03)2Z;!AT MY%U0H*!KF$GJY%T(IBG++G.5CY-WP0>=]=ZEL*TFK2T./QV?'[1T8?C:9$^% MX85HO.TDA (%4_=-3AH?,F0?*%"@"4;2?4M1T%7;Y!KP 4/F@0(%*LHFW;<4 M!5-S3;X!'S)D'RA0H+2!=-]2%$S9 ?D&?,B0?:! @0JB2?N6#@XKZ)"QS#2P$A0E"Z3[]KD% M6OL_=JNE>MU%AXQEIH&5H*ADF'3?/K= U<*'55I6('*B3 &-U.W2?7PN@3*% M8_>@5-^OHD/&,M/ 2E!4)4RZ;Y];H +AX_I^:>^ )I#0$=0F[C6,OD"X<2LD MOQ',#Q,A19SHG8=C=-7S5"],[RS8B@(5#1_7G*73.#*.U4#P*SX :&*/U-Y2 M%*AHN.;4T*%BF6U@= E4+$QJ;R<*5#%,/J%X"##Z!$H32.WM1(&* ,@G% \! M1I] 9<*D]G:B0+7"M)I0. 0870*E":3V=J) :0+YA.(AP.@3J$:8U-Y.%*A0 MF'Q"\1#\NI("8<0[".,6_U_J+YU Z*K@(W0E\U053"\JV(H"505C18;L P4* M-)]'NF\I"E0=C!08,@\4*%"5,.F^I2A0E3!69,@^4*! :0/IOJ4H4!D 5F3( M/E"@0%7#I/N6HD!5PTB!(?- @0*E#:3[EJ) :0-69,@^4*! 5<2D^Y:B0%7$ M6)&QWCYHN^$"8/@L.LEVYP.ZLGJJ)*:7&?">!D!;"Z_3- XJ;H5LHW 8<#(4 MS>N1[MOG%ZB F-P"$AAP$A15$)/NV^<6J'B8_ (6&' R%*4+I/OV^06J ""_ M@ 4&G Q%E<.D^_;Y!2H:KNSOE0[*973(6&8:6 F*T@72??O< J4+E"Y@@0$G M0U'%,.F^?7Z!BH4I7\ !PPJKA1'O/8R^6KAQ*R2_$

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